TABLE 14.2__2000.2.1.1.7.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
LOGMAR LEFT EYE									
BSL VALUE	PLO	8	0.17	0.197	-0.02	0.04	0.14	0.22	0.60
	ADA	6	0.02	0.097	-0.08	-0.08	0.02	0.06	0.18
	TOT	14	0.11	0.175	-0.08	-0.02	0.08	0.18	0.60
FINAL/ET VALUE	PLO	8	0.16	0.236	-0.10	0.01	0.12	0.25	0.64
	ADA	6	-0.03	0.126	-0.12	-0.10	-0.07	-0.02	0.22
	TOT	14	0.08	0.213	-0.12	-0.08	0.03	0.16	0.64
CHG FROM BSL	PLO	8	-0.01	0.080	-0.12	-0.06	-0.02	0.03	0.14
	ADA	6	-0.05	0.070	-0.14	-0.12	-0.03	0.00	0.04
	TOT	14	-0.03	0.075	-0.14	-0.08	-0.03	0.02	0.14
LOGMAR RIGHT EYE									
BSL VALUE	PLO	8	0.23	0.354	-0.04	-0.03	0.12	0.33	1.00
	ADA	6	0.20	0.201	-0.08	0.08	0.17	0.42	0.44
	TOT	14	0.21	0.288	-0.08	-0.02	0.17	0.40	1.00
FINAL/ET VALUE	PLO	8	0.20	0.387	-0.10	-0.06	0.07	0.29	1.06
	ADA	6	0.16	0.285	-0.12	0.00	0.02	0.48	0.56
	TOT	14	0.18	0.335	-0.12	-0.02	0.03	0.40	1.06
CHG FROM BSL	PLO	8	-0.03	0.063	-0.14	-0.06	-0.04	0.02	0.06
	ADA	6	-0.04	0.157	-0.26	-0.20	0.01	0.08	0.12
	TOT	14	-0.03	0.108	-0.26	-0.06	-0.04	0.06	0.12

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.7.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
CRT LEFT EYE									
%CHG FROM BSL	PLO	8	-3.2	9.76	-15.1	-13.2	-0.9	3.0	11.8
	ADA	6	-1.0	9.74	-17.2	-6.4	0.9	5.3	10.7
	TOT	14	-2.2	9.43	-17.2	-11.2	-0.4	4.9	11.8
CRT RIGHT EYE									
%CHG FROM BSL	PLO	8	2.0	13.76	-10.2	-4.8	-0.4	1.0	34.6
	ADA	6	42.8	107.51	-15.8	-8.2	-1.0	22.2	260.7
	TOT	14	19.5	70.61	-15.8	-6.7	-0.7	1.5	260.7

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.7.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
AC LEFT EYE									
BSL VALUE	PLO	19	0.13	0.226	0.0	0.00	0.00	0.50	0.5
	ADA	19	0.21	0.254	0.0	0.00	0.00	0.50	0.5
	TOT	38	0.17	0.240	0.0	0.00	0.00	0.50	0.5
FINAL/ET VALUE	PLO	19	1.16	1.143	0.0	0.00	1.00	2.00	3.0
	ADA	19	0.97	1.160	0.0	0.00	0.00	2.00	3.0
	TOT	38	1.07	1.140	0.0	0.00	0.50	2.00	3.0
CHG FROM BSL	PLO	19	1.03	1.073	0.0	0.00	0.50	2.00	3.0
	ADA	19	0.76	1.123	-0.5	0.00	0.00	2.00	2.5
	TOT	38	0.89	1.091	-0.5	0.00	0.50	2.00	3.0
AC RIGHT EYE									
BSL VALUE	PLO	19	0.16	0.239	0.0	0.00	0.00	0.50	0.5
	ADA	19	0.13	0.226	0.0	0.00	0.00	0.50	0.5
	TOT	38	0.14	0.230	0.0	0.00	0.00	0.50	0.5
FINAL/ET VALUE	PLO	19	1.11	1.088	0.0	0.00	1.00	2.00	3.0
	ADA	19	0.74	1.085	0.0	0.00	0.00	2.00	3.0
	TOT	38	0.92	1.088	0.0	0.00	0.50	2.00	3.0
CHG FROM BSL	PLO	19	0.95	1.039	0.0	0.00	0.50	2.00	3.0
	ADA	19	0.61	1.035	-0.5	0.00	0.00	2.00	2.5
	TOT	38	0.78	1.038	-0.5	0.00	0.25	2.00	3.0

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.7.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
VH LEFT EYE									
BSL VALUE	PLO	19	0.18	0.248	0.0	0.00	0.00	0.50	0.5
	ADA	19	0.29	0.254	0.0	0.00	0.50	0.50	0.5
	TOT	38	0.24	0.253	0.0	0.00	0.00	0.50	0.5
FINAL/ET VALUE	PLO	19	0.63	0.847	0.0	0.00	0.50	1.00	3.0
	ADA	19	0.53	0.754	0.0	0.00	0.00	1.00	2.0
	TOT	38	0.58	0.793	0.0	0.00	0.25	1.00	3.0
CHG FROM BSL	PLO	19	0.45	0.797	0.0	0.00	0.00	0.50	2.5
	ADA	19	0.24	0.674	-0.5	0.00	0.00	0.50	1.5
	TOT	38	0.34	0.736	-0.5	0.00	0.00	0.50	2.5
VH RIGHT EYE									
BSL VALUE	PLO	19	0.26	0.256	0.0	0.00	0.50	0.50	0.5
	ADA	19	0.29	0.254	0.0	0.00	0.50	0.50	0.5
	TOT	38	0.28	0.252	0.0	0.00	0.50	0.50	0.5
FINAL/ET VALUE	PLO	19	1.08	1.182	0.0	0.00	0.50	2.00	3.0
	ADA	19	0.45	0.685	0.0	0.00	0.00	1.00	2.0
	TOT	38	0.76	1.005	0.0	0.00	0.50	1.00	3.0
CHG FROM BSL	PLO	19	0.82	1.121	-0.5	0.00	0.50	2.00	3.0
	ADA	19	0.16	0.579	-0.5	0.00	0.00	0.50	1.5
	TOT	38	0.49	0.941	-0.5	0.00	0.00	0.50	3.0

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.7.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
LOGMAR LEFT EYE									
BSL VALUE	PLO	19	0.21	0.234	-0.12	0.04	0.16	0.40	0.72
	ADA	19	0.20	0.263	-0.10	0.00	0.10	0.42	0.84
	TOT	38	0.21	0.246	-0.12	0.02	0.14	0.40	0.84
FINAL/ET VALUE	PLO	19	0.30	0.297	-0.12	0.14	0.18	0.48	0.94
	ADA	19	0.23	0.335	-0.16	-0.02	0.14	0.42	1.20
	TOT	38	0.27	0.314	-0.16	0.06	0.18	0.44	1.20
CHG FROM BSL	PLO	19	0.09	0.142	-0.14	-0.02	0.06	0.18	0.46
	ADA	19	0.03	0.140	-0.20	-0.06	0.02	0.08	0.36
	TOT	38	0.06	0.143	-0.20	-0.04	0.03	0.16	0.46
LOGMAR RIGHT EYE									
BSL VALUE	PLO	19	0.33	0.290	0.04	0.10	0.28	0.40	1.20
	ADA	19	0.17	0.250	-0.10	-0.02	0.12	0.28	0.88
	TOT	38	0.25	0.279	-0.10	0.06	0.19	0.36	1.20
FINAL/ET VALUE	PLO	19	0.47	0.394	0.08	0.20	0.28	0.78	1.30
	ADA	19	0.23	0.374	-0.16	0.02	0.10	0.32	1.10
	TOT	38	0.35	0.399	-0.16	0.08	0.22	0.42	1.30
CHG FROM BSL	PLO	19	0.15	0.274	-0.08	0.02	0.04	0.18	0.96
	ADA	19	0.06	0.185	-0.14	-0.10	0.02	0.14	0.52
	TOT	38	0.10	0.235	-0.14	-0.02	0.04	0.14	0.96

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.7.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
CRT LEFT EYE									
%CHG FROM BSL	PLO	18	4.4	10.77	-7.9	-2.0	0.9	3.1	31.8
	ADA	19	8.7	28.71	-47.1	-5.9	1.4	12.2	91.7
	TOT	37	6.6	21.72	-47.1	-2.2	1.1	8.1	91.7
CRT RIGHT EYE									
%CHG FROM BSL	PLO	19	20.1	37.52	-30.4	0.0	5.7	33.1	132.9
	ADA	19	-6.0	15.63	-63.4	-4.7	-3.0	2.0	4.4
	TOT	38	7.1	31.29	-63.4	-4.3	1.5	5.7	132.9

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.7.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
AC LEFT EYE									
BSL VALUE	PLO	1	0.50		0.5	0.50	0.50	0.50	0.5
	ADA	0							
	TOT	1	0.50		0.5	0.50	0.50	0.50	0.5
FINAL/ET VALUE	PLO	1	2.00		2.0	2.00	2.00	2.00	2.0
	ADA	0							
	TOT	1	2.00		2.0	2.00	2.00	2.00	2.0
CHG FROM BSL	PLO	1	1.50		1.5	1.50	1.50	1.50	1.5
	ADA	0							
	TOT	1	1.50		1.5	1.50	1.50	1.50	1.5
AC RIGHT EYE									
BSL VALUE	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0
FINAL/ET VALUE	PLO	1	2.00		2.0	2.00	2.00	2.00	2.0
	ADA	0							
	TOT	1	2.00		2.0	2.00	2.00	2.00	2.0
CHG FROM BSL	PLO	1	2.00		2.0	2.00	2.00	2.00	2.0
	ADA	0							
	TOT	1	2.00		2.0	2.00	2.00	2.00	2.0

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.7.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
VH LEFT EYE									
BSL VALUE	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0
FINAL/ET VALUE	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0
VH RIGHT EYE									
BSL VALUE	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0
FINAL/ET VALUE	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.7.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
LOGMAR LEFT EYE									
BSL VALUE	PLO	1	-0.10		-0.10	-0.10	-0.10	-0.10	-0.10
	ADA	0							
	TOT	1	-0.10		-0.10	-0.10	-0.10	-0.10	-0.10
FINAL/ET VALUE	PLO	1	-0.04		-0.04	-0.04	-0.04	-0.04	-0.04
	ADA	0							
	TOT	1	-0.04		-0.04	-0.04	-0.04	-0.04	-0.04
CHG FROM BSL	PLO	1	0.06		0.06	0.06	0.06	0.06	0.06
	ADA	0							
	TOT	1	0.06		0.06	0.06	0.06	0.06	0.06
LOGMAR RIGHT EYE									
BSL VALUE	PLO	1	-0.06		-0.06	-0.06	-0.06	-0.06	-0.06
	ADA	0							
	TOT	1	-0.06		-0.06	-0.06	-0.06	-0.06	-0.06
FINAL/ET VALUE	PLO	1	-0.04		-0.04	-0.04	-0.04	-0.04	-0.04
	ADA	0							
	TOT	1	-0.04		-0.04	-0.04	-0.04	-0.04	-0.04
CHG FROM BSL	PLO	1	0.02		0.02	0.02	0.02	0.02	0.02
	ADA	0							
	TOT	1	0.02		0.02	0.02	0.02	0.02	0.02

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.7.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
CRT LEFT EYE									
%CHG FROM BSL	PLO	1	0.5		0.5	0.5	0.5	0.5	0.5
	ADA	0							
	TOT	1	0.5		0.5	0.5	0.5	0.5	0.5
CRT RIGHT EYE									
%CHG FROM BSL	PLO	1	-1.5		-1.5	-1.5	-1.5	-1.5	-1.5
	ADA	0							
	TOT	1	-1.5		-1.5	-1.5	-1.5	-1.5	-1.5

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.7.5.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX

** NO DATA IN THIS SEGMENT OR PART OF THIS TABLE. **

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.7.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
AC LEFT EYE									
BSL VALUE	PLO	5	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	ADA	9	0.06	0.167	0.0	0.00	0.00	0.00	0.5
	TOT	14	0.04	0.134	0.0	0.00	0.00	0.00	0.5
FINAL/ET VALUE	PLO	5	0.70	0.837	0.0	0.00	0.50	1.00	2.0
	ADA	9	0.39	0.697	0.0	0.00	0.00	0.50	2.0
	TOT	14	0.50	0.734	0.0	0.00	0.00	1.00	2.0
CHG FROM BSL	PLO	5	0.70	0.837	0.0	0.00	0.50	1.00	2.0
	ADA	9	0.33	0.750	-0.5	0.00	0.00	0.50	2.0
	TOT	14	0.46	0.771	-0.5	0.00	0.00	1.00	2.0
AC RIGHT EYE									
BSL VALUE	PLO	5	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	ADA	9	0.11	0.220	0.0	0.00	0.00	0.00	0.5
	TOT	14	0.07	0.182	0.0	0.00	0.00	0.00	0.5
FINAL/ET VALUE	PLO	5	0.50	0.500	0.0	0.00	0.50	1.00	1.0
	ADA	9	0.94	1.333	0.0	0.00	0.00	2.00	3.0
	TOT	14	0.79	1.104	0.0	0.00	0.25	1.00	3.0
CHG FROM BSL	PLO	5	0.50	0.500	0.0	0.00	0.50	1.00	1.0
	ADA	9	0.83	1.299	-0.5	0.00	0.00	2.00	3.0
	TOT	14	0.71	1.069	-0.5	0.00	0.25	1.00	3.0

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.7.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
VH LEFT EYE									
BSL VALUE	PLO	5	0.10	0.224	0.0	0.00	0.00	0.00	0.5
	ADA	9	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	14	0.04	0.134	0.0	0.00	0.00	0.00	0.5
FINAL/ET VALUE	PLO	5	0.20	0.274	0.0	0.00	0.00	0.50	0.5
	ADA	9	0.06	0.167	0.0	0.00	0.00	0.00	0.5
	TOT	14	0.11	0.213	0.0	0.00	0.00	0.00	0.5
CHG FROM BSL	PLO	5	0.10	0.418	-0.5	0.00	0.00	0.50	0.5
	ADA	9	0.06	0.167	0.0	0.00	0.00	0.00	0.5
	TOT	14	0.07	0.267	-0.5	0.00	0.00	0.00	0.5
VH RIGHT EYE									
BSL VALUE	PLO	5	0.10	0.224	0.0	0.00	0.00	0.00	0.5
	ADA	9	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	14	0.04	0.134	0.0	0.00	0.00	0.00	0.5
FINAL/ET VALUE	PLO	5	0.10	0.224	0.0	0.00	0.00	0.00	0.5
	ADA	9	0.33	0.661	0.0	0.00	0.00	0.50	2.0
	TOT	14	0.25	0.546	0.0	0.00	0.00	0.50	2.0
CHG FROM BSL	PLO	5	0.00	0.354	-0.5	0.00	0.00	0.00	0.5
	ADA	9	0.33	0.661	0.0	0.00	0.00	0.50	2.0
	TOT	14	0.21	0.579	-0.5	0.00	0.00	0.50	2.0

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.7.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
LOGMAR LEFT EYE									
BSL VALUE	PLO	5	0.46	0.488	0.00	0.10	0.24	0.98	1.00
	ADA	9	0.26	0.284	-0.04	0.04	0.16	0.40	0.76
	TOT	14	0.33	0.365	-0.04	0.04	0.19	0.64	1.00
FINAL/ET VALUE	PLO	5	0.69	0.510	0.00	0.36	0.84	0.94	1.30
	ADA	9	0.30	0.285	-0.06	0.12	0.24	0.58	0.72
	TOT	14	0.44	0.410	-0.06	0.12	0.32	0.72	1.30
CHG FROM BSL	PLO	5	0.22	0.330	-0.16	0.00	0.26	0.32	0.70
	ADA	9	0.04	0.153	-0.18	-0.04	0.00	0.06	0.32
	TOT	14	0.10	0.237	-0.18	-0.04	0.00	0.26	0.70
LOGMAR RIGHT EYE									
BSL VALUE	PLO	5	0.17	0.280	-0.10	0.04	0.12	0.14	0.64
	ADA	9	0.22	0.279	-0.08	0.06	0.18	0.32	0.84
	TOT	14	0.20	0.270	-0.10	0.04	0.13	0.32	0.84
FINAL/ET VALUE	PLO	5	0.16	0.270	-0.20	0.04	0.18	0.22	0.54
	ADA	9	0.19	0.356	-0.18	0.02	0.04	0.20	1.06
	TOT	14	0.18	0.318	-0.20	0.02	0.11	0.22	1.06
CHG FROM BSL	PLO	5	-0.01	0.088	-0.10	-0.10	0.00	0.04	0.10
	ADA	9	-0.04	0.208	-0.40	-0.10	0.00	0.02	0.24
	TOT	14	-0.03	0.171	-0.40	-0.10	0.00	0.04	0.24

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.7.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
CRT LEFT EYE									
%CHG FROM BSL	PLO	5	-7.6	15.25	-27.5	-19.2	-3.7	5.3	7.3
	ADA	8	16.7	41.12	-4.6	-0.6	2.0	8.6	117.7
	TOT	13	7.3	34.84	-27.5	-3.7	1.1	6.0	117.7
CRT RIGHT EYE									
%CHG FROM BSL	PLO	5	15.7	20.19	0.0	0.0	12.5	16.8	49.3
	ADA	8	11.6	21.94	0.0	0.5	3.2	10.1	64.9
	TOT	13	13.2	20.52	0.0	0.4	4.5	12.5	64.9

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.7.7.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
AC LEFT EYE									
BSL VALUE	PLO	1	0.50		0.5	0.50	0.50	0.50	0.5
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.25	0.354	0.0	0.00	0.25	0.50	0.5
FINAL/ET VALUE	PLO	1	3.00		3.0	3.00	3.00	3.00	3.0
	ADA	1	4.00		4.0	4.00	4.00	4.00	4.0
	TOT	2	3.50	0.707	3.0	3.00	3.50	4.00	4.0
CHG FROM BSL	PLO	1	2.50		2.5	2.50	2.50	2.50	2.5
	ADA	1	4.00		4.0	4.00	4.00	4.00	4.0
	TOT	2	3.25	1.061	2.5	2.50	3.25	4.00	4.0
AC RIGHT EYE									
BSL VALUE	PLO	1	0.50		0.5	0.50	0.50	0.50	0.5
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.25	0.354	0.0	0.00	0.25	0.50	0.5
FINAL/ET VALUE	PLO	1	3.00		3.0	3.00	3.00	3.00	3.0
	ADA	1	3.00		3.0	3.00	3.00	3.00	3.0
	TOT	2	3.00	0.000	3.0	3.00	3.00	3.00	3.0
CHG FROM BSL	PLO	1	2.50		2.5	2.50	2.50	2.50	2.5
	ADA	1	3.00		3.0	3.00	3.00	3.00	3.0
	TOT	2	2.75	0.354	2.5	2.50	2.75	3.00	3.0

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.7.7.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
VH LEFT EYE									
BSL VALUE	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0
FINAL/ET VALUE	PLO	1	0.50		0.5	0.50	0.50	0.50	0.5
	ADA	1	1.00		1.0	1.00	1.00	1.00	1.0
	TOT	2	0.75	0.354	0.5	0.50	0.75	1.00	1.0
CHG FROM BSL	PLO	1	0.50		0.5	0.50	0.50	0.50	0.5
	ADA	1	1.00		1.0	1.00	1.00	1.00	1.0
	TOT	2	0.75	0.354	0.5	0.50	0.75	1.00	1.0
VH RIGHT EYE									
BSL VALUE	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0
FINAL/ET VALUE	PLO	1	0.50		0.5	0.50	0.50	0.50	0.5
	ADA	1	1.00		1.0	1.00	1.00	1.00	1.0
	TOT	2	0.75	0.354	0.5	0.50	0.75	1.00	1.0
CHG FROM BSL	PLO	1	0.50		0.5	0.50	0.50	0.50	0.5
	ADA	1	1.00		1.0	1.00	1.00	1.00	1.0
	TOT	2	0.75	0.354	0.5	0.50	0.75	1.00	1.0

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.7.7.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
LOGMAR LEFT EYE									
BSL VALUE	PLO	1	-0.04		-0.04	-0.04	-0.04	-0.04	-0.04
	ADA	1	-0.12		-0.12	-0.12	-0.12	-0.12	-0.12
	TOT	2	-0.08	0.057	-0.12	-0.12	-0.08	-0.04	-0.04
FINAL/ET VALUE	PLO	1	-0.16		-0.16	-0.16	-0.16	-0.16	-0.16
	ADA	1	-0.16		-0.16	-0.16	-0.16	-0.16	-0.16
	TOT	2	-0.16	0.000	-0.16	-0.16	-0.16	-0.16	-0.16
CHG FROM BSL	PLO	1	-0.12		-0.12	-0.12	-0.12	-0.12	-0.12
	ADA	1	-0.04		-0.04	-0.04	-0.04	-0.04	-0.04
	TOT	2	-0.08	0.057	-0.12	-0.12	-0.08	-0.04	-0.04
LOGMAR RIGHT EYE									
BSL VALUE	PLO	1	0.00		0.00	0.00	0.00	0.00	0.00
	ADA	1	-0.18		-0.18	-0.18	-0.18	-0.18	-0.18
	TOT	2	-0.09	0.127	-0.18	-0.18	-0.09	0.00	0.00
FINAL/ET VALUE	PLO	1	-0.06		-0.06	-0.06	-0.06	-0.06	-0.06
	ADA	1	-0.26		-0.26	-0.26	-0.26	-0.26	-0.26
	TOT	2	-0.16	0.141	-0.26	-0.26	-0.16	-0.06	-0.06
CHG FROM BSL	PLO	1	-0.06		-0.06	-0.06	-0.06	-0.06	-0.06
	ADA	1	-0.08		-0.08	-0.08	-0.08	-0.08	-0.08
	TOT	2	-0.07	0.014	-0.08	-0.08	-0.07	-0.06	-0.06

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.7.7.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
CRT LEFT EYE									
%CHG FROM BSL	PLO	1	11.6		11.6	11.6	11.6	11.6	11.6
	ADA	1	3.4		3.4	3.4	3.4	3.4	3.4
	TOT	2	7.5	5.76	3.4	3.4	7.5	11.6	11.6
CRT RIGHT EYE									
%CHG FROM BSL	PLO	1	18.4		18.4	18.4	18.4	18.4	18.4
	ADA	1	0.8		0.8	0.8	0.8	0.8	0.8
	TOT	2	9.6	12.40	0.8	0.8	9.6	18.4	18.4

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.8.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	24	0.15	0.232	0.0	0.00	0.00	0.50	0.5			
	ADA	22	0.14	0.228	0.0	0.00	0.00	0.50	0.5			
	TOT	46	0.14	0.228	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	24	1.13	1.287	0.0	0.00	0.75	2.00	4.0			
	ADA	22	0.80	1.172	0.0	0.00	0.00	2.00	4.0			
	TOT	46	0.97	1.231	0.0	0.00	0.50	2.00	4.0			
CHG FROM BSL	PLO	24	0.98	1.147	0.0	0.00	0.50	1.75	4.0			
	ADA	22	0.66	1.209	-0.5	0.00	0.00	2.00	4.0			
	TOT	46	0.83	1.175	-0.5	0.00	0.00	2.00	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	24	0.10	0.207	0.0	0.00	0.00	0.00	0.5			
	ADA	22	0.16	0.238	0.0	0.00	0.00	0.50	0.5			
	TOT	46	0.13	0.222	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	24	0.83	1.158	0.0	0.00	0.00	1.50	3.0			
	ADA	22	0.68	1.030	0.0	0.00	0.00	1.00	3.0			
	TOT	46	0.76	1.089	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	24	0.73	1.042	0.0	0.00	0.00	1.50	3.0			
	ADA	22	0.52	1.029	-0.5	0.00	0.00	1.00	3.0			
	TOT	46	0.63	1.030	-0.5	0.00	0.00	1.00	3.0			
										-0.26	(-0.88, 0.35)	0.391A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.8.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	24	0.10	0.207	0.0	0.00	0.00	0.00	0.5			
	ADA	22	0.14	0.228	0.0	0.00	0.00	0.50	0.5			
	TOT	46	0.12	0.216	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	24	0.50	0.752	0.0	0.00	0.00	1.00	3.0			
	ADA	22	0.23	0.528	0.0	0.00	0.00	0.00	2.0			
	TOT	46	0.37	0.662	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	24	0.40	0.691	-0.5	0.00	0.00	0.50	2.5			
	ADA	22	0.09	0.453	-0.5	0.00	0.00	0.00	1.5			
	TOT	46	0.25	0.603	-0.5	0.00	0.00	0.50	2.5			
VH RIGHT EYE												
BSL VALUE	PLO	24	0.15	0.232	0.0	0.00	0.00	0.50	0.5			
	ADA	22	0.11	0.214	0.0	0.00	0.00	0.00	0.5			
	TOT	46	0.13	0.222	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	24	0.56	0.864	0.0	0.00	0.00	1.00	3.0			
	ADA	22	0.14	0.316	0.0	0.00	0.00	0.00	1.0			
	TOT	46	0.36	0.689	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	24	0.42	0.747	-0.5	0.00	0.00	0.50	2.5			
	ADA	22	0.02	0.326	-0.5	0.00	0.00	0.00	1.0			
	TOT	46	0.23	0.612	-0.5	0.00	0.00	0.50	2.5			
										-0.35	(-0.65, -0.05)	0.023A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.8.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	24	0.13	0.312	-0.18	-0.06	0.01	0.25	1.20			
	ADA	22	0.03	0.165	-0.16	-0.08	0.01	0.02	0.56			
	TOT	46	0.08	0.255	-0.18	-0.06	0.01	0.10	1.20			
FINAL/ET VALUE	PLO	24	0.22	0.446	-0.20	-0.03	0.07	0.36	1.68			
	ADA	22	0.11	0.465	-0.16	-0.08	0.00	0.12	2.08			
	TOT	46	0.17	0.454	-0.20	-0.04	0.01	0.24	2.08			
CHG FROM BSL	PLO	24	0.09	0.194	-0.16	-0.02	0.04	0.13	0.70			
	ADA	22	0.08	0.451	-0.30	-0.08	0.00	0.04	1.98			
	TOT	46	0.08	0.338	-0.30	-0.04	0.00	0.06	1.98			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	24	0.10	0.195	-0.10	-0.04	0.02	0.20	0.60			
	ADA	22	0.03	0.166	-0.18	-0.04	0.00	0.04	0.54			
	TOT	46	0.07	0.184	-0.18	-0.04	0.00	0.12	0.60			
FINAL/ET VALUE	PLO	24	0.22	0.439	-0.20	-0.01	0.03	0.22	1.62			
	ADA	22	-0.02	0.143	-0.26	-0.10	-0.05	0.00	0.32			
	TOT	46	0.11	0.350	-0.26	-0.06	0.00	0.14	1.62			
CHG FROM BSL	PLO	24	0.11	0.318	-0.22	-0.04	0.03	0.10	1.26			
	ADA	22	-0.04	0.122	-0.32	-0.08	-0.06	0.04	0.26			
	TOT	46	0.04	0.255	-0.32	-0.08	-0.01	0.06	1.26			
										-0.08	(-0.22, 0.05)	0.226A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.8.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	22	4.4	16.17	-9.4	-2.0	0.8	4.7	73.2			
	ADA	22	-2.6	14.82	-47.1	-6.4	0.3	3.4	26.5			
	TOT	44	0.9	15.72	-47.1	-2.5	0.8	4.4	73.2			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	23	11.8	27.43	-18.3	-1.2	0.8	9.8	101.1			
	ADA	22	-5.1	14.59	-63.4	-4.8	-3.4	0.8	9.9			
	TOT	45	3.5	23.48	-63.4	-3.7	0.0	6.7	101.1			
										-12.6	(-24.5, -0.7)	0.039A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.9.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	102	0.09	0.196	0.0	0.00	0.00	0.00	0.5			
	ADA	109	0.11	0.205	0.0	0.00	0.00	0.00	0.5			
	TOT	211	0.10	0.200	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	102	0.61	0.954	0.0	0.00	0.00	1.00	4.0			
	ADA	109	0.52	0.958	0.0	0.00	0.00	0.50	3.0			
	TOT	211	0.57	0.955	0.0	0.00	0.00	1.00	4.0			
CHG FROM BSL	PLO	102	0.52	0.954	-0.5	0.00	0.00	0.50	4.0			
	ADA	109	0.42	0.949	-0.5	0.00	0.00	0.50	3.0			
	TOT	211	0.47	0.951	-0.5	0.00	0.00	0.50	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	102	0.10	0.199	0.0	0.00	0.00	0.00	0.5			
	ADA	109	0.11	0.205	0.0	0.00	0.00	0.00	0.5			
	TOT	211	0.10	0.202	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	102	0.67	1.025	0.0	0.00	0.00	1.00	3.0			
	ADA	109	0.53	0.931	0.0	0.00	0.00	0.50	3.0			
	TOT	211	0.60	0.978	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	102	0.57	0.983	-0.5	0.00	0.00	1.00	3.0			
	ADA	109	0.43	0.937	-0.5	0.00	0.00	0.50	3.0			
	TOT	211	0.50	0.960	-0.5	0.00	0.00	0.50	3.0			
										-0.12	(-0.35, 0.10)	0.290A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.9.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	102	0.16	0.233	0.0	0.00	0.00	0.50	0.5			
	ADA	109	0.19	0.243	0.0	0.00	0.00	0.50	0.5			
	TOT	211	0.17	0.238	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	102	0.50	0.756	0.0	0.00	0.00	0.50	4.0			
	ADA	109	0.38	0.642	0.0	0.00	0.00	0.50	3.0			
	TOT	211	0.44	0.700	0.0	0.00	0.00	0.50	4.0			
CHG FROM BSL	PLO	102	0.34	0.765	-0.5	0.00	0.00	0.50	4.0			
	ADA	109	0.19	0.642	-0.5	0.00	0.00	0.50	2.5			
	TOT	211	0.26	0.706	-0.5	0.00	0.00	0.50	4.0			
VH RIGHT EYE												
BSL VALUE	PLO	102	0.16	0.235	0.0	0.00	0.00	0.50	0.5			
	ADA	109	0.17	0.238	0.0	0.00	0.00	0.50	0.5			
	TOT	211	0.17	0.236	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	102	0.50	0.756	0.0	0.00	0.00	0.50	3.0			
	ADA	109	0.39	0.655	0.0	0.00	0.00	0.50	3.0			
	TOT	211	0.44	0.706	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	102	0.34	0.728	-0.5	0.00	0.00	0.50	3.0			
	ADA	109	0.22	0.640	-0.5	0.00	0.00	0.50	2.5			
	TOT	211	0.28	0.685	-0.5	0.00	0.00	0.50	3.0			
										-0.14	(-0.30, 0.02)	0.096A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.9.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	102	0.18	0.271	-0.26	0.00	0.11	0.24	1.24			
	ADA	109	0.17	0.266	-0.28	-0.02	0.10	0.30	1.04			
	TOT	211	0.18	0.268	-0.28	0.00	0.10	0.26	1.24			
FINAL/ET VALUE	PLO	102	0.24	0.365	-0.30	-0.02	0.16	0.36	1.78			
	ADA	109	0.18	0.309	-0.30	-0.04	0.10	0.30	1.20			
	TOT	211	0.21	0.338	-0.30	-0.02	0.14	0.34	1.78			
CHG FROM BSL	PLO	102	0.06	0.238	-0.64	-0.06	0.01	0.14	1.36			
	ADA	109	0.01	0.172	-0.58	-0.08	-0.02	0.04	0.88			
	TOT	211	0.03	0.208	-0.64	-0.06	0.00	0.08	1.36			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	102	0.18	0.271	-0.16	0.00	0.09	0.28	1.20			
	ADA	109	0.15	0.232	-0.24	0.00	0.08	0.26	1.16			
	TOT	211	0.16	0.251	-0.24	0.00	0.08	0.28	1.20			
FINAL/ET VALUE	PLO	102	0.20	0.303	-0.20	0.00	0.12	0.34	1.30			
	ADA	109	0.17	0.313	-0.28	-0.02	0.08	0.28	1.48			
	TOT	211	0.18	0.308	-0.28	-0.02	0.10	0.30	1.48			
CHG FROM BSL	PLO	102	0.02	0.183	-0.52	-0.08	0.00	0.08	0.96			
	ADA	109	0.01	0.176	-0.42	-0.08	0.00	0.10	0.94			
	TOT	211	0.02	0.179	-0.52	-0.08	0.00	0.10	0.96			
										-0.03	(-0.08, 0.01)	0.120A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.9.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	100	6.7	20.50	-46.1	-2.0	1.5	9.2	105.6			
	ADA	108	6.8	31.95	-61.7	-5.4	-0.4	5.3	165.6			
	TOT	208	6.7	26.99	-61.7	-3.7	0.4	7.9	165.6			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	101	9.4	31.61	-40.4	-1.7	2.2	9.1	232.5			
	ADA	107	5.7	35.77	-59.3	-4.8	0.0	3.4	260.7			
	TOT	208	7.5	33.79	-59.3	-3.7	0.8	6.4	260.7			
										-2.2	(-8.7, 4.2)	0.500A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.10.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	30	0.13	0.225	0.0	0.00	0.00	0.50	0.5			
	ADA	17	0.12	0.219	0.0	0.00	0.00	0.00	0.5			
	TOT	47	0.13	0.220	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	30	0.72	1.064	0.0	0.00	0.00	1.00	3.0			
	ADA	17	0.35	0.580	0.0	0.00	0.00	0.50	2.0			
	TOT	47	0.59	0.929	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	30	0.58	0.957	-0.5	0.00	0.00	1.00	2.5			
	ADA	17	0.24	0.640	-0.5	0.00	0.00	0.00	2.0			
	TOT	47	0.46	0.865	-0.5	0.00	0.00	1.00	2.5			
AC RIGHT EYE												
BSL VALUE	PLO	30	0.15	0.233	0.0	0.00	0.00	0.50	0.5			
	ADA	17	0.12	0.219	0.0	0.00	0.00	0.00	0.5			
	TOT	47	0.14	0.226	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	30	0.77	1.158	0.0	0.00	0.00	1.00	3.0			
	ADA	17	0.56	0.933	0.0	0.00	0.00	1.00	3.0			
	TOT	47	0.69	1.076	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	30	0.62	1.056	-0.5	0.00	0.00	0.50	3.0			
	ADA	17	0.44	0.982	-0.5	0.00	0.00	0.50	3.0			
	TOT	47	0.55	1.023	-0.5	0.00	0.00	0.50	3.0			
										-0.26	(-0.76, 0.23)	0.293A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.10.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	30	0.17	0.240	0.0	0.00	0.00	0.50	0.5			
	ADA	17	0.12	0.219	0.0	0.00	0.00	0.00	0.5			
	TOT	47	0.15	0.231	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	30	0.65	0.709	0.0	0.00	0.50	1.00	3.0			
	ADA	17	0.50	0.707	0.0	0.00	0.00	1.00	2.0			
	TOT	47	0.60	0.704	0.0	0.00	0.50	1.00	3.0			
CHG FROM BSL	PLO	30	0.48	0.688	0.0	0.00	0.00	1.00	2.5			
	ADA	17	0.38	0.781	-0.5	0.00	0.00	1.00	2.0			
	TOT	47	0.45	0.717	-0.5	0.00	0.00	1.00	2.5			
VH RIGHT EYE												
BSL VALUE	PLO	30	0.22	0.252	0.0	0.00	0.00	0.50	0.5			
	ADA	17	0.18	0.246	0.0	0.00	0.00	0.50	0.5			
	TOT	47	0.20	0.248	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	30	0.58	0.671	0.0	0.00	0.50	1.00	3.0			
	ADA	17	0.76	0.937	0.0	0.00	0.50	1.00	3.0			
	TOT	47	0.65	0.773	0.0	0.00	0.50	1.00	3.0			
CHG FROM BSL	PLO	30	0.37	0.615	-0.5	0.00	0.00	0.50	2.5			
	ADA	17	0.59	0.905	-0.5	0.00	0.50	1.00	2.5			
	TOT	47	0.45	0.732	-0.5	0.00	0.00	0.50	2.5			
										0.06	(-0.28, 0.41)	0.726A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.10.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	30	0.09	0.230	-0.26	-0.08	0.03	0.22	0.70			
	ADA	17	0.16	0.231	-0.12	-0.02	0.14	0.22	0.64			
	TOT	47	0.12	0.230	-0.26	-0.04	0.06	0.22	0.70			
FINAL/ET VALUE	PLO	30	0.11	0.242	-0.30	-0.04	0.13	0.22	0.76			
	ADA	17	0.10	0.189	-0.12	-0.08	0.08	0.18	0.46			
	TOT	47	0.11	0.222	-0.30	-0.08	0.12	0.22	0.76			
CHG FROM BSL	PLO	30	0.02	0.115	-0.20	-0.06	0.00	0.06	0.32			
	ADA	17	-0.06	0.104	-0.30	-0.06	-0.04	0.00	0.04			
	TOT	47	-0.01	0.116	-0.30	-0.06	-0.02	0.04	0.32			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	30	0.08	0.191	-0.16	-0.04	0.02	0.14	0.62			
	ADA	17	0.08	0.155	-0.12	-0.02	0.06	0.16	0.54			
	TOT	47	0.08	0.177	-0.16	-0.02	0.04	0.16	0.62			
FINAL/ET VALUE	PLO	30	0.09	0.172	-0.18	-0.04	0.07	0.20	0.42			
	ADA	17	0.08	0.142	-0.16	-0.02	0.08	0.20	0.30			
	TOT	47	0.09	0.160	-0.18	-0.04	0.08	0.20	0.42			
CHG FROM BSL	PLO	30	0.01	0.137	-0.52	-0.04	0.02	0.06	0.28			
	ADA	17	-0.01	0.137	-0.32	-0.06	0.02	0.06	0.24			
	TOT	47	0.01	0.136	-0.52	-0.06	0.02	0.06	0.28			
										-0.05	(-0.11, 0.01)	0.127A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.10.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	28	10.6	20.61	-10.4	-0.6	3.5	12.2	73.2			
	ADA	17	13.6	37.50	-24.5	-2.8	-0.3	11.2	136.9			
	TOT	45	11.7	27.83	-24.5	-1.3	2.4	12.1	136.9			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	28	10.4	26.18	-25.6	-0.6	2.3	11.3	101.1			
	ADA	17	5.3	23.84	-13.6	-5.5	1.2	6.9	93.1			
	TOT	45	8.5	25.17	-25.6	-1.2	1.7	7.6	101.1			
										0.5	(-15.0, 16.0)	0.948A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.11.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	34	0.09	0.193	0.0	0.00	0.00	0.00	0.5			
	ADA	41	0.05	0.150	0.0	0.00	0.00	0.00	0.5			
	TOT	75	0.07	0.171	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	34	0.26	0.480	0.0	0.00	0.00	0.50	2.0			
	ADA	41	0.52	0.942	0.0	0.00	0.00	0.50	3.0			
	TOT	75	0.41	0.774	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	34	0.18	0.491	-0.5	0.00	0.00	0.50	2.0			
	ADA	41	0.48	0.968	-0.5	0.00	0.00	0.50	3.0			
	TOT	75	0.34	0.798	-0.5	0.00	0.00	0.50	3.0			
AC RIGHT EYE												
BSL VALUE	PLO	34	0.07	0.180	0.0	0.00	0.00	0.00	0.5			
	ADA	41	0.10	0.201	0.0	0.00	0.00	0.00	0.5			
	TOT	75	0.09	0.191	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	34	0.31	0.788	0.0	0.00	0.00	0.00	3.0			
	ADA	41	0.46	0.809	0.0	0.00	0.00	0.50	3.0			
	TOT	75	0.39	0.798	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	34	0.24	0.720	-0.5	0.00	0.00	0.00	3.0			
	ADA	41	0.37	0.814	-0.5	0.00	0.00	0.50	3.0			
	TOT	75	0.31	0.771	-0.5	0.00	0.00	0.00	3.0			
										0.21	(-0.10, 0.53)	0.172A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.11.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	34	0.13	0.224	0.0	0.00	0.00	0.50	0.5			
	ADA	41	0.12	0.217	0.0	0.00	0.00	0.00	0.5			
	TOT	75	0.13	0.219	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	34	0.19	0.427	0.0	0.00	0.00	0.00	2.0			
	ADA	41	0.27	0.653	0.0	0.00	0.00	0.00	3.0			
	TOT	75	0.23	0.560	0.0	0.00	0.00	0.00	3.0			
CHG FROM BSL	PLO	34	0.06	0.489	-0.5	0.00	0.00	0.00	2.0			
	ADA	41	0.15	0.635	-0.5	0.00	0.00	0.00	2.5			
	TOT	75	0.11	0.571	-0.5	0.00	0.00	0.00	2.5			
VH RIGHT EYE												
BSL VALUE	PLO	34	0.07	0.180	0.0	0.00	0.00	0.00	0.5			
	ADA	41	0.11	0.210	0.0	0.00	0.00	0.00	0.5			
	TOT	75	0.09	0.196	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	34	0.18	0.406	0.0	0.00	0.00	0.00	2.0			
	ADA	41	0.21	0.500	0.0	0.00	0.00	0.00	2.0			
	TOT	75	0.19	0.457	0.0	0.00	0.00	0.00	2.0			
CHG FROM BSL	PLO	34	0.10	0.440	-0.5	0.00	0.00	0.00	2.0			
	ADA	41	0.10	0.539	-0.5	0.00	0.00	0.00	2.0			
	TOT	75	0.10	0.493	-0.5	0.00	0.00	0.00	2.0			
										0.04	(-0.17, 0.25)	0.703A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.11.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	34	0.11	0.264	-0.16	-0.06	0.04	0.14	1.24			
	ADA	41	0.14	0.256	-0.16	0.00	0.02	0.22	0.96			
	TOT	75	0.12	0.258	-0.16	-0.04	0.04	0.16	1.24			
FINAL/ET VALUE	PLO	34	0.16	0.319	-0.16	-0.04	0.08	0.20	1.24			
	ADA	41	0.19	0.325	-0.16	0.00	0.02	0.32	1.20			
	TOT	75	0.18	0.321	-0.16	-0.02	0.06	0.28	1.24			
CHG FROM BSL	PLO	34	0.05	0.183	-0.32	-0.04	0.01	0.06	0.66			
	ADA	41	0.06	0.213	-0.24	-0.06	0.00	0.04	0.88			
	TOT	75	0.05	0.199	-0.32	-0.04	0.00	0.06	0.88			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	34	0.10	0.183	-0.10	-0.02	0.02	0.16	0.68			
	ADA	41	0.12	0.178	-0.18	0.00	0.04	0.22	0.58			
	TOT	75	0.11	0.179	-0.18	0.00	0.04	0.18	0.68			
FINAL/ET VALUE	PLO	34	0.12	0.229	-0.20	-0.02	0.05	0.18	0.84			
	ADA	41	0.13	0.287	-0.20	-0.06	0.00	0.26	1.16			
	TOT	75	0.12	0.260	-0.20	-0.06	0.02	0.26	1.16			
CHG FROM BSL	PLO	34	0.02	0.141	-0.16	-0.06	0.00	0.06	0.52			
	ADA	41	0.01	0.197	-0.40	-0.08	-0.02	0.04	0.94			
	TOT	75	0.02	0.173	-0.40	-0.08	0.00	0.06	0.94			
										0.00	(-0.07, 0.07)	0.985A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.11.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	34	2.2	15.66	-27.5	-3.8	-1.0	5.1	66.7			
	ADA	40	6.3	33.27	-28.4	-4.8	0.0	3.5	165.6			
	TOT	74	4.4	26.58	-28.4	-4.3	-0.2	4.7	165.6			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	34	6.3	41.47	-40.4	-3.1	0.2	3.7	232.5			
	ADA	39	11.3	51.51	-20.2	-3.9	-1.1	2.0	260.7			
	TOT	73	9.0	46.85	-40.4	-3.8	0.0	2.6	260.7			
										4.4	(-8.8, 17.7)	0.505A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.12.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	61	0.10	0.200	0.0	0.00	0.00	0.00	0.5			
	ADA	71	0.15	0.230	0.0	0.00	0.00	0.50	0.5			
	TOT	132	0.13	0.217	0.0	0.00	0.00	0.25	0.5			
FINAL/ET VALUE	PLO	61	0.97	1.179	0.0	0.00	0.50	2.00	4.0			
	ADA	71	0.66	1.111	0.0	0.00	0.00	1.00	4.0			
	TOT	132	0.80	1.149	0.0	0.00	0.00	2.00	4.0			
CHG FROM BSL	PLO	61	0.87	1.162	-0.5	0.00	0.50	2.00	4.0			
	ADA	71	0.51	1.092	-0.5	0.00	0.00	1.00	4.0			
	TOT	132	0.68	1.134	-0.5	0.00	0.00	1.50	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	61	0.09	0.194	0.0	0.00	0.00	0.00	0.5			
	ADA	71	0.13	0.219	0.0	0.00	0.00	0.50	0.5			
	TOT	132	0.11	0.208	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	61	0.86	1.077	0.0	0.00	0.50	2.00	3.0			
	ADA	71	0.62	1.037	0.0	0.00	0.00	1.00	3.0			
	TOT	132	0.73	1.058	0.0	0.00	0.00	2.00	3.0			
CHG FROM BSL	PLO	61	0.77	1.043	-0.5	0.00	0.00	2.00	3.0			
	ADA	71	0.49	1.033	-0.5	0.00	0.00	1.00	3.0			
	TOT	132	0.62	1.043	-0.5	0.00	0.00	1.50	3.0			
										-0.32	(-0.65, 0.02)	0.065A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.12.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	61	0.15	0.230	0.0	0.00	0.00	0.50	0.5			
	ADA	71	0.23	0.251	0.0	0.00	0.00	0.50	0.5			
	TOT	132	0.19	0.243	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	61	0.60	0.870	0.0	0.00	0.50	1.00	4.0			
	ADA	71	0.37	0.596	0.0	0.00	0.00	1.00	2.0			
	TOT	132	0.48	0.741	0.0	0.00	0.00	1.00	4.0			
CHG FROM BSL	PLO	61	0.45	0.860	-0.5	0.00	0.00	0.50	4.0			
	ADA	71	0.15	0.563	-0.5	0.00	0.00	0.50	2.0			
	TOT	132	0.29	0.729	-0.5	0.00	0.00	0.50	4.0			
VH RIGHT EYE												
BSL VALUE	PLO	61	0.17	0.240	0.0	0.00	0.00	0.50	0.5			
	ADA	71	0.18	0.243	0.0	0.00	0.00	0.50	0.5			
	TOT	132	0.18	0.240	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	61	0.66	0.921	0.0	0.00	0.50	1.00	3.0			
	ADA	71	0.32	0.555	0.0	0.00	0.00	0.50	2.0			
	TOT	132	0.48	0.763	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	61	0.49	0.873	-0.5	0.00	0.00	0.50	3.0			
	ADA	71	0.14	0.522	-0.5	0.00	0.00	0.50	2.0			
	TOT	132	0.30	0.725	-0.5	0.00	0.00	0.50	3.0			
										-0.33	(-0.54, -0.11)	0.003A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.12.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	61	0.24	0.294	-0.14	0.02	0.16	0.40	1.20			
	ADA	71	0.16	0.267	-0.28	-0.02	0.08	0.30	1.04			
	TOT	132	0.20	0.282	-0.28	0.00	0.10	0.32	1.20			
FINAL/ET VALUE	PLO	61	0.35	0.437	-0.18	0.06	0.22	0.56	1.78			
	ADA	71	0.18	0.375	-0.30	-0.08	0.10	0.28	2.08			
	TOT	132	0.26	0.412	-0.30	-0.04	0.14	0.43	2.08			
CHG FROM BSL	PLO	61	0.11	0.286	-0.64	-0.04	0.04	0.20	1.36			
	ADA	71	0.02	0.277	-0.58	-0.08	-0.02	0.06	1.98			
	TOT	132	0.06	0.284	-0.64	-0.06	0.00	0.10	1.98			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	61	0.24	0.303	-0.10	0.00	0.12	0.36	1.20			
	ADA	71	0.14	0.236	-0.24	-0.04	0.08	0.30	0.88			
	TOT	132	0.18	0.273	-0.24	-0.02	0.10	0.34	1.20			
FINAL/ET VALUE	PLO	61	0.31	0.406	-0.20	0.04	0.20	0.42	1.62			
	ADA	71	0.14	0.294	-0.28	-0.04	0.04	0.28	1.10			
	TOT	132	0.22	0.359	-0.28	0.00	0.10	0.34	1.62			
CHG FROM BSL	PLO	61	0.07	0.275	-0.48	-0.08	0.02	0.12	1.26			
	ADA	71	0.00	0.158	-0.42	-0.10	-0.02	0.08	0.52			
	TOT	132	0.03	0.222	-0.48	-0.09	0.00	0.10	1.26			
										-0.08	(-0.15, -0.01)	0.026A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.12.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	59	6.8	21.35	-46.1	-1.2	1.1	9.0	105.6			
	ADA	71	2.7	26.17	-61.7	-7.5	-0.5	5.3	117.7			
	TOT	130	4.6	24.10	-61.7	-3.7	0.9	7.3	117.7			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	61	11.6	26.05	-30.4	-1.4	4.4	16.3	132.9			
	ADA	71	-1.3	18.77	-63.4	-6.9	-1.5	2.1	74.1			
	TOT	132	4.7	23.25	-63.4	-4.4	0.6	7.9	132.9			
										-8.8	(-15.8, -1.8)	0.014A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.13.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	54	0.06	0.170	0.0	0.00	0.00	0.00	0.5			
	ADA	45	0.12	0.217	0.0	0.00	0.00	0.00	0.5			
	TOT	99	0.09	0.194	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	54	0.64	1.016	0.0	0.00	0.00	1.00	4.0			
	ADA	45	0.31	0.677	0.0	0.00	0.00	0.50	3.0			
	TOT	99	0.49	0.889	0.0	0.00	0.00	0.50	4.0			
CHG FROM BSL	PLO	54	0.57	0.978	-0.5	0.00	0.00	1.00	4.0			
	ADA	45	0.19	0.733	-0.5	0.00	0.00	0.00	3.0			
	TOT	99	0.40	0.892	-0.5	0.00	0.00	0.50	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	54	0.07	0.179	0.0	0.00	0.00	0.00	0.5			
	ADA	45	0.12	0.217	0.0	0.00	0.00	0.00	0.5			
	TOT	99	0.10	0.198	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	54	0.60	0.988	0.0	0.00	0.00	1.00	3.0			
	ADA	45	0.39	0.790	0.0	0.00	0.00	0.50	3.0			
	TOT	99	0.51	0.905	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	54	0.53	0.954	-0.5	0.00	0.00	0.50	3.0			
	ADA	45	0.27	0.809	-0.5	0.00	0.00	0.00	3.0			
	TOT	99	0.41	0.896	-0.5	0.00	0.00	0.50	3.0			
										-0.32	(-0.62, -0.02)	0.034A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.13.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	54	0.13	0.221	0.0	0.00	0.00	0.50	0.5			
	ADA	45	0.22	0.251	0.0	0.00	0.00	0.50	0.5			
	TOT	99	0.17	0.239	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	54	0.62	0.771	0.0	0.00	0.50	1.00	3.0			
	ADA	45	0.41	0.709	0.0	0.00	0.00	1.00	3.0			
	TOT	99	0.53	0.747	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	54	0.49	0.755	-0.5	0.00	0.00	1.00	3.0			
	ADA	45	0.19	0.709	-0.5	0.00	0.00	0.50	2.5			
	TOT	99	0.35	0.747	-0.5	0.00	0.00	0.50	3.0			
VH RIGHT EYE												
BSL VALUE	PLO	54	0.16	0.234	0.0	0.00	0.00	0.50	0.5			
	ADA	45	0.21	0.250	0.0	0.00	0.00	0.50	0.5			
	TOT	99	0.18	0.242	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	54	0.59	0.830	0.0	0.00	0.25	1.00	3.0			
	ADA	45	0.48	0.776	0.0	0.00	0.00	1.00	3.0			
	TOT	99	0.54	0.804	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	54	0.44	0.765	-0.5	0.00	0.00	0.50	2.5			
	ADA	45	0.27	0.758	-0.5	0.00	0.00	0.50	2.5			
	TOT	99	0.36	0.763	-0.5	0.00	0.00	0.50	2.5			
										-0.24	(-0.48, 0.00)	0.055A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.13.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	54	0.14	0.276	-0.26	-0.04	0.08	0.24	1.20			
	ADA	45	0.12	0.218	-0.28	-0.04	0.10	0.22	0.82			
	TOT	99	0.13	0.250	-0.28	-0.04	0.10	0.24	1.20			
FINAL/ET VALUE	PLO	54	0.22	0.352	-0.30	-0.02	0.16	0.34	1.68			
	ADA	45	0.13	0.372	-0.30	-0.10	0.04	0.24	2.08			
	TOT	99	0.18	0.362	-0.30	-0.08	0.12	0.28	2.08			
CHG FROM BSL	PLO	54	0.07	0.183	-0.32	-0.04	0.02	0.12	0.54			
	ADA	45	0.01	0.332	-0.58	-0.10	-0.02	0.04	1.98			
	TOT	99	0.05	0.262	-0.58	-0.06	0.00	0.06	1.98			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	54	0.16	0.290	-0.16	0.00	0.04	0.26	1.20			
	ADA	45	0.13	0.231	-0.24	-0.02	0.08	0.20	1.16			
	TOT	99	0.15	0.264	-0.24	0.00	0.06	0.24	1.20			
FINAL/ET VALUE	PLO	54	0.19	0.356	-0.18	-0.02	0.09	0.26	1.62			
	ADA	45	0.11	0.284	-0.28	-0.04	0.04	0.22	1.48			
	TOT	99	0.15	0.326	-0.28	-0.04	0.06	0.24	1.62			
CHG FROM BSL	PLO	54	0.03	0.212	-0.52	-0.06	0.01	0.06	1.26			
	ADA	45	-0.01	0.151	-0.42	-0.06	-0.02	0.06	0.40			
	TOT	99	0.01	0.187	-0.52	-0.06	0.00	0.06	1.26			
										-0.05	(-0.12, 0.02)	0.141A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.13.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	50	8.6	21.17	-19.4	-1.6	2.3	11.4	73.2			
	ADA	45	6.2	33.42	-61.7	-6.4	-0.5	3.4	136.9			
	TOT	95	7.5	27.53	-61.7	-3.9	0.4	8.9	136.9			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	52	13.7	43.29	-40.4	-2.9	2.0	10.4	232.5			
	ADA	44	3.1	29.13	-59.3	-6.9	0.0	5.6	127.1			
	TOT	96	8.8	37.66	-59.3	-4.0	0.8	7.5	232.5			
										-7.9	(-19.1, 3.3)	0.162A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.14.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
AC LEFT EYE									
BSL VALUE	PLO	14	0.11	0.213	0.0	0.00	0.00	0.00	0.5
	ADA	15	0.07	0.176	0.0	0.00	0.00	0.00	0.5
	TOT	29	0.09	0.192	0.0	0.00	0.00	0.00	0.5
FINAL/ET VALUE	PLO	14	0.18	0.317	0.0	0.00	0.00	0.50	1.0
	ADA	15	0.03	0.129	0.0	0.00	0.00	0.00	0.5
	TOT	29	0.10	0.246	0.0	0.00	0.00	0.00	1.0
CHG FROM BSL	PLO	14	0.07	0.267	-0.5	0.00	0.00	0.00	0.5
	ADA	15	-0.03	0.129	-0.5	0.00	0.00	0.00	0.0
	TOT	29	0.02	0.211	-0.5	0.00	0.00	0.00	0.5
AC RIGHT EYE									
BSL VALUE	PLO	14	0.11	0.213	0.0	0.00	0.00	0.00	0.5
	ADA	15	0.13	0.229	0.0	0.00	0.00	0.50	0.5
	TOT	29	0.12	0.218	0.0	0.00	0.00	0.00	0.5
FINAL/ET VALUE	PLO	14	0.21	0.545	0.0	0.00	0.00	0.00	2.0
	ADA	15	0.20	0.316	0.0	0.00	0.00	0.50	1.0
	TOT	29	0.21	0.433	0.0	0.00	0.00	0.50	2.0
CHG FROM BSL	PLO	14	0.11	0.446	-0.5	0.00	0.00	0.00	1.5
	ADA	15	0.07	0.320	-0.5	0.00	0.00	0.00	1.0
	TOT	29	0.09	0.380	-0.5	0.00	0.00	0.00	1.5

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.14.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
VH LEFT EYE									
BSL VALUE	PLO	14	0.21	0.257	0.0	0.00	0.00	0.50	0.5
	ADA	15	0.13	0.229	0.0	0.00	0.00	0.50	0.5
	TOT	29	0.17	0.242	0.0	0.00	0.00	0.50	0.5
FINAL/ET VALUE	PLO	14	0.18	0.317	0.0	0.00	0.00	0.50	1.0
	ADA	15	0.13	0.297	0.0	0.00	0.00	0.00	1.0
	TOT	29	0.16	0.302	0.0	0.00	0.00	0.00	1.0
CHG FROM BSL	PLO	14	-0.04	0.365	-0.5	-0.50	0.00	0.00	0.5
	ADA	15	0.00	0.378	-0.5	0.00	0.00	0.00	1.0
	TOT	29	-0.02	0.366	-0.5	0.00	0.00	0.00	1.0
VH RIGHT EYE									
BSL VALUE	PLO	14	0.14	0.234	0.0	0.00	0.00	0.50	0.5
	ADA	15	0.13	0.229	0.0	0.00	0.00	0.50	0.5
	TOT	29	0.14	0.227	0.0	0.00	0.00	0.50	0.5
FINAL/ET VALUE	PLO	14	0.25	0.325	0.0	0.00	0.00	0.50	1.0
	ADA	15	0.17	0.309	0.0	0.00	0.00	0.50	1.0
	TOT	29	0.21	0.314	0.0	0.00	0.00	0.50	1.0
CHG FROM BSL	PLO	14	0.11	0.401	-0.5	0.00	0.00	0.50	1.0
	ADA	15	0.03	0.352	-0.5	0.00	0.00	0.00	1.0
	TOT	29	0.07	0.371	-0.5	0.00	0.00	0.00	1.0

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.14.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
LOGMAR LEFT EYE									
BSL VALUE	PLO	14	0.15	0.329	-0.12	0.00	0.10	0.14	1.24
	ADA	15	0.16	0.346	-0.24	-0.06	0.00	0.40	1.04
	TOT	29	0.16	0.332	-0.24	-0.04	0.06	0.22	1.24
FINAL/ET VALUE	PLO	14	0.17	0.329	-0.08	0.00	0.09	0.16	1.24
	ADA	15	0.12	0.306	-0.24	-0.04	0.00	0.32	0.84
	TOT	29	0.14	0.313	-0.24	-0.02	0.04	0.16	1.24
CHG FROM BSL	PLO	14	0.02	0.081	-0.10	-0.02	0.00	0.08	0.18
	ADA	15	-0.05	0.085	-0.24	-0.08	-0.02	0.02	0.04
	TOT	29	-0.01	0.089	-0.24	-0.04	0.00	0.02	0.18
LOGMAR RIGHT EYE									
BSL VALUE	PLO	14	0.10	0.192	-0.10	-0.06	0.07	0.18	0.54
	ADA	15	0.11	0.169	-0.12	-0.04	0.06	0.28	0.44
	TOT	29	0.11	0.178	-0.12	-0.04	0.06	0.18	0.54
FINAL/ET VALUE	PLO	14	0.10	0.154	-0.10	0.00	0.06	0.12	0.44
	ADA	15	0.07	0.201	-0.20	-0.08	-0.02	0.26	0.44
	TOT	29	0.08	0.177	-0.20	-0.06	0.04	0.20	0.44
CHG FROM BSL	PLO	14	-0.01	0.082	-0.14	-0.08	0.00	0.04	0.14
	ADA	15	-0.04	0.096	-0.18	-0.10	-0.04	0.04	0.14
	TOT	29	-0.02	0.089	-0.18	-0.10	-0.02	0.04	0.14

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.14.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
CRT LEFT EYE									
%CHG FROM BSL	PLO	14	3.9	11.42	-15.4	-2.2	3.5	12.8	24.0
	ADA	15	-6.5	11.60	-28.4	-17.1	-3.9	0.9	12.1
	TOT	29	-1.5	12.48	-28.4	-8.4	-1.9	5.1	24.0
CRT RIGHT EYE									
%CHG FROM BSL	PLO	14	-1.6	9.62	-18.1	-5.4	-1.5	0.8	23.6
	ADA	15	-2.7	8.03	-20.1	-4.8	-3.1	-1.1	19.8
	TOT	29	-2.1	8.69	-20.1	-4.8	-3.0	0.4	23.6

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.15.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
AC LEFT EYE									
BSL VALUE	PLO	2	0.25	0.354	0.0	0.00	0.25	0.50	0.5
	ADA	5	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	7	0.07	0.189	0.0	0.00	0.00	0.00	0.5
FINAL/ET VALUE	PLO	2	0.25	0.354	0.0	0.00	0.25	0.50	0.5
	ADA	5	0.50	0.866	0.0	0.00	0.00	0.50	2.0
	TOT	7	0.43	0.732	0.0	0.00	0.00	0.50	2.0
CHG FROM BSL	PLO	2	0.00	0.707	-0.5	-0.50	0.00	0.50	0.5
	ADA	5	0.50	0.866	0.0	0.00	0.00	0.50	2.0
	TOT	7	0.36	0.802	-0.5	0.00	0.00	0.50	2.0
AC RIGHT EYE									
BSL VALUE	PLO	2	0.25	0.354	0.0	0.00	0.25	0.50	0.5
	ADA	5	0.30	0.274	0.0	0.00	0.50	0.50	0.5
	TOT	7	0.29	0.267	0.0	0.00	0.50	0.50	0.5
FINAL/ET VALUE	PLO	2	0.50	0.707	0.0	0.00	0.50	1.00	1.0
	ADA	5	0.30	0.447	0.0	0.00	0.00	0.50	1.0
	TOT	7	0.36	0.476	0.0	0.00	0.00	1.00	1.0
CHG FROM BSL	PLO	2	0.25	1.061	-0.5	-0.50	0.25	1.00	1.0
	ADA	5	0.00	0.612	-0.5	-0.50	0.00	0.00	1.0
	TOT	7	0.07	0.673	-0.5	-0.50	0.00	1.00	1.0

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.15.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
VH LEFT EYE									
BSL VALUE	PLO	2	0.50	0.000	0.5	0.50	0.50	0.50	0.5
	ADA	5	0.10	0.224	0.0	0.00	0.00	0.00	0.5
	TOT	7	0.21	0.267	0.0	0.00	0.00	0.50	0.5
FINAL/ET VALUE	PLO	2	0.75	0.354	0.5	0.50	0.75	1.00	1.0
	ADA	5	0.40	0.894	0.0	0.00	0.00	0.00	2.0
	TOT	7	0.50	0.764	0.0	0.00	0.00	1.00	2.0
CHG FROM BSL	PLO	2	0.25	0.354	0.0	0.00	0.25	0.50	0.5
	ADA	5	0.30	0.671	0.0	0.00	0.00	0.00	1.5
	TOT	7	0.29	0.567	0.0	0.00	0.00	0.50	1.5
VH RIGHT EYE									
BSL VALUE	PLO	2	0.50	0.000	0.5	0.50	0.50	0.50	0.5
	ADA	5	0.10	0.224	0.0	0.00	0.00	0.00	0.5
	TOT	7	0.21	0.267	0.0	0.00	0.00	0.50	0.5
FINAL/ET VALUE	PLO	2	0.75	0.354	0.5	0.50	0.75	1.00	1.0
	ADA	5	0.60	0.894	0.0	0.00	0.00	1.00	2.0
	TOT	7	0.64	0.748	0.0	0.00	0.50	1.00	2.0
CHG FROM BSL	PLO	2	0.25	0.354	0.0	0.00	0.25	0.50	0.5
	ADA	5	0.50	0.866	0.0	0.00	0.00	0.50	2.0
	TOT	7	0.43	0.732	0.0	0.00	0.00	0.50	2.0

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.15.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
LOGMAR LEFT EYE									
BSL VALUE	PLO	2	0.20	0.283	0.00	0.00	0.20	0.40	0.40
	ADA	5	0.25	0.421	-0.04	0.00	0.02	0.32	0.96
	TOT	7	0.24	0.363	-0.04	0.00	0.02	0.40	0.96
FINAL/ET VALUE	PLO	2	0.49	0.382	0.22	0.22	0.49	0.76	0.76
	ADA	5	0.25	0.376	0.00	0.00	0.12	0.24	0.90
	TOT	7	0.32	0.363	0.00	0.00	0.22	0.76	0.90
CHG FROM BSL	PLO	2	0.29	0.099	0.22	0.22	0.29	0.36	0.36
	ADA	5	0.00	0.073	-0.08	-0.06	0.00	0.04	0.10
	TOT	7	0.08	0.159	-0.08	-0.06	0.04	0.22	0.36
LOGMAR RIGHT EYE									
BSL VALUE	PLO	2	0.40	0.424	0.10	0.10	0.40	0.70	0.70
	ADA	5	0.05	0.091	-0.04	0.00	0.04	0.06	0.20
	TOT	7	0.15	0.254	-0.04	0.00	0.06	0.20	0.70
FINAL/ET VALUE	PLO	2	0.53	0.184	0.40	0.40	0.53	0.66	0.66
	ADA	5	0.03	0.178	-0.16	-0.08	0.00	0.10	0.30
	TOT	7	0.17	0.293	-0.16	-0.08	0.10	0.40	0.66
CHG FROM BSL	PLO	2	0.13	0.240	-0.04	-0.04	0.13	0.30	0.30
	ADA	5	-0.02	0.095	-0.12	-0.08	-0.06	0.06	0.10
	TOT	7	0.02	0.145	-0.12	-0.08	-0.04	0.10	0.30

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.15.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
CRT LEFT EYE									
%CHG FROM BSL	PLO	2	28.7	39.26	0.9	0.9	28.7	56.5	56.5
	ADA	5	-0.5	17.40	-25.7	-5.2	-1.4	8.6	21.2
	TOT	7	7.8	25.72	-25.7	-5.2	0.9	21.2	56.5
CRT RIGHT EYE									
%CHG FROM BSL	PLO	2	-1.3	1.23	-2.2	-2.2	-1.3	-0.4	-0.4
	ADA	5	-3.2	9.33	-19.2	-2.9	0.5	0.9	4.6
	TOT	7	-2.7	7.69	-19.2	-2.9	-0.4	0.9	4.6

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.16.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	29	0.14	0.227	0.0	0.00	0.00	0.50	0.5			
	ADA	34	0.13	0.224	0.0	0.00	0.00	0.50	0.5			
	TOT	63	0.13	0.224	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	29	1.19	1.153	0.0	0.00	1.00	2.00	3.0			
	ADA	34	1.07	1.268	0.0	0.00	0.25	2.00	4.0			
	TOT	63	1.13	1.208	0.0	0.00	1.00	2.00	4.0			
CHG FROM BSL	PLO	29	1.05	1.121	-0.5	0.00	0.50	2.00	3.0			
	ADA	34	0.94	1.301	-0.5	0.00	0.00	2.00	4.0			
	TOT	63	0.99	1.213	-0.5	0.00	0.50	2.00	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	29	0.10	0.206	0.0	0.00	0.00	0.00	0.5			
	ADA	34	0.12	0.215	0.0	0.00	0.00	0.00	0.5			
	TOT	63	0.11	0.210	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	29	1.21	1.257	0.0	0.00	1.00	2.00	3.0			
	ADA	34	0.93	1.122	0.0	0.00	0.25	2.00	3.0			
	TOT	63	1.06	1.185	0.0	0.00	0.50	2.00	3.0			
CHG FROM BSL	PLO	29	1.10	1.198	-0.5	0.00	1.00	2.00	3.0			
	ADA	34	0.81	1.128	-0.5	0.00	0.00	2.00	3.0			
	TOT	63	0.94	1.161	-0.5	0.00	0.50	2.00	3.0			
										-0.20	(-0.77, 0.36)	0.474A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.16.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	29	0.09	0.192	0.0	0.00	0.00	0.00	0.5			
	ADA	34	0.13	0.224	0.0	0.00	0.00	0.50	0.5			
	TOT	63	0.11	0.210	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	29	0.34	0.599	0.0	0.00	0.00	0.50	2.0			
	ADA	34	0.38	0.640	0.0	0.00	0.00	1.00	2.0			
	TOT	63	0.37	0.617	0.0	0.00	0.00	1.00	2.0			
CHG FROM BSL	PLO	29	0.26	0.592	-0.5	0.00	0.00	0.50	2.0			
	ADA	34	0.25	0.631	-0.5	0.00	0.00	0.50	2.0			
	TOT	63	0.25	0.608	-0.5	0.00	0.00	0.50	2.0			
VH RIGHT EYE												
BSL VALUE	PLO	29	0.10	0.206	0.0	0.00	0.00	0.00	0.5			
	ADA	34	0.13	0.224	0.0	0.00	0.00	0.50	0.5			
	TOT	63	0.12	0.215	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	29	0.40	0.712	0.0	0.00	0.00	0.50	3.0			
	ADA	34	0.26	0.480	0.0	0.00	0.00	0.50	2.0			
	TOT	63	0.33	0.597	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	29	0.29	0.714	-0.5	0.00	0.00	0.50	3.0			
	ADA	34	0.13	0.449	-0.5	0.00	0.00	0.00	1.5			
	TOT	63	0.21	0.586	-0.5	0.00	0.00	0.50	3.0			
										-0.08	(-0.37, 0.20)	0.557A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.16.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	29	0.22	0.301	-0.14	0.02	0.10	0.30	1.00			
	ADA	34	0.15	0.221	-0.12	0.00	0.10	0.22	0.62			
	TOT	63	0.18	0.261	-0.14	0.00	0.10	0.30	1.00			
FINAL/ET VALUE	PLO	29	0.32	0.423	-0.18	0.00	0.22	0.48	1.30			
	ADA	34	0.24	0.342	-0.18	0.00	0.16	0.46	1.20			
	TOT	63	0.28	0.380	-0.18	0.00	0.18	0.48	1.30			
CHG FROM BSL	PLO	29	0.10	0.223	-0.22	-0.04	0.06	0.18	0.70			
	ADA	34	0.09	0.233	-0.30	-0.06	0.04	0.14	0.88			
	TOT	63	0.10	0.226	-0.30	-0.06	0.06	0.18	0.88			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	29	0.18	0.271	-0.10	-0.02	0.04	0.34	0.82			
	ADA	34	0.15	0.262	-0.18	-0.02	0.04	0.32	0.84			
	TOT	63	0.16	0.264	-0.18	-0.02	0.04	0.34	0.84			
FINAL/ET VALUE	PLO	29	0.28	0.406	-0.20	-0.02	0.18	0.52	1.30			
	ADA	34	0.20	0.359	-0.26	-0.04	0.09	0.34	1.16			
	TOT	63	0.24	0.380	-0.26	-0.02	0.12	0.36	1.30			
CHG FROM BSL	PLO	29	0.10	0.285	-0.30	-0.08	0.04	0.18	0.96			
	ADA	34	0.05	0.219	-0.32	-0.08	0.03	0.12	0.94			
	TOT	63	0.08	0.251	-0.32	-0.08	0.04	0.14	0.96			
										-0.03	(-0.13, 0.07)	0.587A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.16.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	29	3.7	12.37	-27.5	-1.3	1.2	8.0	37.3			
	ADA	34	12.4	36.53	-17.2	-1.5	2.0	6.6	165.6			
	TOT	63	8.4	28.26	-27.5	-1.5	1.8	8.0	165.6			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	29	11.5	20.39	-7.7	0.0	4.4	10.2	90.5			
	ADA	34	2.0	14.24	-20.2	-4.6	1.0	3.4	64.9			
	TOT	63	6.4	17.84	-20.2	-1.4	2.0	9.0	90.5			
										-0.6	(-9.8, 8.7)	0.902A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.17.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	20	0.15	0.235	0.0	0.00	0.00	0.50	0.5			
	ADA	22	0.14	0.228	0.0	0.00	0.00	0.50	0.5			
	TOT	42	0.14	0.229	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	20	0.58	0.963	0.0	0.00	0.00	0.50	3.0			
	ADA	22	0.95	1.204	0.0	0.00	0.25	2.00	3.0			
	TOT	42	0.77	1.100	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	20	0.43	0.878	-0.5	0.00	0.00	0.50	2.5			
	ADA	22	0.82	1.108	-0.5	0.00	0.00	2.00	3.0			
	TOT	42	0.63	1.012	-0.5	0.00	0.00	1.00	3.0			
AC RIGHT EYE												
BSL VALUE	PLO	20	0.15	0.235	0.0	0.00	0.00	0.50	0.5			
	ADA	22	0.09	0.197	0.0	0.00	0.00	0.00	0.5			
	TOT	42	0.12	0.216	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	20	0.60	0.981	0.0	0.00	0.00	1.00	3.0			
	ADA	22	0.89	1.224	0.0	0.00	0.00	2.00	3.0			
	TOT	42	0.75	1.111	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	20	0.45	0.857	-0.5	0.00	0.00	0.50	2.5			
	ADA	22	0.80	1.192	-0.5	0.00	0.00	2.00	3.0			
	TOT	42	0.63	1.048	-0.5	0.00	0.00	0.50	3.0			
										0.37	(-0.16, 0.90)	0.168A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.17.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	20	0.20	0.251	0.0	0.00	0.00	0.50	0.5			
	ADA	22	0.18	0.246	0.0	0.00	0.00	0.50	0.5			
	TOT	42	0.19	0.246	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	20	0.43	0.783	0.0	0.00	0.00	0.50	3.0			
	ADA	22	0.45	0.635	0.0	0.00	0.00	1.00	2.0			
	TOT	42	0.44	0.700	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	20	0.23	0.752	-0.5	0.00	0.00	0.00	2.5			
	ADA	22	0.27	0.592	-0.5	0.00	0.00	0.50	1.5			
	TOT	42	0.25	0.665	-0.5	0.00	0.00	0.50	2.5			
VH RIGHT EYE												
BSL VALUE	PLO	20	0.23	0.255	0.0	0.00	0.00	0.50	0.5			
	ADA	22	0.11	0.214	0.0	0.00	0.00	0.00	0.5			
	TOT	42	0.17	0.239	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	20	0.60	0.954	0.0	0.00	0.25	0.50	3.0			
	ADA	22	0.41	0.610	0.0	0.00	0.00	0.50	2.0			
	TOT	42	0.50	0.789	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	20	0.38	0.901	-0.5	0.00	0.00	0.25	2.5			
	ADA	22	0.30	0.570	-0.5	0.00	0.00	0.50	2.0			
	TOT	42	0.33	0.738	-0.5	0.00	0.00	0.50	2.5			
										-0.02	(-0.43, 0.40)	0.938A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.17.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	20	0.19	0.253	-0.12	0.00	0.13	0.46	0.70			
	ADA	22	0.20	0.279	-0.08	0.02	0.07	0.32	0.84			
	TOT	42	0.20	0.264	-0.12	0.02	0.08	0.40	0.84			
FINAL/ET VALUE	PLO	20	0.14	0.235	-0.12	-0.07	0.10	0.29	0.68			
	ADA	22	0.20	0.314	-0.08	-0.02	0.08	0.28	1.20			
	TOT	42	0.17	0.277	-0.12	-0.02	0.10	0.28	1.20			
CHG FROM BSL	PLO	20	-0.05	0.200	-0.64	-0.08	-0.02	0.05	0.20			
	ADA	22	0.00	0.141	-0.22	-0.10	-0.03	0.08	0.36			
	TOT	42	-0.03	0.171	-0.64	-0.08	-0.02	0.06	0.36			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	20	0.17	0.173	-0.04	-0.01	0.18	0.27	0.54			
	ADA	22	0.14	0.240	-0.10	0.00	0.04	0.24	0.88			
	TOT	42	0.15	0.209	-0.10	0.00	0.08	0.26	0.88			
FINAL/ET VALUE	PLO	20	0.19	0.237	-0.14	0.01	0.17	0.33	0.84			
	ADA	22	0.19	0.335	-0.16	0.00	0.04	0.32	1.10			
	TOT	42	0.19	0.289	-0.16	0.00	0.11	0.32	1.10			
CHG FROM BSL	PLO	20	0.02	0.204	-0.48	-0.07	-0.03	0.09	0.38			
	ADA	22	0.05	0.151	-0.14	-0.06	0.02	0.12	0.44			
	TOT	42	0.04	0.177	-0.48	-0.06	-0.02	0.12	0.44			
										0.04	(-0.06, 0.14)	0.403A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.17.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	20	0.6	16.69	-46.1	-2.9	-0.2	2.6	45.5			
	ADA	22	2.8	26.06	-47.1	-5.6	-1.9	1.8	95.1			
	TOT	42	1.8	21.87	-47.1	-3.8	-0.9	2.5	95.1			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	20	9.3	14.99	-10.2	0.0	2.4	17.3	49.3			
	ADA	22	16.3	66.20	-63.4	-5.1	-1.4	1.9	260.7			
	TOT	42	13.0	48.59	-63.4	-3.1	0.2	7.0	260.7			
										4.0	(-14.9, 22.8)	0.672A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.18.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
AC LEFT EYE									
BSL VALUE	PLO	7	0.07	0.189	0.0	0.00	0.00	0.00	0.5
	ADA	10	0.05	0.158	0.0	0.00	0.00	0.00	0.5
	TOT	17	0.06	0.166	0.0	0.00	0.00	0.00	0.5
FINAL/ET VALUE	PLO	7	0.86	1.435	0.0	0.00	0.50	1.00	4.0
	ADA	10	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	17	0.35	0.981	0.0	0.00	0.00	0.00	4.0
CHG FROM BSL	PLO	7	0.79	1.468	0.0	0.00	0.00	1.00	4.0
	ADA	10	-0.05	0.158	-0.5	0.00	0.00	0.00	0.0
	TOT	17	0.29	1.001	-0.5	0.00	0.00	0.00	4.0
AC RIGHT EYE									
BSL VALUE	PLO	7	0.07	0.189	0.0	0.00	0.00	0.00	0.5
	ADA	10	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	17	0.03	0.121	0.0	0.00	0.00	0.00	0.5
FINAL/ET VALUE	PLO	7	0.64	1.107	0.0	0.00	0.00	1.00	3.0
	ADA	10	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	17	0.26	0.752	0.0	0.00	0.00	0.00	3.0
CHG FROM BSL	PLO	7	0.57	0.932	0.0	0.00	0.00	1.00	2.5
	ADA	10	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	17	0.24	0.640	0.0	0.00	0.00	0.00	2.5

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.18.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
VH LEFT EYE									
BSL VALUE	PLO	7	0.14	0.244	0.0	0.00	0.00	0.50	0.5
	ADA	10	0.25	0.264	0.0	0.00	0.25	0.50	0.5
	TOT	17	0.21	0.254	0.0	0.00	0.00	0.50	0.5
FINAL/ET VALUE	PLO	7	0.93	1.397	0.0	0.00	0.50	1.00	4.0
	ADA	10	0.10	0.211	0.0	0.00	0.00	0.00	0.5
	TOT	17	0.44	0.966	0.0	0.00	0.00	0.50	4.0
CHG FROM BSL	PLO	7	0.79	1.439	0.0	0.00	0.50	0.50	4.0
	ADA	10	-0.15	0.242	-0.5	-0.50	0.00	0.00	0.0
	TOT	17	0.24	1.017	-0.5	0.00	0.00	0.00	4.0
VH RIGHT EYE									
BSL VALUE	PLO	7	0.14	0.244	0.0	0.00	0.00	0.50	0.5
	ADA	10	0.20	0.258	0.0	0.00	0.00	0.50	0.5
	TOT	17	0.18	0.246	0.0	0.00	0.00	0.50	0.5
FINAL/ET VALUE	PLO	7	0.64	0.748	0.0	0.00	0.50	1.00	2.0
	ADA	10	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	17	0.26	0.562	0.0	0.00	0.00	0.00	2.0
CHG FROM BSL	PLO	7	0.50	0.577	0.0	0.00	0.50	1.00	1.5
	ADA	10	-0.20	0.258	-0.5	-0.50	0.00	0.00	0.0
	TOT	17	0.09	0.537	-0.5	0.00	0.00	0.00	1.5

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.18.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
LOGMAR LEFT EYE									
BSL VALUE	PLO	7	0.09	0.200	-0.16	-0.10	0.08	0.24	0.42
	ADA	10	0.10	0.275	-0.12	-0.08	-0.02	0.20	0.76
	TOT	17	0.10	0.240	-0.16	-0.08	0.02	0.20	0.76
FINAL/ET VALUE	PLO	7	0.38	0.720	-0.16	-0.08	0.06	0.94	1.78
	ADA	10	0.04	0.246	-0.26	-0.12	-0.05	0.18	0.58
	TOT	17	0.18	0.507	-0.26	-0.10	-0.02	0.18	1.78
CHG FROM BSL	PLO	7	0.29	0.544	-0.10	-0.02	0.02	0.70	1.36
	ADA	10	-0.05	0.067	-0.18	-0.10	-0.04	-0.02	0.04
	TOT	17	0.09	0.378	-0.18	-0.04	-0.02	0.02	1.36
LOGMAR RIGHT EYE									
BSL VALUE	PLO	7	0.16	0.285	-0.08	-0.04	0.04	0.24	0.74
	ADA	10	0.15	0.210	-0.10	-0.04	0.11	0.42	0.44
	TOT	17	0.16	0.235	-0.10	-0.04	0.04	0.24	0.74
FINAL/ET VALUE	PLO	7	0.17	0.270	0.04	0.04	0.10	0.10	0.78
	ADA	10	0.03	0.191	-0.20	-0.14	0.00	0.20	0.36
	TOT	17	0.09	0.230	-0.20	0.00	0.04	0.10	0.78
CHG FROM BSL	PLO	7	0.01	0.116	-0.14	-0.14	0.04	0.08	0.18
	ADA	10	-0.12	0.135	-0.40	-0.16	-0.14	-0.04	0.10
	TOT	17	-0.07	0.140	-0.40	-0.14	-0.08	0.04	0.18

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.18.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
CRT LEFT EYE									
%CHG FROM BSL	PLO	7	14.7	40.27	-5.9	-3.7	-0.4	7.3	105.6
	ADA	9	1.5	8.66	-8.0	-4.6	-0.9	5.3	17.3
	TOT	16	7.3	27.11	-8.0	-4.2	-0.6	6.3	105.6
CRT RIGHT EYE									
%CHG FROM BSL	PLO	7	2.1	9.48	-17.7	0.0	4.1	9.4	10.6
	ADA	9	-0.8	12.17	-22.5	-4.8	0.4	3.0	22.2
	TOT	16	0.4	10.82	-22.5	-4.4	1.8	6.3	22.2

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.19.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	51	0.09	0.193	0.0	0.00	0.00	0.00	0.5			
	ADA	57	0.03	0.113	0.0	0.00	0.00	0.00	0.5			
	TOT	108	0.06	0.158	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	51	0.53	0.946	0.0	0.00	0.00	0.50	4.0			
	ADA	57	0.44	0.887	0.0	0.00	0.00	0.00	3.0			
	TOT	108	0.48	0.912	0.0	0.00	0.00	0.50	4.0			
CHG FROM BSL	PLO	51	0.44	0.947	-0.5	0.00	0.00	0.50	4.0			
	ADA	57	0.41	0.907	-0.5	0.00	0.00	0.00	3.0			
	TOT	108	0.43	0.922	-0.5	0.00	0.00	0.50	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	51	0.10	0.200	0.0	0.00	0.00	0.00	0.5			
	ADA	57	0.04	0.129	0.0	0.00	0.00	0.00	0.5			
	TOT	108	0.06	0.169	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	51	0.43	0.860	0.0	0.00	0.00	0.50	3.0			
	ADA	57	0.50	0.921	0.0	0.00	0.00	0.50	3.0			
	TOT	108	0.47	0.889	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	51	0.33	0.816	-0.5	0.00	0.00	0.50	3.0			
	ADA	57	0.46	0.949	-0.5	0.00	0.00	0.50	3.0			
	TOT	108	0.40	0.887	-0.5	0.00	0.00	0.50	3.0			
										0.05	(-0.24, 0.34)	0.729A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.19.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	51	0.20	0.247	0.0	0.00	0.00	0.50	0.5			
	ADA	57	0.22	0.250	0.0	0.00	0.00	0.50	0.5			
	TOT	108	0.21	0.248	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	51	0.56	0.864	0.0	0.00	0.00	0.50	4.0			
	ADA	57	0.37	0.678	0.0	0.00	0.00	0.50	3.0			
	TOT	108	0.46	0.774	0.0	0.00	0.00	0.50	4.0			
CHG FROM BSL	PLO	51	0.36	0.884	-0.5	0.00	0.00	0.50	4.0			
	ADA	57	0.15	0.675	-0.5	0.00	0.00	0.00	2.5			
	TOT	108	0.25	0.784	-0.5	0.00	0.00	0.50	4.0			
VH RIGHT EYE												
BSL VALUE	PLO	51	0.18	0.241	0.0	0.00	0.00	0.50	0.5			
	ADA	57	0.19	0.246	0.0	0.00	0.00	0.50	0.5			
	TOT	108	0.19	0.243	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	51	0.41	0.746	0.0	0.00	0.00	0.50	3.0			
	ADA	57	0.32	0.609	0.0	0.00	0.00	0.50	2.0			
	TOT	108	0.37	0.675	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	51	0.24	0.703	-0.5	0.00	0.00	0.50	2.5			
	ADA	57	0.13	0.638	-0.5	0.00	0.00	0.00	2.0			
	TOT	108	0.18	0.668	-0.5	0.00	0.00	0.00	2.5			
										-0.16	(-0.39, 0.07)	0.180A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.19.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	51	0.20	0.313	-0.18	0.00	0.12	0.34	1.24			
	ADA	57	0.15	0.246	-0.24	0.00	0.06	0.26	1.04			
	TOT	108	0.17	0.280	-0.24	0.00	0.10	0.30	1.24			
FINAL/ET VALUE	PLO	51	0.25	0.410	-0.24	-0.02	0.12	0.38	1.78			
	ADA	57	0.17	0.299	-0.26	-0.02	0.06	0.32	1.20			
	TOT	108	0.21	0.356	-0.26	-0.02	0.11	0.34	1.78			
CHG FROM BSL	PLO	51	0.04	0.258	-0.64	-0.06	0.00	0.08	1.36			
	ADA	57	0.03	0.187	-0.24	-0.06	-0.02	0.04	0.88			
	TOT	108	0.03	0.223	-0.64	-0.06	0.00	0.06	1.36			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	51	0.16	0.253	-0.16	0.00	0.04	0.30	1.00			
	ADA	57	0.13	0.171	-0.12	0.00	0.08	0.22	0.58			
	TOT	108	0.14	0.213	-0.16	0.00	0.08	0.26	1.00			
FINAL/ET VALUE	PLO	51	0.17	0.271	-0.18	-0.02	0.12	0.34	1.06			
	ADA	57	0.14	0.270	-0.20	-0.04	0.08	0.26	1.16			
	TOT	108	0.16	0.270	-0.20	-0.04	0.09	0.28	1.16			
CHG FROM BSL	PLO	51	0.01	0.152	-0.48	-0.06	0.00	0.04	0.52			
	ADA	57	0.02	0.194	-0.40	-0.10	0.00	0.06	0.94			
	TOT	108	0.01	0.175	-0.48	-0.08	0.00	0.06	0.94			
										-0.01	(-0.07, 0.06)	0.853A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.19.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	50	10.9	24.99	-19.2	-1.9	2.1	9.5	105.6			
	ADA	56	9.0	36.59	-50.9	-7.1	0.0	7.2	165.6			
	TOT	106	9.9	31.52	-50.9	-3.5	0.5	8.7	165.6			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	50	7.5	17.05	-17.7	-1.9	1.6	9.0	81.4			
	ADA	56	5.8	39.68	-27.5	-4.4	-0.5	2.9	260.7			
	TOT	106	6.6	31.00	-27.5	-3.1	0.9	6.8	260.7			
										-2.9	(-12.1, 6.4)	0.540A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.20.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	44	0.10	0.204	0.0	0.00	0.00	0.00	0.5			
	ADA	46	0.17	0.241	0.0	0.00	0.00	0.50	0.5			
	TOT	90	0.14	0.225	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	44	0.70	1.075	0.0	0.00	0.00	1.00	4.0			
	ADA	46	0.48	0.869	0.0	0.00	0.00	0.50	3.0			
	TOT	90	0.59	0.976	0.0	0.00	0.00	1.00	4.0			
CHG FROM BSL	PLO	44	0.60	0.992	-0.5	0.00	0.00	1.00	4.0			
	ADA	46	0.30	0.885	-0.5	0.00	0.00	0.00	3.0			
	TOT	90	0.45	0.945	-0.5	0.00	0.00	0.50	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	44	0.07	0.174	0.0	0.00	0.00	0.00	0.5			
	ADA	46	0.18	0.244	0.0	0.00	0.00	0.50	0.5			
	TOT	90	0.13	0.219	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	44	0.72	1.080	0.0	0.00	0.00	1.50	3.0			
	ADA	46	0.55	0.938	0.0	0.00	0.00	0.50	3.0			
	TOT	90	0.63	1.008	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	44	0.65	1.015	-0.5	0.00	0.00	1.25	3.0			
	ADA	46	0.37	0.922	-0.5	0.00	0.00	0.50	2.5			
	TOT	90	0.51	0.973	-0.5	0.00	0.00	1.00	3.0			
										-0.29	(-0.66, 0.08)	0.127A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.20.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	44	0.08	0.185	0.0	0.00	0.00	0.00	0.5			
	ADA	46	0.16	0.237	0.0	0.00	0.00	0.50	0.5			
	TOT	90	0.12	0.216	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	44	0.39	0.609	0.0	0.00	0.00	0.50	3.0			
	ADA	46	0.25	0.514	0.0	0.00	0.00	0.00	2.0			
	TOT	90	0.32	0.563	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	44	0.31	0.621	-0.5	0.00	0.00	0.50	3.0			
	ADA	46	0.09	0.475	-0.5	0.00	0.00	0.00	1.5			
	TOT	90	0.19	0.559	-0.5	0.00	0.00	0.50	3.0			
VH RIGHT EYE												
BSL VALUE	PLO	44	0.11	0.212	0.0	0.00	0.00	0.00	0.5			
	ADA	46	0.15	0.233	0.0	0.00	0.00	0.50	0.5			
	TOT	90	0.13	0.222	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	44	0.49	0.719	0.0	0.00	0.25	0.75	3.0			
	ADA	46	0.23	0.491	0.0	0.00	0.00	0.00	2.0			
	TOT	90	0.36	0.624	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	44	0.38	0.674	-0.5	0.00	0.00	0.50	2.5			
	ADA	46	0.08	0.447	-0.5	0.00	0.00	0.00	1.5			
	TOT	90	0.22	0.586	-0.5	0.00	0.00	0.50	2.5			
										-0.26	(-0.48, -0.04)	0.020A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.20.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	44	0.12	0.255	-0.26	-0.03	0.04	0.18	1.20			
	ADA	46	0.12	0.252	-0.28	-0.04	0.02	0.20	0.84			
	TOT	90	0.12	0.252	-0.28	-0.04	0.02	0.20	1.20			
FINAL/ET VALUE	PLO	44	0.19	0.342	-0.30	-0.03	0.13	0.30	1.68			
	ADA	46	0.16	0.423	-0.30	-0.10	0.02	0.24	2.08			
	TOT	90	0.18	0.383	-0.30	-0.08	0.10	0.24	2.08			
CHG FROM BSL	PLO	44	0.07	0.195	-0.46	-0.03	0.01	0.15	0.54			
	ADA	46	0.04	0.334	-0.58	-0.08	0.00	0.04	1.98			
	TOT	90	0.06	0.274	-0.58	-0.06	0.00	0.10	1.98			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	44	0.13	0.263	-0.10	-0.02	0.04	0.17	1.20			
	ADA	46	0.15	0.273	-0.24	-0.02	0.05	0.34	1.16			
	TOT	90	0.14	0.267	-0.24	-0.02	0.04	0.18	1.20			
FINAL/ET VALUE	PLO	44	0.17	0.348	-0.20	-0.03	0.10	0.24	1.62			
	ADA	46	0.13	0.344	-0.28	-0.06	0.01	0.14	1.48			
	TOT	90	0.15	0.345	-0.28	-0.04	0.06	0.24	1.62			
CHG FROM BSL	PLO	44	0.05	0.245	-0.52	-0.09	0.02	0.12	1.26			
	ADA	46	-0.02	0.156	-0.42	-0.08	-0.02	0.06	0.44			
	TOT	90	0.01	0.206	-0.52	-0.08	0.00	0.08	1.26			
										-0.05	(-0.13, 0.04)	0.276A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.20.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	41	1.7	16.87	-46.1	-3.7	0.9	7.3	73.2			
	ADA	46	-0.9	23.15	-61.7	-5.7	-1.2	2.0	117.7			
	TOT	87	0.3	20.36	-61.7	-4.9	-0.4	3.4	117.7			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	43	7.4	30.84	-40.4	-3.0	0.4	9.4	132.9			
	ADA	45	-2.4	21.49	-63.4	-7.0	-3.2	0.8	64.9			
	TOT	88	2.4	26.78	-63.4	-5.8	-0.2	4.9	132.9			
										-7.4	(-17.1, 2.3)	0.132A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.21.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	31	0.13	0.222	0.0	0.00	0.00	0.50	0.5			
	ADA	28	0.18	0.244	0.0	0.00	0.00	0.50	0.5			
	TOT	59	0.15	0.232	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	31	1.02	1.099	0.0	0.00	0.50	2.00	3.0			
	ADA	28	0.98	1.294	0.0	0.00	0.50	2.00	4.0			
	TOT	59	1.00	1.185	0.0	0.00	0.50	2.00	4.0			
CHG FROM BSL	PLO	31	0.89	1.086	-0.5	0.00	0.50	2.00	3.0			
	ADA	28	0.80	1.264	-0.5	0.00	0.00	2.00	4.0			
	TOT	59	0.85	1.164	-0.5	0.00	0.00	2.00	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	31	0.15	0.231	0.0	0.00	0.00	0.50	0.5			
	ADA	28	0.16	0.238	0.0	0.00	0.00	0.50	0.5			
	TOT	59	0.15	0.232	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	31	1.11	1.174	0.0	0.00	0.50	2.00	3.0			
	ADA	28	0.68	1.029	0.0	0.00	0.00	0.75	3.0			
	TOT	59	0.91	1.120	0.0	0.00	0.50	2.00	3.0			
CHG FROM BSL	PLO	31	0.97	1.118	-0.5	0.00	0.50	2.00	3.0			
	ADA	28	0.52	1.023	-0.5	0.00	0.00	0.50	3.0			
	TOT	59	0.75	1.088	-0.5	0.00	0.00	2.00	3.0			
										-0.27	(-0.78, 0.25)	0.305A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.21.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	31	0.16	0.238	0.0	0.00	0.00	0.50	0.5			
	ADA	28	0.13	0.220	0.0	0.00	0.00	0.25	0.5			
	TOT	59	0.14	0.228	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	31	0.55	0.746	0.0	0.00	0.00	1.00	3.0			
	ADA	28	0.50	0.667	0.0	0.00	0.00	1.00	2.0			
	TOT	59	0.53	0.704	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	31	0.39	0.692	-0.5	0.00	0.00	0.50	2.5			
	ADA	28	0.38	0.661	-0.5	0.00	0.00	0.75	2.0			
	TOT	59	0.38	0.672	-0.5	0.00	0.00	0.50	2.5			
VH RIGHT EYE												
BSL VALUE	PLO	31	0.19	0.248	0.0	0.00	0.00	0.50	0.5			
	ADA	28	0.11	0.209	0.0	0.00	0.00	0.00	0.5			
	TOT	59	0.15	0.232	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	31	0.73	0.874	0.0	0.00	0.50	1.00	3.0			
	ADA	28	0.57	0.766	0.0	0.00	0.25	1.00	3.0			
	TOT	59	0.65	0.821	0.0	0.00	0.50	1.00	3.0			
CHG FROM BSL	PLO	31	0.53	0.826	0.0	0.00	0.00	0.50	3.0			
	ADA	28	0.46	0.679	-0.5	0.00	0.25	0.75	2.5			
	TOT	59	0.50	0.754	-0.5	0.00	0.00	0.50	3.0			
										-0.04	(-0.34, 0.26)	0.792A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.21.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	31	0.18	0.246	-0.18	0.00	0.14	0.28	0.72			
	ADA	28	0.21	0.284	-0.16	-0.02	0.14	0.40	0.96			
	TOT	59	0.20	0.263	-0.18	0.00	0.14	0.32	0.96			
FINAL/ET VALUE	PLO	31	0.29	0.384	-0.20	0.00	0.16	0.48	1.30			
	ADA	28	0.17	0.264	-0.16	-0.03	0.11	0.29	0.90			
	TOT	59	0.23	0.335	-0.20	-0.02	0.14	0.42	1.30			
CHG FROM BSL	PLO	31	0.11	0.226	-0.20	-0.02	0.02	0.16	0.70			
	ADA	28	-0.04	0.130	-0.30	-0.10	-0.04	0.03	0.20			
	TOT	59	0.04	0.199	-0.30	-0.06	0.02	0.10	0.70			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	31	0.21	0.262	-0.08	-0.02	0.16	0.36	0.74			
	ADA	28	0.10	0.248	-0.18	-0.04	0.00	0.19	0.88			
	TOT	59	0.16	0.260	-0.18	-0.02	0.04	0.32	0.88			
FINAL/ET VALUE	PLO	31	0.30	0.386	-0.18	0.02	0.20	0.42	1.30			
	ADA	28	0.12	0.285	-0.26	-0.07	0.04	0.24	1.10			
	TOT	59	0.21	0.351	-0.26	0.00	0.10	0.30	1.30			
CHG FROM BSL	PLO	31	0.09	0.258	-0.22	-0.06	0.04	0.18	0.96			
	ADA	28	0.01	0.137	-0.32	-0.08	0.01	0.10	0.36			
	TOT	59	0.05	0.211	-0.32	-0.08	0.02	0.12	0.96			
										-0.11	(-0.19, -0.03)	0.008A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.21.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	31	4.9	10.44	-15.1	-1.3	1.4	8.9	37.3			
	ADA	28	7.4	23.57	-24.5	-3.6	0.4	8.3	95.1			
	TOT	59	6.1	17.79	-24.5	-2.0	0.9	8.9	95.1			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	31	17.2	44.79	-18.1	0.0	3.1	13.9	232.5			
	ADA	28	10.1	34.60	-20.1	-3.4	0.7	4.9	140.9			
	TOT	59	13.8	40.09	-20.1	-0.5	2.0	9.0	232.5			
										-0.8	(-13.4, 11.8)	0.898A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.22.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	88	0.13	0.218	0.0	0.00	0.00	0.25	0.5			
	ADA	84	0.12	0.214	0.0	0.00	0.00	0.00	0.5			
	TOT	172	0.12	0.215	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	88	0.83	1.132	0.0	0.00	0.25	1.00	4.0			
	ADA	84	0.71	1.101	0.0	0.00	0.00	1.00	4.0			
	TOT	172	0.77	1.115	0.0	0.00	0.00	1.00	4.0			
CHG FROM BSL	PLO	88	0.70	1.090	-0.5	0.00	0.00	1.00	4.0			
	ADA	84	0.60	1.080	-0.5	0.00	0.00	1.00	4.0			
	TOT	172	0.65	1.083	-0.5	0.00	0.00	1.00	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	88	0.11	0.207	0.0	0.00	0.00	0.00	0.5			
	ADA	84	0.13	0.221	0.0	0.00	0.00	0.50	0.5			
	TOT	172	0.12	0.214	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	88	0.79	1.131	0.0	0.00	0.00	2.00	3.0			
	ADA	84	0.53	0.890	0.0	0.00	0.00	0.50	3.0			
	TOT	172	0.66	1.026	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	88	0.68	1.075	-0.5	0.00	0.00	1.75	3.0			
	ADA	84	0.40	0.874	-0.5	0.00	0.00	0.50	3.0			
	TOT	172	0.54	0.989	-0.5	0.00	0.00	1.00	3.0			
										-0.20	(-0.48, 0.08)	0.169A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.22.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	88	0.11	0.211	0.0	0.00	0.00	0.00	0.5			
	ADA	84	0.15	0.233	0.0	0.00	0.00	0.50	0.5			
	TOT	172	0.13	0.222	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	88	0.53	0.789	0.0	0.00	0.00	1.00	4.0			
	ADA	84	0.39	0.642	0.0	0.00	0.00	0.75	2.0			
	TOT	172	0.46	0.722	0.0	0.00	0.00	1.00	4.0			
CHG FROM BSL	PLO	88	0.41	0.785	-0.5	0.00	0.00	0.50	4.0			
	ADA	84	0.23	0.618	-0.5	0.00	0.00	0.50	2.0			
	TOT	172	0.33	0.712	-0.5	0.00	0.00	0.50	4.0			
VH RIGHT EYE												
BSL VALUE	PLO	88	0.14	0.227	0.0	0.00	0.00	0.50	0.5			
	ADA	84	0.15	0.230	0.0	0.00	0.00	0.50	0.5			
	TOT	172	0.15	0.228	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	88	0.56	0.826	0.0	0.00	0.00	1.00	3.0			
	ADA	84	0.35	0.625	0.0	0.00	0.00	0.50	3.0			
	TOT	172	0.46	0.740	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	88	0.42	0.769	-0.5	0.00	0.00	0.50	3.0			
	ADA	84	0.20	0.581	-0.5	0.00	0.00	0.50	2.5			
	TOT	172	0.31	0.691	-0.5	0.00	0.00	0.50	3.0			
										-0.20	(-0.38, -0.02)	0.026A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.22.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	88	0.16	0.268	-0.26	-0.02	0.10	0.25	1.20			
	ADA	84	0.12	0.240	-0.28	-0.04	0.02	0.22	0.96			
	TOT	172	0.14	0.255	-0.28	-0.02	0.08	0.23	1.20			
FINAL/ET VALUE	PLO	88	0.26	0.392	-0.30	-0.01	0.15	0.40	1.78			
	ADA	84	0.16	0.374	-0.30	-0.08	0.05	0.25	2.08			
	TOT	172	0.21	0.385	-0.30	-0.05	0.11	0.35	2.08			
CHG FROM BSL	PLO	88	0.10	0.249	-0.46	-0.04	0.03	0.16	1.36			
	ADA	84	0.05	0.279	-0.28	-0.08	0.00	0.05	1.98			
	TOT	172	0.07	0.264	-0.46	-0.06	0.01	0.10	1.98			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	88	0.16	0.257	-0.10	-0.02	0.04	0.24	1.20			
	ADA	84	0.09	0.186	-0.24	-0.02	0.04	0.19	0.88			
	TOT	172	0.13	0.227	-0.24	-0.02	0.04	0.21	1.20			
FINAL/ET VALUE	PLO	88	0.22	0.352	-0.20	0.00	0.12	0.30	1.62			
	ADA	84	0.09	0.264	-0.28	-0.06	0.02	0.20	1.16			
	TOT	172	0.16	0.318	-0.28	-0.04	0.06	0.26	1.62			
CHG FROM BSL	PLO	88	0.06	0.236	-0.52	-0.06	0.04	0.12	1.26			
	ADA	84	0.00	0.167	-0.40	-0.08	-0.02	0.06	0.94			
	TOT	172	0.03	0.207	-0.52	-0.08	0.00	0.10	1.26			
										-0.06	(-0.11, 0.00)	0.043A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.22.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	85	7.4	19.72	-46.1	-1.4	2.5	9.5	105.6			
	ADA	84	5.5	27.66	-47.1	-5.7	-0.4	6.2	165.6			
	TOT	169	6.5	23.95	-47.1	-3.4	1.1	8.6	165.6			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	87	11.1	34.61	-40.4	-1.2	2.6	9.8	232.5			
	ADA	83	0.8	23.28	-63.4	-5.1	-1.1	2.0	140.9			
	TOT	170	6.1	29.98	-63.4	-3.6	0.5	6.0	232.5			
										-6.4	(-12.9, 0.0)	0.051A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.23.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	38	0.05	0.156	0.0	0.00	0.00	0.00	0.5			
	ADA	47	0.10	0.199	0.0	0.00	0.00	0.00	0.5			
	TOT	85	0.08	0.181	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	38	0.43	0.728	0.0	0.00	0.00	0.50	3.0			
	ADA	47	0.31	0.719	0.0	0.00	0.00	0.00	3.0			
	TOT	85	0.36	0.721	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	38	0.38	0.739	-0.5	0.00	0.00	0.50	3.0			
	ADA	47	0.21	0.778	-0.5	0.00	0.00	0.00	3.0			
	TOT	85	0.29	0.761	-0.5	0.00	0.00	0.00	3.0			
AC RIGHT EYE												
BSL VALUE	PLO	38	0.08	0.185	0.0	0.00	0.00	0.00	0.5			
	ADA	47	0.09	0.190	0.0	0.00	0.00	0.00	0.5			
	TOT	85	0.08	0.187	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	38	0.49	0.801	0.0	0.00	0.00	0.50	3.0			
	ADA	47	0.61	1.047	0.0	0.00	0.00	1.00	3.0			
	TOT	85	0.55	0.942	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	38	0.41	0.743	0.0	0.00	0.00	0.50	2.5			
	ADA	47	0.52	1.078	-0.5	0.00	0.00	1.00	3.0			
	TOT	85	0.47	0.940	-0.5	0.00	0.00	0.50	3.0			
										-0.03	(-0.35, 0.29)	0.863A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.23.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	38	0.22	0.252	0.0	0.00	0.00	0.50	0.5			
	ADA	47	0.22	0.251	0.0	0.00	0.00	0.50	0.5			
	TOT	85	0.22	0.250	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	38	0.42	0.663	0.0	0.00	0.00	0.50	3.0			
	ADA	47	0.30	0.596	0.0	0.00	0.00	0.50	3.0			
	TOT	85	0.35	0.626	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	38	0.20	0.642	-0.5	0.00	0.00	0.00	2.5			
	ADA	47	0.07	0.599	-0.5	-0.50	0.00	0.00	2.5			
	TOT	85	0.13	0.618	-0.5	0.00	0.00	0.00	2.5			
VH RIGHT EYE												
BSL VALUE	PLO	38	0.20	0.248	0.0	0.00	0.00	0.50	0.5			
	ADA	47	0.18	0.243	0.0	0.00	0.00	0.50	0.5			
	TOT	85	0.19	0.244	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	38	0.41	0.635	0.0	0.00	0.00	0.50	3.0			
	ADA	47	0.33	0.610	0.0	0.00	0.00	0.50	2.0			
	TOT	85	0.36	0.619	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	38	0.21	0.611	-0.5	0.00	0.00	0.50	2.5			
	ADA	47	0.15	0.642	-0.5	0.00	0.00	0.00	2.0			
	TOT	85	0.18	0.625	-0.5	0.00	0.00	0.50	2.5			
										-0.09	(-0.33, 0.15)	0.445A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.23.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	38	0.18	0.305	-0.18	0.00	0.11	0.20	1.24			
	ADA	47	0.21	0.277	-0.10	-0.02	0.10	0.40	1.04			
	TOT	85	0.19	0.288	-0.18	0.00	0.10	0.32	1.24			
FINAL/ET VALUE	PLO	38	0.18	0.348	-0.24	-0.04	0.12	0.20	1.30			
	ADA	47	0.18	0.270	-0.16	-0.02	0.06	0.32	0.84			
	TOT	85	0.18	0.305	-0.24	-0.02	0.12	0.28	1.30			
CHG FROM BSL	PLO	38	0.01	0.164	-0.64	-0.04	0.00	0.06	0.38			
	ADA	47	-0.03	0.140	-0.58	-0.08	-0.04	0.02	0.32			
	TOT	85	-0.02	0.152	-0.64	-0.06	-0.02	0.04	0.38			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	38	0.18	0.266	-0.16	0.00	0.10	0.32	1.00			
	ADA	47	0.20	0.276	-0.12	0.00	0.12	0.36	1.16			
	TOT	85	0.19	0.270	-0.16	0.00	0.10	0.34	1.16			
FINAL/ET VALUE	PLO	38	0.16	0.279	-0.20	-0.06	0.11	0.34	1.06			
	ADA	47	0.21	0.343	-0.20	0.00	0.10	0.30	1.48			
	TOT	85	0.19	0.315	-0.20	-0.02	0.10	0.34	1.48			
CHG FROM BSL	PLO	38	-0.02	0.151	-0.48	-0.10	-0.02	0.04	0.38			
	ADA	47	0.02	0.175	-0.42	-0.08	0.02	0.10	0.52			
	TOT	85	0.00	0.165	-0.48	-0.08	0.00	0.06	0.52			
										0.00	(-0.06, 0.05)	0.882A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.23.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	37	3.7	19.85	-27.5	-4.1	0.0	4.3	69.7			
	ADA	46	4.6	33.95	-61.7	-4.3	-0.2	3.0	136.9			
	TOT	83	4.2	28.38	-61.7	-4.3	0.0	3.4	136.9			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	37	7.0	19.10	-17.7	-3.1	1.4	7.4	81.4			
	ADA	46	9.4	46.11	-59.3	-4.6	0.0	4.5	260.7			
	TOT	83	8.3	36.45	-59.3	-3.9	0.8	6.8	260.7			
										1.1	(-10.6, 12.9)	0.846A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.24.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	94	0.11	0.206	0.0	0.00	0.00	0.00	0.5			
	ADA	103	0.12	0.215	0.0	0.00	0.00	0.00	0.5			
	TOT	197	0.11	0.210	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	94	0.62	0.999	0.0	0.00	0.00	1.00	4.0			
	ADA	103	0.54	0.964	0.0	0.00	0.00	0.50	4.0			
	TOT	197	0.58	0.979	0.0	0.00	0.00	1.00	4.0			
CHG FROM BSL	PLO	94	0.52	0.966	-0.5	0.00	0.00	0.50	4.0			
	ADA	103	0.42	0.973	-0.5	0.00	0.00	0.50	4.0			
	TOT	197	0.46	0.968	-0.5	0.00	0.00	0.50	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	94	0.11	0.206	0.0	0.00	0.00	0.00	0.5			
	ADA	103	0.13	0.218	0.0	0.00	0.00	0.50	0.5			
	TOT	197	0.12	0.212	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	94	0.63	1.029	0.0	0.00	0.00	1.00	3.0			
	ADA	103	0.62	0.996	0.0	0.00	0.00	1.00	3.0			
	TOT	197	0.62	1.009	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	94	0.52	0.973	-0.5	0.00	0.00	0.50	3.0			
	ADA	103	0.49	1.007	-0.5	0.00	0.00	0.50	3.0			
	TOT	197	0.51	0.988	-0.5	0.00	0.00	0.50	3.0			
										-0.06	(-0.31, 0.18)	0.602A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.24.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	94	0.13	0.222	0.0	0.00	0.00	0.50	0.5			
	ADA	103	0.17	0.240	0.0	0.00	0.00	0.50	0.5			
	TOT	197	0.15	0.232	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	94	0.45	0.733	0.0	0.00	0.00	0.50	4.0			
	ADA	103	0.32	0.559	0.0	0.00	0.00	0.50	2.0			
	TOT	197	0.38	0.650	0.0	0.00	0.00	0.50	4.0			
CHG FROM BSL	PLO	94	0.32	0.758	-0.5	0.00	0.00	0.50	4.0			
	ADA	103	0.15	0.558	-0.5	0.00	0.00	0.00	2.0			
	TOT	197	0.23	0.665	-0.5	0.00	0.00	0.50	4.0			
VH RIGHT EYE												
BSL VALUE	PLO	94	0.15	0.230	0.0	0.00	0.00	0.50	0.5			
	ADA	103	0.16	0.233	0.0	0.00	0.00	0.50	0.5			
	TOT	197	0.15	0.231	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	94	0.48	0.765	0.0	0.00	0.00	0.50	3.0			
	ADA	103	0.32	0.582	0.0	0.00	0.00	0.50	3.0			
	TOT	197	0.39	0.679	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	94	0.33	0.739	-0.5	0.00	0.00	0.50	3.0			
	ADA	103	0.16	0.543	-0.5	0.00	0.00	0.00	2.5			
	TOT	197	0.24	0.648	-0.5	0.00	0.00	0.50	3.0			
										-0.17	(-0.33, -0.01)	0.033A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.24.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	94	0.13	0.240	-0.26	-0.02	0.09	0.22	1.00			
	ADA	103	0.15	0.266	-0.24	-0.04	0.06	0.22	1.04			
	TOT	197	0.14	0.253	-0.26	-0.02	0.06	0.22	1.04			
FINAL/ET VALUE	PLO	94	0.19	0.333	-0.30	-0.04	0.12	0.32	1.78			
	ADA	103	0.18	0.362	-0.26	-0.06	0.06	0.28	2.08			
	TOT	197	0.18	0.348	-0.30	-0.06	0.10	0.28	2.08			
CHG FROM BSL	PLO	94	0.06	0.227	-0.64	-0.04	0.02	0.12	1.36			
	ADA	103	0.03	0.262	-0.58	-0.08	-0.02	0.04	1.98			
	TOT	197	0.04	0.246	-0.64	-0.06	0.00	0.08	1.98			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	94	0.12	0.215	-0.16	-0.02	0.02	0.20	0.90			
	ADA	103	0.14	0.234	-0.18	0.00	0.06	0.26	1.16			
	TOT	197	0.13	0.225	-0.18	-0.02	0.04	0.22	1.16			
FINAL/ET VALUE	PLO	94	0.15	0.286	-0.20	-0.02	0.10	0.24	1.30			
	ADA	103	0.15	0.318	-0.26	-0.06	0.02	0.28	1.48			
	TOT	197	0.15	0.302	-0.26	-0.04	0.04	0.26	1.48			
CHG FROM BSL	PLO	94	0.03	0.202	-0.52	-0.06	0.00	0.10	0.96			
	ADA	103	0.00	0.183	-0.42	-0.10	-0.02	0.06	0.94			
	TOT	197	0.02	0.192	-0.52	-0.08	0.00	0.08	0.96			
										-0.03	(-0.08, 0.02)	0.220A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.24.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	91	7.6	22.04	-46.1	-2.0	1.4	9.0	105.6			
	ADA	102	3.5	27.65	-61.7	-4.6	-0.4	3.4	165.6			
	TOT	193	5.4	25.19	-61.7	-3.5	0.4	6.0	165.6			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	92	10.5	33.93	-40.4	-1.8	1.0	9.1	232.5			
	ADA	101	4.3	35.20	-63.4	-4.8	-0.7	2.1	260.7			
	TOT	193	7.3	34.65	-63.4	-3.6	0.4	5.7	260.7			
										-5.5	(-12.2, 1.3)	0.115A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.25.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	29	0.09	0.192	0.0	0.00	0.00	0.00	0.5			
	ADA	22	0.05	0.147	0.0	0.00	0.00	0.00	0.5			
	TOT	51	0.07	0.174	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	29	0.91	1.150	0.0	0.00	0.50	1.00	4.0			
	ADA	22	0.73	1.120	0.0	0.00	0.00	2.00	3.0			
	TOT	51	0.83	1.130	0.0	0.00	0.00	2.00	4.0			
CHG FROM BSL	PLO	29	0.83	1.088	0.0	0.00	0.50	1.00	4.0			
	ADA	22	0.68	1.030	0.0	0.00	0.00	2.00	2.5			
	TOT	51	0.76	1.055	0.0	0.00	0.00	2.00	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	29	0.07	0.175	0.0	0.00	0.00	0.00	0.5			
	ADA	22	0.05	0.147	0.0	0.00	0.00	0.00	0.5			
	TOT	51	0.06	0.163	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	29	0.91	1.119	0.0	0.00	0.50	2.00	3.0			
	ADA	22	0.39	0.786	0.0	0.00	0.00	0.50	3.0			
	TOT	51	0.69	1.015	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	29	0.84	1.036	0.0	0.00	0.50	2.00	3.0			
	ADA	22	0.34	0.730	-0.5	0.00	0.00	0.50	2.5			
	TOT	51	0.63	0.943	-0.5	0.00	0.00	1.00	3.0			
										-0.32	(-0.83, 0.18)	0.203A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.25.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	29	0.17	0.242	0.0	0.00	0.00	0.50	0.5			
	ADA	22	0.23	0.255	0.0	0.00	0.00	0.50	0.5			
	TOT	51	0.20	0.247	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	29	0.64	0.833	0.0	0.00	0.50	1.00	3.0			
	ADA	22	0.57	0.890	0.0	0.00	0.00	1.00	3.0			
	TOT	51	0.61	0.850	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	29	0.47	0.755	-0.5	0.00	0.00	0.50	2.5			
	ADA	22	0.34	0.851	-0.5	0.00	0.00	0.50	2.5			
	TOT	51	0.41	0.792	-0.5	0.00	0.00	0.50	2.5			
VH RIGHT EYE												
BSL VALUE	PLO	29	0.17	0.242	0.0	0.00	0.00	0.50	0.5			
	ADA	22	0.20	0.252	0.0	0.00	0.00	0.50	0.5			
	TOT	51	0.19	0.244	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	29	0.62	0.831	0.0	0.00	0.50	1.00	3.0			
	ADA	22	0.48	0.732	0.0	0.00	0.00	1.00	2.0			
	TOT	51	0.56	0.785	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	29	0.45	0.736	-0.5	0.00	0.00	0.50	2.5			
	ADA	22	0.27	0.783	-0.5	0.00	0.00	0.50	2.0			
	TOT	51	0.37	0.754	-0.5	0.00	0.00	0.50	2.5			
										-0.15	(-0.51, 0.21)	0.410A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.25.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	29	0.27	0.363	-0.16	0.00	0.16	0.52	1.24			
	ADA	22	0.17	0.210	-0.16	0.00	0.10	0.32	0.58			
	TOT	51	0.23	0.308	-0.16	0.00	0.14	0.40	1.24			
FINAL/ET VALUE	PLO	29	0.36	0.458	-0.16	0.06	0.22	0.60	1.68			
	ADA	22	0.17	0.235	-0.16	0.00	0.13	0.32	0.66			
	TOT	51	0.28	0.386	-0.16	0.00	0.20	0.42	1.68			
CHG FROM BSL	PLO	29	0.09	0.217	-0.20	-0.02	0.02	0.18	0.70			
	ADA	22	0.00	0.112	-0.24	-0.08	0.01	0.06	0.32			
	TOT	51	0.05	0.183	-0.24	-0.06	0.02	0.10	0.70			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	29	0.30	0.337	-0.10	0.04	0.18	0.46	1.20			
	ADA	22	0.10	0.175	-0.14	-0.02	0.05	0.20	0.58			
	TOT	51	0.21	0.295	-0.14	0.00	0.10	0.36	1.20			
FINAL/ET VALUE	PLO	29	0.37	0.423	-0.10	0.04	0.30	0.52	1.62			
	ADA	22	0.12	0.214	-0.14	0.00	0.09	0.14	0.78			
	TOT	51	0.26	0.368	-0.14	0.02	0.12	0.40	1.62			
CHG FROM BSL	PLO	29	0.07	0.265	-0.30	-0.02	0.02	0.10	1.26			
	ADA	22	0.02	0.095	-0.16	-0.04	0.04	0.10	0.20			
	TOT	51	0.05	0.209	-0.30	-0.04	0.02	0.10	1.26			
										-0.07	(-0.16, 0.03)	0.160A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.25.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	28	2.7	9.60	-11.2	-1.2	0.9	6.1	37.3			
	ADA	22	16.3	40.17	-25.8	-7.5	1.4	26.5	136.9			
	TOT	50	8.7	28.08	-25.8	-4.1	0.9	11.1	136.9			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	29	8.0	20.34	-30.4	-1.2	3.2	10.6	77.4			
	ADA	22	3.0	29.10	-27.5	-4.6	-0.9	4.4	127.1			
	TOT	51	5.9	24.36	-30.4	-3.9	1.9	7.4	127.1			
										3.2	(-9.4, 15.8)	0.613A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.26.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
AC LEFT EYE									
BSL VALUE	PLO	3	0.17	0.289	0.0	0.00	0.00	0.50	0.5
	ADA	6	0.17	0.258	0.0	0.00	0.00	0.50	0.5
	TOT	9	0.17	0.250	0.0	0.00	0.00	0.50	0.5
FINAL/ET VALUE	PLO	3	1.50	0.866	0.5	0.50	2.00	2.00	2.0
	ADA	6	0.50	1.225	0.0	0.00	0.00	0.00	3.0
	TOT	9	0.83	1.173	0.0	0.00	0.00	2.00	3.0
CHG FROM BSL	PLO	3	1.33	1.155	0.0	0.00	2.00	2.00	2.0
	ADA	6	0.33	1.329	-0.5	-0.50	0.00	0.00	3.0
	TOT	9	0.67	1.299	-0.5	0.00	0.00	2.00	3.0
AC RIGHT EYE									
BSL VALUE	PLO	3	0.17	0.289	0.0	0.00	0.00	0.50	0.5
	ADA	6	0.17	0.258	0.0	0.00	0.00	0.50	0.5
	TOT	9	0.17	0.250	0.0	0.00	0.00	0.50	0.5
FINAL/ET VALUE	PLO	3	0.83	1.041	0.0	0.00	0.50	2.00	2.0
	ADA	6	0.17	0.258	0.0	0.00	0.00	0.50	0.5
	TOT	9	0.39	0.651	0.0	0.00	0.00	0.50	2.0
CHG FROM BSL	PLO	3	0.67	1.155	0.0	0.00	0.00	2.00	2.0
	ADA	6	0.00	0.447	-0.5	-0.50	0.00	0.50	0.5
	TOT	9	0.22	0.755	-0.5	0.00	0.00	0.50	2.0

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.26.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
VH LEFT EYE									
BSL VALUE	PLO	3	0.33	0.289	0.0	0.00	0.50	0.50	0.5
	ADA	6	0.08	0.204	0.0	0.00	0.00	0.00	0.5
	TOT	9	0.17	0.250	0.0	0.00	0.00	0.50	0.5
FINAL/ET VALUE	PLO	3	0.50	0.500	0.0	0.00	0.50	1.00	1.0
	ADA	6	0.17	0.408	0.0	0.00	0.00	0.00	1.0
	TOT	9	0.28	0.441	0.0	0.00	0.00	0.50	1.0
CHG FROM BSL	PLO	3	0.17	0.289	0.0	0.00	0.00	0.50	0.5
	ADA	6	0.08	0.492	-0.5	0.00	0.00	0.00	1.0
	TOT	9	0.11	0.417	-0.5	0.00	0.00	0.00	1.0
VH RIGHT EYE									
BSL VALUE	PLO	3	0.33	0.289	0.0	0.00	0.50	0.50	0.5
	ADA	6	0.08	0.204	0.0	0.00	0.00	0.00	0.5
	TOT	9	0.17	0.250	0.0	0.00	0.00	0.50	0.5
FINAL/ET VALUE	PLO	3	0.67	0.577	0.0	0.00	1.00	1.00	1.0
	ADA	6	0.33	0.816	0.0	0.00	0.00	0.00	2.0
	TOT	9	0.44	0.726	0.0	0.00	0.00	1.00	2.0
CHG FROM BSL	PLO	3	0.33	0.289	0.0	0.00	0.50	0.50	0.5
	ADA	6	0.25	0.880	-0.5	0.00	0.00	0.00	2.0
	TOT	9	0.28	0.712	-0.5	0.00	0.00	0.50	2.0

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.26.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
LOGMAR LEFT EYE									
BSL VALUE	PLO	3	0.33	0.242	0.14	0.14	0.24	0.60	0.60
	ADA	6	0.11	0.292	-0.28	-0.08	0.11	0.22	0.56
	TOT	9	0.18	0.283	-0.28	0.00	0.22	0.24	0.60
FINAL/ET VALUE	PLO	3	0.53	0.665	0.12	0.12	0.18	1.30	1.30
	ADA	6	0.00	0.223	-0.30	-0.18	0.01	0.22	0.26
	TOT	9	0.18	0.460	-0.30	-0.06	0.12	0.22	1.30
CHG FROM BSL	PLO	3	0.21	0.435	-0.12	-0.12	0.04	0.70	0.70
	ADA	6	-0.10	0.191	-0.30	-0.28	-0.12	-0.02	0.22
	TOT	9	0.00	0.307	-0.30	-0.14	-0.10	0.04	0.70
LOGMAR RIGHT EYE									
BSL VALUE	PLO	3	0.26	0.242	0.04	0.04	0.22	0.52	0.52
	ADA	6	0.04	0.279	-0.24	-0.14	-0.03	0.16	0.54
	TOT	9	0.12	0.274	-0.24	-0.08	0.04	0.22	0.54
FINAL/ET VALUE	PLO	3	0.19	0.110	0.08	0.08	0.18	0.30	0.30
	ADA	6	-0.01	0.206	-0.28	-0.14	-0.01	0.18	0.22
	TOT	9	0.06	0.197	-0.28	-0.14	0.12	0.18	0.30
CHG FROM BSL	PLO	3	-0.07	0.133	-0.22	-0.22	-0.04	0.04	0.04
	ADA	6	-0.05	0.155	-0.32	-0.06	-0.04	0.00	0.16
	TOT	9	-0.06	0.140	-0.32	-0.06	-0.04	0.00	0.16

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.26.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
CRT LEFT EYE									
%CHG FROM BSL	PLO	3	-0.9	12.39	-15.1	-15.1	4.2	8.0	8.0
	ADA	6	-6.2	9.94	-24.5	-9.1	-3.9	0.9	2.9
	TOT	9	-4.5	10.35	-24.5	-9.1	-2.0	2.9	8.0
CRT RIGHT EYE									
%CHG FROM BSL	PLO	3	7.7	7.55	-0.7	-0.7	9.8	13.9	13.9
	ADA	6	-0.9	8.89	-13.0	-7.0	0.2	1.0	13.4
	TOT	9	2.0	9.04	-13.0	-0.7	0.4	9.8	13.9

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.27.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	17	0.06	0.166	0.0	0.00	0.00	0.00	0.5			
	ADA	26	0.13	0.226	0.0	0.00	0.00	0.50	0.5			
	TOT	43	0.10	0.206	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	17	0.68	1.158	0.0	0.00	0.00	1.00	4.0			
	ADA	26	0.58	1.055	0.0	0.00	0.00	0.50	3.0			
	TOT	43	0.62	1.085	0.0	0.00	0.00	1.00	4.0			
CHG FROM BSL	PLO	17	0.62	1.097	0.0	0.00	0.00	1.00	4.0			
	ADA	26	0.44	0.993	-0.5	0.00	0.00	0.50	3.0			
	TOT	43	0.51	1.026	-0.5	0.00	0.00	1.00	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	17	0.06	0.166	0.0	0.00	0.00	0.00	0.5			
	ADA	26	0.10	0.201	0.0	0.00	0.00	0.00	0.5			
	TOT	43	0.08	0.187	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	17	0.68	1.103	0.0	0.00	0.00	1.00	3.0			
	ADA	26	0.38	0.779	0.0	0.00	0.00	0.50	3.0			
	TOT	43	0.50	0.919	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	17	0.62	1.068	0.0	0.00	0.00	0.50	3.0			
	ADA	26	0.29	0.777	-0.5	0.00	0.00	0.50	2.5			
	TOT	43	0.42	0.906	-0.5	0.00	0.00	0.50	3.0			
										-0.25	(-0.80, 0.29)	0.355A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.27.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	17	0.06	0.166	0.0	0.00	0.00	0.00	0.5			
	ADA	26	0.23	0.254	0.0	0.00	0.00	0.50	0.5			
	TOT	43	0.16	0.237	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	17	0.32	0.393	0.0	0.00	0.00	0.50	1.0			
	ADA	26	0.52	0.608	0.0	0.00	0.50	1.00	2.0			
	TOT	43	0.44	0.537	0.0	0.00	0.50	1.00	2.0			
CHG FROM BSL	PLO	17	0.26	0.400	0.0	0.00	0.00	0.50	1.0			
	ADA	26	0.29	0.651	-0.5	0.00	0.00	0.50	2.0			
	TOT	43	0.28	0.560	-0.5	0.00	0.00	0.50	2.0			
VH RIGHT EYE												
BSL VALUE	PLO	17	0.09	0.196	0.0	0.00	0.00	0.00	0.5			
	ADA	26	0.19	0.248	0.0	0.00	0.00	0.50	0.5			
	TOT	43	0.15	0.232	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	17	0.47	0.760	0.0	0.00	0.00	0.50	3.0			
	ADA	26	0.67	0.860	0.0	0.00	0.50	1.00	3.0			
	TOT	43	0.59	0.818	0.0	0.00	0.50	1.00	3.0			
CHG FROM BSL	PLO	17	0.38	0.697	-0.5	0.00	0.00	0.50	2.5			
	ADA	26	0.48	0.866	-0.5	0.00	0.00	1.00	2.5			
	TOT	43	0.44	0.796	-0.5	0.00	0.00	1.00	2.5			
										0.06	(-0.29, 0.41)	0.726A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.27.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	17	0.25	0.324	-0.12	0.06	0.16	0.34	1.20			
	ADA	26	0.28	0.256	-0.24	0.08	0.24	0.42	0.82			
	TOT	43	0.27	0.282	-0.24	0.08	0.22	0.42	1.20			
FINAL/ET VALUE	PLO	17	0.40	0.420	-0.12	0.18	0.32	0.52	1.68			
	ADA	26	0.27	0.246	-0.24	0.12	0.23	0.40	0.84			
	TOT	43	0.32	0.329	-0.24	0.12	0.26	0.44	1.68			
CHG FROM BSL	PLO	17	0.15	0.268	-0.46	0.04	0.12	0.30	0.70			
	ADA	26	-0.01	0.178	-0.58	-0.08	0.00	0.08	0.32			
	TOT	43	0.05	0.230	-0.58	-0.06	0.04	0.12	0.70			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	17	0.21	0.222	0.02	0.04	0.18	0.30	0.90			
	ADA	26	0.24	0.285	-0.06	0.04	0.13	0.34	1.16			
	TOT	43	0.23	0.260	-0.06	0.04	0.18	0.34	1.16			
FINAL/ET VALUE	PLO	17	0.31	0.393	0.02	0.10	0.18	0.34	1.62			
	ADA	26	0.27	0.380	-0.16	0.00	0.20	0.38	1.48			
	TOT	43	0.29	0.381	-0.16	0.04	0.18	0.38	1.62			
CHG FROM BSL	PLO	17	0.09	0.316	-0.16	0.00	0.04	0.10	1.26			
	ADA	26	0.04	0.164	-0.42	-0.04	0.05	0.12	0.36			
	TOT	43	0.06	0.234	-0.42	-0.04	0.04	0.12	1.26			
										-0.11	(-0.23, 0.01)	0.068A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.27.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	16	10.8	27.27	-46.1	-1.3	4.9	24.6	69.7			
	ADA	26	13.0	47.98	-61.7	-8.9	1.6	19.8	136.9			
	TOT	42	12.2	40.95	-61.7	-2.4	2.0	24.0	136.9			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	17	9.7	29.71	-40.4	-6.7	0.0	28.7	77.4			
	ADA	26	11.0	47.87	-63.4	-13.7	1.2	18.7	140.9			
	TOT	43	10.5	41.24	-63.4	-11.6	0.5	19.8	140.9			
										4.3	(-20.6, 29.3)	0.728A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.28.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	105	0.11	0.211	0.0	0.00	0.00	0.00	0.5			
	ADA	102	0.11	0.207	0.0	0.00	0.00	0.00	0.5			
	TOT	207	0.11	0.208	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	105	0.72	1.031	0.0	0.00	0.00	1.00	4.0			
	ADA	102	0.58	0.998	0.0	0.00	0.00	1.00	4.0			
	TOT	207	0.65	1.015	0.0	0.00	0.00	1.00	4.0			
CHG FROM BSL	PLO	105	0.61	1.000	-0.5	0.00	0.00	1.00	4.0			
	ADA	102	0.48	1.013	-0.5	0.00	0.00	1.00	4.0			
	TOT	207	0.54	1.006	-0.5	0.00	0.00	1.00	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	105	0.11	0.208	0.0	0.00	0.00	0.00	0.5			
	ADA	102	0.12	0.216	0.0	0.00	0.00	0.00	0.5			
	TOT	207	0.12	0.212	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	105	0.71	1.051	0.0	0.00	0.00	1.00	3.0			
	ADA	102	0.62	0.990	0.0	0.00	0.00	1.00	3.0			
	TOT	207	0.66	1.020	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	105	0.60	0.989	-0.5	0.00	0.00	1.00	3.0			
	ADA	102	0.50	0.999	-0.5	0.00	0.00	1.00	3.0			
	TOT	207	0.55	0.993	-0.5	0.00	0.00	1.00	3.0			
										-0.12	(-0.36, 0.12)	0.332A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.28.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	105	0.17	0.237	0.0	0.00	0.00	0.50	0.5			
	ADA	102	0.17	0.237	0.0	0.00	0.00	0.50	0.5			
	TOT	207	0.17	0.236	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	105	0.52	0.790	0.0	0.00	0.00	1.00	4.0			
	ADA	102	0.32	0.632	0.0	0.00	0.00	0.50	3.0			
	TOT	207	0.42	0.722	0.0	0.00	0.00	0.50	4.0			
CHG FROM BSL	PLO	105	0.35	0.787	-0.5	0.00	0.00	0.50	4.0			
	ADA	102	0.15	0.613	-0.5	0.00	0.00	0.00	2.5			
	TOT	207	0.25	0.712	-0.5	0.00	0.00	0.50	4.0			
VH RIGHT EYE												
BSL VALUE	PLO	105	0.18	0.240	0.0	0.00	0.00	0.50	0.5			
	ADA	102	0.15	0.231	0.0	0.00	0.00	0.50	0.5			
	TOT	207	0.16	0.235	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	105	0.53	0.790	0.0	0.00	0.00	1.00	3.0			
	ADA	102	0.26	0.520	0.0	0.00	0.00	0.50	2.0			
	TOT	207	0.40	0.682	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	105	0.35	0.747	-0.5	0.00	0.00	0.50	3.0			
	ADA	102	0.11	0.502	-0.5	0.00	0.00	0.00	2.0			
	TOT	207	0.23	0.648	-0.5	0.00	0.00	0.50	3.0			
										-0.22	(-0.38, -0.06)	0.007A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.28.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	105	0.15	0.268	-0.26	-0.02	0.10	0.24	1.24			
	ADA	102	0.11	0.242	-0.28	-0.04	0.02	0.20	1.04			
	TOT	207	0.13	0.256	-0.28	-0.04	0.06	0.22	1.24			
FINAL/ET VALUE	PLO	105	0.20	0.365	-0.30	-0.04	0.12	0.32	1.78			
	ADA	102	0.14	0.357	-0.30	-0.08	0.01	0.24	2.08			
	TOT	207	0.17	0.362	-0.30	-0.06	0.08	0.28	2.08			
CHG FROM BSL	PLO	105	0.06	0.222	-0.64	-0.04	0.00	0.10	1.36			
	ADA	102	0.03	0.257	-0.30	-0.08	-0.02	0.04	1.98			
	TOT	207	0.04	0.240	-0.64	-0.06	0.00	0.06	1.98			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	105	0.16	0.267	-0.16	-0.02	0.04	0.26	1.20			
	ADA	102	0.10	0.204	-0.24	-0.04	0.04	0.18	0.88			
	TOT	207	0.13	0.239	-0.24	-0.02	0.04	0.22	1.20			
FINAL/ET VALUE	PLO	105	0.19	0.321	-0.20	-0.02	0.10	0.32	1.30			
	ADA	102	0.10	0.270	-0.28	-0.06	0.03	0.20	1.16			
	TOT	207	0.15	0.300	-0.28	-0.04	0.06	0.26	1.30			
CHG FROM BSL	PLO	105	0.03	0.200	-0.52	-0.06	0.00	0.08	0.96			
	ADA	102	0.00	0.168	-0.40	-0.08	-0.02	0.06	0.94			
	TOT	207	0.02	0.185	-0.52	-0.08	0.00	0.08	0.96			
										-0.03	(-0.08, 0.02)	0.201A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.28.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	104	5.9	18.32	-19.2	-2.0	1.1	8.0	105.6			
	ADA	102	3.3	23.50	-28.4	-5.6	-0.5	3.4	165.6			
	TOT	206	4.6	21.03	-28.4	-3.6	0.0	5.3	165.6			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	104	8.6	29.08	-30.4	-1.4	1.6	8.9	232.5			
	ADA	102	2.1	28.72	-25.7	-4.6	-0.9	2.0	260.7			
	TOT	206	5.4	29.02	-30.4	-3.2	0.5	5.2	260.7			
										-4.5	(-9.7, 0.7)	0.086A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.29.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	53	0.10	0.205	0.0	0.00	0.00	0.00	0.5			
	ADA	56	0.10	0.200	0.0	0.00	0.00	0.00	0.5			
	TOT	109	0.10	0.202	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	53	0.57	0.904	0.0	0.00	0.00	1.00	4.0			
	ADA	56	0.30	0.665	0.0	0.00	0.00	0.25	3.0			
	TOT	109	0.43	0.798	0.0	0.00	0.00	0.50	4.0			
CHG FROM BSL	PLO	53	0.46	0.882	-0.5	0.00	0.00	0.50	4.0			
	ADA	56	0.21	0.718	-0.5	0.00	0.00	0.00	3.0			
	TOT	109	0.33	0.809	-0.5	0.00	0.00	0.50	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	53	0.11	0.211	0.0	0.00	0.00	0.00	0.5			
	ADA	56	0.12	0.213	0.0	0.00	0.00	0.00	0.5			
	TOT	109	0.11	0.211	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	53	0.42	0.775	0.0	0.00	0.00	0.50	3.0			
	ADA	56	0.41	0.874	0.0	0.00	0.00	0.50	3.0			
	TOT	109	0.42	0.824	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	53	0.31	0.722	-0.5	0.00	0.00	0.50	2.5			
	ADA	56	0.29	0.878	-0.5	0.00	0.00	0.00	3.0			
	TOT	109	0.30	0.802	-0.5	0.00	0.00	0.00	3.0			
										-0.14	(-0.40, 0.12)	0.299A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.29.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	53	0.17	0.239	0.0	0.00	0.00	0.50	0.5			
	ADA	56	0.16	0.236	0.0	0.00	0.00	0.50	0.5			
	TOT	109	0.17	0.236	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	53	0.43	0.727	0.0	0.00	0.00	0.50	4.0			
	ADA	56	0.20	0.454	0.0	0.00	0.00	0.00	2.0			
	TOT	109	0.31	0.612	0.0	0.00	0.00	0.50	4.0			
CHG FROM BSL	PLO	53	0.26	0.744	-0.5	0.00	0.00	0.50	4.0			
	ADA	56	0.04	0.512	-0.5	0.00	0.00	0.00	2.0			
	TOT	109	0.15	0.643	-0.5	0.00	0.00	0.00	4.0			
VH RIGHT EYE												
BSL VALUE	PLO	53	0.16	0.236	0.0	0.00	0.00	0.50	0.5			
	ADA	56	0.16	0.236	0.0	0.00	0.00	0.50	0.5			
	TOT	109	0.16	0.235	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	53	0.30	0.442	0.0	0.00	0.00	0.50	2.0			
	ADA	56	0.28	0.563	0.0	0.00	0.00	0.50	2.0			
	TOT	109	0.29	0.506	0.0	0.00	0.00	0.50	2.0			
CHG FROM BSL	PLO	53	0.14	0.464	-0.5	0.00	0.00	0.00	2.0			
	ADA	56	0.12	0.603	-0.5	0.00	0.00	0.00	2.0			
	TOT	109	0.13	0.537	-0.5	0.00	0.00	0.00	2.0			
										-0.13	(-0.32, 0.06)	0.187A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.29.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	53	0.16	0.261	-0.26	-0.02	0.10	0.24	1.00			
	ADA	56	0.14	0.265	-0.16	-0.04	0.05	0.24	1.04			
	TOT	109	0.15	0.262	-0.26	-0.04	0.08	0.24	1.04			
FINAL/ET VALUE	PLO	53	0.25	0.431	-0.30	-0.04	0.12	0.36	1.78			
	ADA	56	0.12	0.248	-0.16	-0.08	0.03	0.24	0.84			
	TOT	109	0.18	0.354	-0.30	-0.06	0.08	0.26	1.78			
CHG FROM BSL	PLO	53	0.10	0.279	-0.22	-0.06	0.00	0.10	1.36			
	ADA	56	-0.02	0.136	-0.58	-0.08	-0.02	0.03	0.32			
	TOT	109	0.03	0.225	-0.58	-0.06	-0.02	0.04	1.36			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	53	0.17	0.269	-0.16	-0.02	0.04	0.26	1.00			
	ADA	56	0.13	0.206	-0.14	-0.02	0.06	0.26	0.84			
	TOT	109	0.15	0.238	-0.16	-0.02	0.06	0.26	1.00			
FINAL/ET VALUE	PLO	53	0.15	0.258	-0.18	-0.06	0.10	0.24	1.06			
	ADA	56	0.10	0.221	-0.20	-0.03	0.03	0.22	1.06			
	TOT	109	0.12	0.240	-0.20	-0.04	0.06	0.22	1.06			
CHG FROM BSL	PLO	53	-0.03	0.145	-0.52	-0.12	-0.02	0.04	0.36			
	ADA	56	-0.03	0.131	-0.42	-0.10	-0.03	0.07	0.24			
	TOT	109	-0.03	0.137	-0.52	-0.10	-0.02	0.04	0.36			
										-0.06	(-0.11, -0.01)	0.024A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.29.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	52	8.7	22.87	-19.2	-2.1	0.7	8.6	105.6			
	ADA	55	2.9	30.44	-61.7	-7.5	-0.9	3.0	136.9			
	TOT	107	5.7	27.06	-61.7	-4.3	-0.3	7.6	136.9			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	52	2.6	16.78	-40.4	-3.0	0.2	4.7	81.4			
	ADA	55	0.4	19.89	-59.3	-4.8	0.0	3.4	93.1			
	TOT	107	1.5	18.39	-59.3	-4.3	0.0	4.4	93.1			
										-4.0	(-11.3, 3.4)	0.290A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.30.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	73	0.10	0.203	0.0	0.00	0.00	0.00	0.5			
	ADA	75	0.12	0.215	0.0	0.00	0.00	0.00	0.5			
	TOT	148	0.11	0.209	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	73	0.82	1.123	0.0	0.00	0.00	1.00	4.0			
	ADA	75	0.77	1.152	0.0	0.00	0.00	2.00	4.0			
	TOT	148	0.79	1.134	0.0	0.00	0.00	2.00	4.0			
CHG FROM BSL	PLO	73	0.71	1.080	-0.5	0.00	0.00	1.00	4.0			
	ADA	75	0.65	1.129	-0.5	0.00	0.00	1.50	4.0			
	TOT	148	0.68	1.102	-0.5	0.00	0.00	1.50	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	73	0.09	0.193	0.0	0.00	0.00	0.00	0.5			
	ADA	75	0.11	0.211	0.0	0.00	0.00	0.00	0.5			
	TOT	148	0.10	0.202	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	73	0.90	1.175	0.0	0.00	0.00	2.00	3.0			
	ADA	75	0.67	0.988	0.0	0.00	0.00	1.00	3.0			
	TOT	148	0.78	1.087	0.0	0.00	0.00	2.00	3.0			
CHG FROM BSL	PLO	73	0.81	1.108	-0.5	0.00	0.00	2.00	3.0			
	ADA	75	0.55	0.992	-0.5	0.00	0.00	1.00	3.0			
	TOT	148	0.68	1.055	-0.5	0.00	0.00	2.00	3.0			
										-0.16	(-0.47, 0.15)	0.315A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.30.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	73	0.13	0.221	0.0	0.00	0.00	0.50	0.5			
	ADA	75	0.19	0.245	0.0	0.00	0.00	0.50	0.5			
	TOT	148	0.16	0.235	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	73	0.54	0.772	0.0	0.00	0.00	1.00	3.0			
	ADA	75	0.47	0.707	0.0	0.00	0.00	1.00	3.0			
	TOT	148	0.51	0.738	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	73	0.41	0.752	-0.5	0.00	0.00	0.50	3.0			
	ADA	75	0.28	0.664	-0.5	0.00	0.00	0.50	2.5			
	TOT	148	0.34	0.709	-0.5	0.00	0.00	0.50	3.0			
VH RIGHT EYE												
BSL VALUE	PLO	73	0.16	0.234	0.0	0.00	0.00	0.50	0.5			
	ADA	75	0.16	0.235	0.0	0.00	0.00	0.50	0.5			
	TOT	148	0.16	0.234	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	73	0.67	0.917	0.0	0.00	0.50	1.00	3.0			
	ADA	75	0.39	0.654	0.0	0.00	0.00	0.50	3.0			
	TOT	148	0.53	0.804	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	73	0.51	0.842	-0.5	0.00	0.00	0.50	3.0			
	ADA	75	0.23	0.600	-0.5	0.00	0.00	0.50	2.5			
	TOT	148	0.37	0.740	-0.5	0.00	0.00	0.50	3.0			
										-0.21	(-0.41, -0.01)	0.044A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.30.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	73	0.17	0.292	-0.18	0.00	0.10	0.28	1.24			
	ADA	75	0.15	0.253	-0.28	0.00	0.10	0.26	0.96			
	TOT	148	0.16	0.272	-0.28	0.00	0.10	0.27	1.24			
FINAL/ET VALUE	PLO	73	0.22	0.340	-0.24	0.00	0.16	0.36	1.68			
	ADA	75	0.20	0.391	-0.30	-0.02	0.10	0.32	2.08			
	TOT	148	0.21	0.366	-0.30	-0.01	0.12	0.35	2.08			
CHG FROM BSL	PLO	73	0.05	0.185	-0.64	-0.02	0.02	0.14	0.54			
	ADA	75	0.05	0.293	-0.30	-0.08	0.00	0.08	1.98			
	TOT	148	0.05	0.245	-0.64	-0.06	0.00	0.10	1.98			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	73	0.16	0.254	-0.16	0.00	0.06	0.26	1.20			
	ADA	75	0.13	0.243	-0.24	-0.02	0.04	0.22	1.16			
	TOT	148	0.14	0.248	-0.24	0.00	0.06	0.24	1.20			
FINAL/ET VALUE	PLO	73	0.24	0.372	-0.20	0.00	0.14	0.34	1.62			
	ADA	75	0.16	0.345	-0.28	-0.06	0.04	0.28	1.48			
	TOT	148	0.20	0.360	-0.28	-0.03	0.09	0.32	1.62			
CHG FROM BSL	PLO	73	0.09	0.246	-0.48	-0.04	0.04	0.14	1.26			
	ADA	75	0.03	0.190	-0.40	-0.06	0.00	0.08	0.94			
	TOT	148	0.06	0.221	-0.48	-0.06	0.02	0.11	1.26			
										-0.03	(-0.09, 0.03)	0.337A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.30.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	70	4.5	17.02	-46.1	-1.9	1.6	8.9	73.2			
	ADA	75	6.9	29.61	-47.1	-3.6	0.0	5.3	165.6			
	TOT	145	5.7	24.31	-47.1	-2.7	1.1	6.4	165.6			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	72	15.1	37.07	-30.4	-0.5	4.0	15.1	232.5			
	ADA	74	6.5	40.50	-63.4	-4.8	-0.4	2.8	260.7			
	TOT	146	10.7	38.95	-63.4	-3.1	1.0	8.6	260.7			
										-3.9	(-12.2, 4.4)	0.355A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.31.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	24	0.06	0.169	0.0	0.00	0.00	0.00	0.5			
	ADA	23	0.11	0.211	0.0	0.00	0.00	0.00	0.5			
	TOT	47	0.09	0.190	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	24	0.94	1.262	0.0	0.00	0.25	2.00	4.0			
	ADA	23	1.02	1.301	0.0	0.00	0.00	2.00	4.0			
	TOT	47	0.98	1.268	0.0	0.00	0.00	2.00	4.0			
CHG FROM BSL	PLO	24	0.88	1.245	0.0	0.00	0.00	2.00	4.0			
	ADA	23	0.91	1.303	-0.5	0.00	0.00	2.00	4.0			
	TOT	47	0.89	1.259	-0.5	0.00	0.00	2.00	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	24	0.06	0.169	0.0	0.00	0.00	0.00	0.5			
	ADA	23	0.09	0.194	0.0	0.00	0.00	0.00	0.5			
	TOT	47	0.07	0.180	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	24	0.79	1.206	0.0	0.00	0.00	2.00	3.0			
	ADA	23	0.65	0.959	0.0	0.00	0.00	1.00	3.0			
	TOT	47	0.72	1.083	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	24	0.73	1.142	0.0	0.00	0.00	2.00	3.0			
	ADA	23	0.57	0.969	-0.5	0.00	0.00	1.00	3.0			
	TOT	47	0.65	1.053	-0.5	0.00	0.00	1.00	3.0			
										-0.06	(-0.65, 0.53)	0.831A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.31.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	24	0.10	0.207	0.0	0.00	0.00	0.00	0.5			
	ADA	23	0.11	0.211	0.0	0.00	0.00	0.00	0.5			
	TOT	47	0.11	0.207	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	24	0.71	0.977	0.0	0.00	0.50	1.00	4.0			
	ADA	23	0.33	0.614	0.0	0.00	0.00	0.50	2.0			
	TOT	47	0.52	0.834	0.0	0.00	0.00	1.00	4.0			
CHG FROM BSL	PLO	24	0.60	1.000	-0.5	0.00	0.25	0.75	4.0			
	ADA	23	0.22	0.618	-0.5	0.00	0.00	0.50	2.0			
	TOT	47	0.41	0.849	-0.5	0.00	0.00	0.50	4.0			
VH RIGHT EYE												
BSL VALUE	PLO	24	0.13	0.221	0.0	0.00	0.00	0.25	0.5			
	ADA	23	0.09	0.194	0.0	0.00	0.00	0.00	0.5			
	TOT	47	0.11	0.207	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	24	0.56	0.812	0.0	0.00	0.00	1.00	3.0			
	ADA	23	0.22	0.496	0.0	0.00	0.00	0.00	2.0			
	TOT	47	0.39	0.691	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	24	0.44	0.696	0.0	0.00	0.00	0.50	2.5			
	ADA	23	0.13	0.527	-0.5	0.00	0.00	0.00	2.0			
	TOT	47	0.29	0.632	-0.5	0.00	0.00	0.50	2.5			
										-0.35	(-0.69, -0.01)	0.045A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.31.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	24	0.30	0.320	-0.18	0.11	0.22	0.56	1.24			
	ADA	23	0.20	0.286	-0.24	0.02	0.10	0.52	0.82			
	TOT	47	0.25	0.305	-0.24	0.06	0.16	0.52	1.24			
FINAL/ET VALUE	PLO	24	0.48	0.514	-0.20	0.12	0.33	0.77	1.78			
	ADA	23	0.22	0.370	-0.24	-0.02	0.12	0.46	1.20			
	TOT	47	0.35	0.463	-0.24	0.00	0.24	0.62	1.78			
CHG FROM BSL	PLO	24	0.17	0.354	-0.16	-0.01	0.04	0.24	1.36			
	ADA	23	0.02	0.301	-0.58	-0.10	0.00	0.08	0.88			
	TOT	47	0.10	0.335	-0.58	-0.06	0.00	0.18	1.36			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	24	0.21	0.265	-0.10	0.02	0.10	0.42	0.74			
	ADA	23	0.07	0.198	-0.18	-0.04	0.00	0.14	0.58			
	TOT	47	0.14	0.243	-0.18	0.00	0.04	0.22	0.74			
FINAL/ET VALUE	PLO	24	0.26	0.287	-0.10	0.01	0.25	0.41	0.84			
	ADA	23	0.10	0.309	-0.26	-0.08	0.04	0.12	1.16			
	TOT	47	0.18	0.305	-0.26	-0.02	0.08	0.30	1.16			
CHG FROM BSL	PLO	24	0.05	0.160	-0.22	-0.03	0.00	0.12	0.52			
	ADA	23	0.04	0.254	-0.42	-0.08	0.00	0.12	0.94			
	TOT	47	0.04	0.209	-0.42	-0.06	0.00	0.12	0.94			
										-0.08	(-0.22, 0.05)	0.228A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.31.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	23	8.2	24.50	-15.4	-3.5	0.9	9.5	105.6			
	ADA	23	11.4	46.67	-61.7	-5.9	2.8	9.6	165.6			
	TOT	46	9.8	36.89	-61.7	-5.6	1.9	9.5	165.6			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	23	4.4	9.48	-13.9	-0.5	2.9	8.6	31.9			
	ADA	23	4.7	34.02	-59.3	-4.6	0.4	2.0	127.1			
	TOT	46	4.5	24.69	-59.3	-3.0	0.9	5.7	127.1			
										2.3	(-14.4, 19.1)	0.780A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.32.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	102	0.11	0.210	0.0	0.00	0.00	0.00	0.5			
	ADA	108	0.11	0.209	0.0	0.00	0.00	0.00	0.5			
	TOT	210	0.11	0.209	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	102	0.66	0.980	0.0	0.00	0.00	1.00	4.0			
	ADA	108	0.47	0.899	0.0	0.00	0.00	0.50	3.0			
	TOT	210	0.56	0.941	0.0	0.00	0.00	1.00	4.0			
CHG FROM BSL	PLO	102	0.54	0.936	-0.5	0.00	0.00	1.00	4.0			
	ADA	108	0.36	0.896	-0.5	0.00	0.00	0.00	3.0			
	TOT	210	0.45	0.918	-0.5	0.00	0.00	0.50	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	102	0.11	0.207	0.0	0.00	0.00	0.00	0.5			
	ADA	108	0.12	0.215	0.0	0.00	0.00	0.00	0.5			
	TOT	210	0.11	0.210	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	102	0.68	1.014	0.0	0.00	0.00	1.00	3.0			
	ADA	108	0.54	0.946	0.0	0.00	0.00	0.50	3.0			
	TOT	210	0.60	0.980	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	102	0.57	0.957	-0.5	0.00	0.00	1.00	3.0			
	ADA	108	0.42	0.948	-0.5	0.00	0.00	0.50	3.0			
	TOT	210	0.49	0.953	-0.5	0.00	0.00	0.50	3.0			
										-0.17	(-0.40, 0.06)	0.149A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.32.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	102	0.16	0.233	0.0	0.00	0.00	0.50	0.5			
	ADA	108	0.19	0.245	0.0	0.00	0.00	0.50	0.5			
	TOT	210	0.18	0.239	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	102	0.45	0.685	0.0	0.00	0.00	0.50	3.0			
	ADA	108	0.36	0.630	0.0	0.00	0.00	0.50	3.0			
	TOT	210	0.40	0.657	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	102	0.29	0.669	-0.5	0.00	0.00	0.50	3.0			
	ADA	108	0.17	0.615	-0.5	0.00	0.00	0.50	2.5			
	TOT	210	0.23	0.643	-0.5	0.00	0.00	0.50	3.0			
VH RIGHT EYE												
BSL VALUE	PLO	102	0.17	0.237	0.0	0.00	0.00	0.50	0.5			
	ADA	108	0.18	0.240	0.0	0.00	0.00	0.50	0.5			
	TOT	210	0.17	0.238	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	102	0.50	0.769	0.0	0.00	0.00	0.50	3.0			
	ADA	108	0.37	0.639	0.0	0.00	0.00	0.50	3.0			
	TOT	210	0.44	0.707	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	102	0.34	0.738	-0.5	0.00	0.00	0.50	3.0			
	ADA	108	0.19	0.618	-0.5	0.00	0.00	0.50	2.5			
	TOT	210	0.26	0.682	-0.5	0.00	0.00	0.50	3.0			
										-0.13	(-0.29, 0.02)	0.096A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.32.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	102	0.14	0.259	-0.26	-0.02	0.06	0.22	1.20			
	ADA	108	0.14	0.250	-0.28	-0.03	0.06	0.22	1.04			
	TOT	210	0.14	0.254	-0.28	-0.02	0.06	0.22	1.20			
FINAL/ET VALUE	PLO	102	0.18	0.318	-0.30	-0.04	0.12	0.32	1.68			
	ADA	108	0.16	0.333	-0.30	-0.07	0.06	0.25	2.08			
	TOT	210	0.17	0.325	-0.30	-0.06	0.10	0.28	2.08			
CHG FROM BSL	PLO	102	0.04	0.183	-0.64	-0.04	0.01	0.12	0.54			
	ADA	108	0.02	0.228	-0.24	-0.08	-0.02	0.04	1.98			
	TOT	210	0.03	0.207	-0.64	-0.06	0.00	0.08	1.98			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	102	0.15	0.258	-0.16	-0.02	0.05	0.24	1.20			
	ADA	108	0.14	0.231	-0.24	-0.01	0.07	0.26	1.16			
	TOT	210	0.15	0.244	-0.24	-0.02	0.06	0.26	1.20			
FINAL/ET VALUE	PLO	102	0.19	0.341	-0.20	-0.02	0.11	0.26	1.62			
	ADA	108	0.14	0.298	-0.28	-0.04	0.04	0.27	1.48			
	TOT	210	0.17	0.320	-0.28	-0.04	0.08	0.26	1.62			
CHG FROM BSL	PLO	102	0.04	0.228	-0.52	-0.06	0.02	0.08	1.26			
	ADA	108	0.00	0.146	-0.40	-0.09	-0.02	0.06	0.52			
	TOT	210	0.02	0.191	-0.52	-0.08	0.00	0.06	1.26			
										-0.03	(-0.08, 0.01)	0.117A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.32.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	99	5.8	18.60	-46.1	-2.0	1.2	8.9	73.2			
	ADA	107	3.8	25.03	-50.9	-4.9	-0.5	3.4	136.9			
	TOT	206	4.8	22.14	-50.9	-3.5	0.0	5.8	136.9			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	101	11.1	33.73	-40.4	-1.7	1.4	10.2	232.5			
	ADA	106	3.7	33.35	-63.4	-4.8	-1.0	3.0	260.7			
	TOT	207	7.3	33.66	-63.4	-3.9	0.4	6.8	260.7			
										-5.3	(-11.3, 0.8)	0.086A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.33.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	42	0.17	0.239	0.0	0.00	0.00	0.50	0.5			
	ADA	32	0.17	0.241	0.0	0.00	0.00	0.50	0.5			
	TOT	74	0.17	0.238	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	42	0.99	1.171	0.0	0.00	0.50	1.00	4.0			
	ADA	32	1.05	1.297	0.0	0.00	0.00	2.00	4.0			
	TOT	74	1.01	1.219	0.0	0.00	0.50	2.00	4.0			
CHG FROM BSL	PLO	42	0.82	1.120	-0.5	0.00	0.50	1.00	4.0			
	ADA	32	0.88	1.295	-0.5	0.00	0.00	2.00	4.0			
	TOT	74	0.84	1.191	-0.5	0.00	0.25	1.50	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	42	0.13	0.223	0.0	0.00	0.00	0.50	0.5			
	ADA	32	0.17	0.241	0.0	0.00	0.00	0.50	0.5			
	TOT	74	0.15	0.230	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	42	1.06	1.211	0.0	0.00	0.50	2.00	3.0			
	ADA	32	1.14	1.226	0.0	0.00	0.75	2.00	3.0			
	TOT	74	1.09	1.210	0.0	0.00	0.50	2.00	3.0			
CHG FROM BSL	PLO	42	0.93	1.124	-0.5	0.00	0.50	2.00	3.0			
	ADA	32	0.97	1.250	-0.5	0.00	0.50	2.00	3.0			
	TOT	74	0.95	1.172	-0.5	0.00	0.50	2.00	3.0			
										0.05	(-0.45, 0.55)	0.852A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.33.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	42	0.08	0.189	0.0	0.00	0.00	0.00	0.5			
	ADA	32	0.13	0.220	0.0	0.00	0.00	0.25	0.5			
	TOT	74	0.10	0.202	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	42	0.48	0.732	0.0	0.00	0.00	0.50	3.0			
	ADA	32	0.52	0.746	0.0	0.00	0.00	1.00	2.0			
	TOT	74	0.49	0.733	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	42	0.39	0.703	0.0	0.00	0.00	0.50	2.5			
	ADA	32	0.39	0.693	-0.5	0.00	0.00	1.00	2.0			
	TOT	74	0.39	0.694	-0.5	0.00	0.00	0.50	2.5			
VH RIGHT EYE												
BSL VALUE	PLO	42	0.14	0.229	0.0	0.00	0.00	0.50	0.5			
	ADA	32	0.13	0.220	0.0	0.00	0.00	0.25	0.5			
	TOT	74	0.14	0.224	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	42	0.75	0.989	0.0	0.00	0.50	1.00	3.0			
	ADA	32	0.47	0.634	0.0	0.00	0.00	1.00	2.0			
	TOT	74	0.63	0.860	0.0	0.00	0.25	1.00	3.0			
CHG FROM BSL	PLO	42	0.61	0.914	-0.5	0.00	0.00	1.00	3.0			
	ADA	32	0.34	0.560	-0.5	0.00	0.00	0.50	2.0			
	TOT	74	0.49	0.787	-0.5	0.00	0.00	1.00	3.0			
										-0.13	(-0.44, 0.17)	0.384A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.33.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	42	0.24	0.322	-0.14	-0.02	0.16	0.48	1.20			
	ADA	32	0.21	0.286	-0.12	0.01	0.10	0.36	1.04			
	TOT	74	0.23	0.305	-0.14	0.00	0.13	0.40	1.20			
FINAL/ET VALUE	PLO	42	0.30	0.367	-0.18	0.10	0.19	0.52	1.68			
	ADA	32	0.25	0.342	-0.18	0.00	0.13	0.47	1.20			
	TOT	74	0.28	0.355	-0.18	0.04	0.18	0.50	1.68			
CHG FROM BSL	PLO	42	0.06	0.155	-0.20	-0.02	0.03	0.16	0.48			
	ADA	32	0.04	0.176	-0.20	-0.07	-0.03	0.10	0.50			
	TOT	74	0.05	0.164	-0.20	-0.04	0.02	0.16	0.50			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	42	0.25	0.296	-0.10	0.02	0.19	0.40	1.20			
	ADA	32	0.19	0.266	-0.18	-0.01	0.14	0.38	0.88			
	TOT	74	0.23	0.283	-0.18	0.00	0.18	0.40	1.20			
FINAL/ET VALUE	PLO	42	0.36	0.403	-0.20	0.10	0.25	0.42	1.62			
	ADA	32	0.23	0.355	-0.26	-0.01	0.13	0.34	1.10			
	TOT	74	0.30	0.386	-0.26	0.04	0.21	0.40	1.62			
CHG FROM BSL	PLO	42	0.11	0.300	-0.52	-0.04	0.04	0.18	1.26			
	ADA	32	0.03	0.182	-0.40	-0.08	0.03	0.11	0.52			
	TOT	74	0.07	0.257	-0.52	-0.06	0.04	0.12	1.26			
										-0.05	(-0.13, 0.03)	0.240A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.33.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	40	6.4	16.89	-19.4	-0.6	1.1	9.1	73.2			
	ADA	32	8.2	30.95	-47.1	-5.7	0.5	7.3	117.7			
	TOT	72	7.2	24.00	-47.1	-3.3	1.1	8.4	117.7			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	42	15.7	31.63	-30.4	0.0	4.9	16.8	132.9			
	ADA	32	10.3	51.73	-63.4	-4.9	-0.8	4.1	260.7			
	TOT	74	13.4	41.30	-63.4	-2.8	1.9	9.6	260.7			
										-2.5	(-15.8, 10.9)	0.715A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.34.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	84	0.07	0.176	0.0	0.00	0.00	0.00	0.5			
	ADA	99	0.09	0.194	0.0	0.00	0.00	0.00	0.5			
	TOT	183	0.08	0.186	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	84	0.57	0.945	0.0	0.00	0.00	1.00	4.0			
	ADA	99	0.41	0.830	0.0	0.00	0.00	0.50	3.0			
	TOT	183	0.49	0.886	0.0	0.00	0.00	0.50	4.0			
CHG FROM BSL	PLO	84	0.50	0.931	-0.5	0.00	0.00	0.75	4.0			
	ADA	99	0.32	0.843	-0.5	0.00	0.00	0.00	3.0			
	TOT	183	0.40	0.887	-0.5	0.00	0.00	0.50	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	84	0.08	0.187	0.0	0.00	0.00	0.00	0.5			
	ADA	99	0.10	0.198	0.0	0.00	0.00	0.00	0.5			
	TOT	183	0.09	0.193	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	84	0.52	0.913	0.0	0.00	0.00	0.50	3.0			
	ADA	99	0.37	0.751	0.0	0.00	0.00	0.50	3.0			
	TOT	183	0.44	0.830	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	84	0.43	0.881	-0.5	0.00	0.00	0.50	3.0			
	ADA	99	0.27	0.764	-0.5	0.00	0.00	0.00	3.0			
	TOT	183	0.35	0.821	-0.5	0.00	0.00	0.50	3.0			
										-0.17	(-0.39, 0.05)	0.125A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.34.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	84	0.18	0.241	0.0	0.00	0.00	0.50	0.5			
	ADA	99	0.20	0.246	0.0	0.00	0.00	0.50	0.5			
	TOT	183	0.19	0.243	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	84	0.51	0.766	0.0	0.00	0.00	1.00	4.0			
	ADA	99	0.30	0.575	0.0	0.00	0.00	0.50	3.0			
	TOT	183	0.40	0.675	0.0	0.00	0.00	0.50	4.0			
CHG FROM BSL	PLO	84	0.33	0.774	-0.5	0.00	0.00	0.50	4.0			
	ADA	99	0.11	0.573	-0.5	0.00	0.00	0.00	2.5			
	TOT	183	0.21	0.680	-0.5	0.00	0.00	0.50	4.0			
VH RIGHT EYE												
BSL VALUE	PLO	84	0.17	0.237	0.0	0.00	0.00	0.50	0.5			
	ADA	99	0.17	0.239	0.0	0.00	0.00	0.50	0.5			
	TOT	183	0.17	0.237	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	84	0.40	0.615	0.0	0.00	0.00	0.50	3.0			
	ADA	99	0.30	0.610	0.0	0.00	0.00	0.50	3.0			
	TOT	183	0.35	0.612	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	84	0.23	0.583	-0.5	0.00	0.00	0.50	2.5			
	ADA	99	0.13	0.609	-0.5	0.00	0.00	0.00	2.5			
	TOT	183	0.18	0.598	-0.5	0.00	0.00	0.50	2.5			
										-0.16	(-0.32, 0.00)	0.044A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.34.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	84	0.13	0.248	-0.26	-0.02	0.10	0.21	1.24			
	ADA	99	0.13	0.245	-0.28	-0.04	0.06	0.24	0.96			
	TOT	183	0.13	0.246	-0.28	-0.02	0.06	0.22	1.24			
FINAL/ET VALUE	PLO	84	0.20	0.384	-0.30	-0.04	0.12	0.33	1.78			
	ADA	99	0.14	0.336	-0.30	-0.08	0.04	0.24	2.08			
	TOT	183	0.17	0.359	-0.30	-0.06	0.06	0.28	2.08			
CHG FROM BSL	PLO	84	0.07	0.260	-0.64	-0.05	0.00	0.12	1.36			
	ADA	99	0.01	0.259	-0.58	-0.08	-0.02	0.04	1.98			
	TOT	183	0.04	0.261	-0.64	-0.06	0.00	0.06	1.98			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	84	0.12	0.228	-0.16	-0.01	0.03	0.18	1.00			
	ADA	99	0.11	0.210	-0.24	-0.02	0.04	0.18	1.16			
	TOT	183	0.11	0.218	-0.24	-0.02	0.04	0.18	1.16			
FINAL/ET VALUE	PLO	84	0.12	0.258	-0.20	-0.05	0.06	0.22	1.12			
	ADA	99	0.11	0.274	-0.28	-0.06	0.02	0.22	1.48			
	TOT	183	0.11	0.266	-0.28	-0.06	0.04	0.22	1.48			
CHG FROM BSL	PLO	84	0.01	0.150	-0.48	-0.08	0.00	0.07	0.52			
	ADA	99	0.00	0.165	-0.42	-0.08	-0.02	0.06	0.94			
	TOT	183	0.00	0.158	-0.48	-0.08	-0.02	0.06	0.94			
										-0.04	(-0.09, 0.01)	0.151A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.34.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	82	6.2	21.10	-46.1	-2.2	1.3	8.9	105.6			
	ADA	98	4.2	29.66	-61.7	-5.2	-0.4	3.4	165.6			
	TOT	180	5.1	26.06	-61.7	-3.8	0.0	5.9	165.6			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	82	6.9	30.11	-40.4	-2.2	0.8	7.3	232.5			
	ADA	97	1.8	24.49	-59.3	-4.8	0.0	2.1	140.9			
	TOT	179	4.1	27.25	-59.3	-3.8	0.4	4.6	232.5			
										-3.9	(-10.0, 2.3)	0.216A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.35.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
AC LEFT EYE									
BSL VALUE	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	4	0.00	0.000	0.0	0.00	0.00	0.00	0.0
FINAL/ET VALUE	PLO	1	0.50		0.5	0.50	0.50	0.50	0.5
	ADA	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	4	0.13	0.250	0.0	0.00	0.00	0.25	0.5
CHG FROM BSL	PLO	1	0.50		0.5	0.50	0.50	0.50	0.5
	ADA	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	4	0.13	0.250	0.0	0.00	0.00	0.25	0.5
AC RIGHT EYE									
BSL VALUE	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	4	0.00	0.000	0.0	0.00	0.00	0.00	0.0
FINAL/ET VALUE	PLO	1	3.00		3.0	3.00	3.00	3.00	3.0
	ADA	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	4	0.75	1.500	0.0	0.00	0.00	1.50	3.0
CHG FROM BSL	PLO	1	3.00		3.0	3.00	3.00	3.00	3.0
	ADA	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	4	0.75	1.500	0.0	0.00	0.00	1.50	3.0

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.35.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
VH LEFT EYE									
BSL VALUE	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	4	0.00	0.000	0.0	0.00	0.00	0.00	0.0
FINAL/ET VALUE	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	4	0.00	0.000	0.0	0.00	0.00	0.00	0.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	4	0.00	0.000	0.0	0.00	0.00	0.00	0.0
VH RIGHT EYE									
BSL VALUE	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	4	0.00	0.000	0.0	0.00	0.00	0.00	0.0
FINAL/ET VALUE	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	4	0.00	0.000	0.0	0.00	0.00	0.00	0.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	4	0.00	0.000	0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.35.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
LOGMAR LEFT EYE									
BSL VALUE	PLO	1	0.22		0.22	0.22	0.22	0.22	0.22
	ADA	3	0.07	0.170	-0.10	-0.10	0.06	0.24	0.24
	TOT	4	0.11	0.159	-0.10	-0.02	0.14	0.23	0.24
FINAL/ET VALUE	PLO	1	0.12		0.12	0.12	0.12	0.12	0.12
	ADA	3	-0.03	0.064	-0.10	-0.10	0.00	0.02	0.02
	TOT	4	0.01	0.090	-0.10	-0.05	0.01	0.07	0.12
CHG FROM BSL	PLO	1	-0.10		-0.10	-0.10	-0.10	-0.10	-0.10
	ADA	3	-0.09	0.129	-0.24	-0.24	-0.04	0.00	0.00
	TOT	4	-0.10	0.105	-0.24	-0.17	-0.07	-0.02	0.00
LOGMAR RIGHT EYE									
BSL VALUE	PLO	1	0.16		0.16	0.16	0.16	0.16	0.16
	ADA	3	0.03	0.031	0.00	0.00	0.02	0.06	0.06
	TOT	4	0.06	0.071	0.00	0.01	0.04	0.11	0.16
FINAL/ET VALUE	PLO	1	0.68		0.68	0.68	0.68	0.68	0.68
	ADA	3	-0.08	0.020	-0.10	-0.10	-0.08	-0.06	-0.06
	TOT	4	0.11	0.380	-0.10	-0.09	-0.07	0.31	0.68
CHG FROM BSL	PLO	1	0.52		0.52	0.52	0.52	0.52	0.52
	ADA	3	-0.11	0.046	-0.16	-0.16	-0.08	-0.08	-0.08
	TOT	4	0.05	0.316	-0.16	-0.12	-0.08	0.22	0.52

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.35.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
CRT LEFT EYE									
%CHG FROM BSL	PLO	1	-3.5		-3.5	-3.5	-3.5	-3.5	-3.5
	ADA	3	-5.8	17.69	-25.8	-25.8	0.4	7.9	7.9
	TOT	4	-5.3	14.49	-25.8	-14.7	-1.6	4.1	7.9
CRT RIGHT EYE									
%CHG FROM BSL	PLO	1	-0.5		-0.5	-0.5	-0.5	-0.5	-0.5
	ADA	3	-1.7	2.00	-3.9	-3.9	-1.1	0.0	0.0
	TOT	4	-1.4	1.74	-3.9	-2.5	-0.8	-0.2	0.0

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.36.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	125	0.10	0.204	0.0	0.00	0.00	0.00	0.5			
	ADA	128	0.11	0.210	0.0	0.00	0.00	0.00	0.5			
	TOT	253	0.11	0.207	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	125	0.71	1.044	0.0	0.00	0.00	1.00	4.0			
	ADA	128	0.58	1.005	0.0	0.00	0.00	0.75	4.0			
	TOT	253	0.65	1.025	0.0	0.00	0.00	1.00	4.0			
CHG FROM BSL	PLO	125	0.61	1.009	-0.5	0.00	0.00	1.00	4.0			
	ADA	128	0.47	1.005	-0.5	0.00	0.00	0.75	4.0			
	TOT	253	0.54	1.008	-0.5	0.00	0.00	1.00	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	125	0.10	0.201	0.0	0.00	0.00	0.00	0.5			
	ADA	128	0.12	0.213	0.0	0.00	0.00	0.00	0.5			
	TOT	253	0.11	0.207	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	125	0.68	1.033	0.0	0.00	0.00	1.00	3.0			
	ADA	128	0.57	0.953	0.0	0.00	0.00	0.50	3.0			
	TOT	253	0.62	0.993	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	125	0.58	0.972	-0.5	0.00	0.00	1.00	3.0			
	ADA	128	0.45	0.959	-0.5	0.00	0.00	0.50	3.0			
	TOT	253	0.52	0.966	-0.5	0.00	0.00	1.00	3.0			
										-0.13	(-0.35, 0.08)	0.229A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.36.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	125	0.15	0.229	0.0	0.00	0.00	0.50	0.5			
	ADA	128	0.18	0.242	0.0	0.00	0.00	0.50	0.5			
	TOT	253	0.17	0.236	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	125	0.50	0.754	0.0	0.00	0.00	1.00	4.0			
	ADA	128	0.36	0.630	0.0	0.00	0.00	0.50	3.0			
	TOT	253	0.43	0.696	0.0	0.00	0.00	0.50	4.0			
CHG FROM BSL	PLO	125	0.35	0.751	-0.5	0.00	0.00	0.50	4.0			
	ADA	128	0.18	0.620	-0.5	0.00	0.00	0.50	2.5			
	TOT	253	0.26	0.692	-0.5	0.00	0.00	0.50	4.0			
VH RIGHT EYE												
BSL VALUE	PLO	125	0.16	0.234	0.0	0.00	0.00	0.50	0.5			
	ADA	128	0.16	0.236	0.0	0.00	0.00	0.50	0.5			
	TOT	253	0.16	0.234	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	125	0.52	0.776	0.0	0.00	0.00	1.00	3.0			
	ADA	128	0.35	0.622	0.0	0.00	0.00	0.50	3.0			
	TOT	253	0.43	0.706	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	125	0.36	0.731	-0.5	0.00	0.00	0.50	3.0			
	ADA	128	0.19	0.608	-0.5	0.00	0.00	0.50	2.5			
	TOT	253	0.27	0.676	-0.5	0.00	0.00	0.50	3.0			
										-0.17	(-0.32, -0.03)	0.019A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.36.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	125	0.17	0.279	-0.26	-0.02	0.10	0.24	1.24			
	ADA	128	0.15	0.259	-0.28	-0.02	0.08	0.25	1.04			
	TOT	253	0.16	0.269	-0.28	-0.02	0.10	0.24	1.24			
FINAL/ET VALUE	PLO	125	0.24	0.381	-0.30	-0.02	0.14	0.36	1.78			
	ADA	128	0.17	0.342	-0.30	-0.06	0.07	0.28	2.08			
	TOT	253	0.20	0.362	-0.30	-0.04	0.12	0.32	2.08			
CHG FROM BSL	PLO	125	0.07	0.230	-0.64	-0.04	0.02	0.14	1.36			
	ADA	128	0.02	0.243	-0.58	-0.08	-0.02	0.04	1.98			
	TOT	253	0.05	0.237	-0.64	-0.06	0.00	0.08	1.98			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	125	0.16	0.260	-0.16	0.00	0.06	0.26	1.20			
	ADA	128	0.13	0.229	-0.24	-0.02	0.06	0.24	1.16			
	TOT	253	0.15	0.245	-0.24	-0.02	0.06	0.26	1.20			
FINAL/ET VALUE	PLO	125	0.20	0.330	-0.20	0.00	0.12	0.30	1.62			
	ADA	128	0.14	0.301	-0.28	-0.04	0.04	0.26	1.48			
	TOT	253	0.17	0.316	-0.28	-0.02	0.08	0.28	1.62			
CHG FROM BSL	PLO	125	0.04	0.213	-0.52	-0.06	0.00	0.08	1.26			
	ADA	128	0.01	0.170	-0.42	-0.08	0.00	0.08	0.94			
	TOT	253	0.02	0.193	-0.52	-0.08	0.00	0.08	1.26			
										-0.04	(-0.08, 0.00)	0.069A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.36.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	121	6.4	19.81	-46.1	-1.9	1.2	8.9	105.6			
	ADA	127	5.4	30.13	-61.7	-5.6	-0.4	4.7	165.6			
	TOT	248	5.9	25.58	-61.7	-3.6	0.5	6.9	165.6			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	123	9.9	30.90	-40.4	-1.6	2.2	9.6	232.5			
	ADA	126	4.0	33.73	-63.4	-4.8	0.0	2.8	260.7			
	TOT	249	6.9	32.43	-63.4	-3.7	0.7	6.8	260.7			
										-3.9	(-9.6, 1.9)	0.189A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.37.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	36	0.14	0.227	0.0	0.00	0.00	0.50	0.5			
	ADA	33	0.14	0.226	0.0	0.00	0.00	0.50	0.5			
	TOT	69	0.14	0.225	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	36	0.89	1.172	0.0	0.00	0.50	2.00	4.0			
	ADA	33	0.70	1.138	0.0	0.00	0.00	0.50	4.0			
	TOT	69	0.80	1.151	0.0	0.00	0.00	1.00	4.0			
CHG FROM BSL	PLO	36	0.75	1.092	0.0	0.00	0.00	1.75	4.0			
	ADA	33	0.56	1.144	-0.5	0.00	0.00	0.50	4.0			
	TOT	69	0.66	1.113	-0.5	0.00	0.00	1.00	4.0			
AC RIGHT EYE												
BSL VALUE	PLO	36	0.13	0.220	0.0	0.00	0.00	0.25	0.5			
	ADA	33	0.15	0.233	0.0	0.00	0.00	0.50	0.5			
	TOT	69	0.14	0.225	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	36	0.82	1.129	0.0	0.00	0.00	2.00	3.0			
	ADA	33	0.65	0.996	0.0	0.00	0.00	0.50	3.0			
	TOT	69	0.74	1.063	0.0	0.00	0.00	1.00	3.0			
CHG FROM BSL	PLO	36	0.69	1.091	-0.5	0.00	0.00	2.00	3.0			
	ADA	33	0.50	1.023	-0.5	0.00	0.00	0.50	3.0			
	TOT	69	0.60	1.056	-0.5	0.00	0.00	1.00	3.0			
										-0.19	(-0.66, 0.28)	0.420A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.37.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	36	0.15	0.234	0.0	0.00	0.00	0.50	0.5			
	ADA	33	0.17	0.239	0.0	0.00	0.00	0.50	0.5			
	TOT	69	0.16	0.235	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	36	0.46	0.565	0.0	0.00	0.25	1.00	2.0			
	ADA	33	0.29	0.625	0.0	0.00	0.00	0.00	2.0			
	TOT	69	0.38	0.597	0.0	0.00	0.00	0.50	2.0			
CHG FROM BSL	PLO	36	0.31	0.511	-0.5	0.00	0.00	0.50	2.0			
	ADA	33	0.12	0.587	-0.5	0.00	0.00	0.00	2.0			
	TOT	69	0.22	0.552	-0.5	0.00	0.00	0.50	2.0			
VH RIGHT EYE												
BSL VALUE	PLO	36	0.11	0.211	0.0	0.00	0.00	0.00	0.5			
	ADA	33	0.14	0.226	0.0	0.00	0.00	0.50	0.5			
	TOT	69	0.12	0.217	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	36	0.36	0.424	0.0	0.00	0.00	0.75	1.0			
	ADA	33	0.33	0.669	0.0	0.00	0.00	0.50	3.0			
	TOT	69	0.35	0.551	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	36	0.25	0.348	0.0	0.00	0.00	0.50	1.0			
	ADA	33	0.20	0.637	-0.5	0.00	0.00	0.00	2.5			
	TOT	69	0.22	0.504	-0.5	0.00	0.00	0.50	2.5			
										-0.12	(-0.33, 0.09)	0.267A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.37.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	36	0.13	0.266	-0.12	-0.05	0.07	0.22	1.20			
	ADA	33	0.10	0.221	-0.12	-0.08	0.02	0.22	0.66			
	TOT	69	0.12	0.245	-0.12	-0.06	0.02	0.22	1.20			
FINAL/ET VALUE	PLO	36	0.18	0.334	-0.20	-0.01	0.12	0.30	1.68			
	ADA	33	0.06	0.222	-0.18	-0.10	0.00	0.20	0.66			
	TOT	69	0.13	0.291	-0.20	-0.08	0.08	0.22	1.68			
CHG FROM BSL	PLO	36	0.05	0.175	-0.46	-0.03	0.03	0.11	0.54			
	ADA	33	-0.03	0.088	-0.24	-0.08	-0.04	0.02	0.14			
	TOT	69	0.01	0.145	-0.46	-0.06	0.00	0.04	0.54			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	36	0.09	0.163	-0.10	-0.04	0.03	0.21	0.60			
	ADA	33	0.11	0.193	-0.18	-0.02	0.08	0.20	0.66			
	TOT	69	0.10	0.177	-0.18	-0.04	0.04	0.20	0.66			
FINAL/ET VALUE	PLO	36	0.13	0.345	-0.18	-0.04	0.03	0.15	1.62			
	ADA	33	0.07	0.218	-0.26	-0.08	0.02	0.12	0.56			
	TOT	69	0.10	0.290	-0.26	-0.06	0.02	0.14	1.62			
CHG FROM BSL	PLO	36	0.04	0.249	-0.16	-0.06	0.00	0.04	1.26			
	ADA	33	-0.04	0.107	-0.28	-0.12	-0.04	0.04	0.14			
	TOT	69	0.00	0.197	-0.28	-0.08	-0.02	0.04	1.26			
										-0.08	(-0.15, -0.01)	0.018A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.37.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	34	5.1	20.49	-46.1	-2.0	1.0	8.9	73.2			
	ADA	33	-0.7	9.21	-25.7	-5.7	-0.3	3.4	19.8			
	TOT	67	2.3	16.12	-46.1	-3.9	0.5	6.0	73.2			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	35	6.0	23.53	-18.1	-2.7	0.0	2.3	101.1			
	ADA	33	5.2	46.72	-25.7	-7.0	-0.7	0.8	260.7			
	TOT	68	5.6	36.38	-25.7	-4.5	0.0	1.8	260.7			
										-4.7	(-15.1, 5.6)	0.365A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.38.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
AC LEFT EYE												
BSL VALUE	PLO	55	0.08	0.187	0.0	0.00	0.00	0.00	0.5			
	ADA	64	0.08	0.183	0.0	0.00	0.00	0.00	0.5			
	TOT	119	0.08	0.184	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	55	0.42	0.762	0.0	0.00	0.00	0.50	3.0			
	ADA	64	0.34	0.791	0.0	0.00	0.00	0.00	3.0			
	TOT	119	0.38	0.776	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	55	0.34	0.746	-0.5	0.00	0.00	0.50	2.5			
	ADA	64	0.27	0.802	-0.5	0.00	0.00	0.00	3.0			
	TOT	119	0.30	0.774	-0.5	0.00	0.00	0.00	3.0			
AC RIGHT EYE												
BSL VALUE	PLO	55	0.08	0.187	0.0	0.00	0.00	0.00	0.5			
	ADA	64	0.10	0.203	0.0	0.00	0.00	0.00	0.5			
	TOT	119	0.09	0.195	0.0	0.00	0.00	0.00	0.5			
FINAL/ET VALUE	PLO	55	0.48	0.887	0.0	0.00	0.00	0.50	3.0			
	ADA	64	0.40	0.855	0.0	0.00	0.00	0.25	3.0			
	TOT	119	0.44	0.867	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	55	0.40	0.819	-0.5	0.00	0.00	0.50	2.5			
	ADA	64	0.30	0.853	-0.5	0.00	0.00	0.00	3.0			
	TOT	119	0.34	0.836	-0.5	0.00	0.00	0.50	3.0			
										-0.09	(-0.35, 0.17)	0.511A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.38.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
VH LEFT EYE												
BSL VALUE	PLO	55	0.17	0.240	0.0	0.00	0.00	0.50	0.5			
	ADA	64	0.20	0.248	0.0	0.00	0.00	0.50	0.5			
	TOT	119	0.19	0.243	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	55	0.52	0.720	0.0	0.00	0.50	1.00	3.0			
	ADA	64	0.32	0.559	0.0	0.00	0.00	0.50	3.0			
	TOT	119	0.41	0.643	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	55	0.35	0.745	-0.5	0.00	0.00	0.50	3.0			
	ADA	64	0.12	0.582	-0.5	0.00	0.00	0.50	2.5			
	TOT	119	0.22	0.669	-0.5	0.00	0.00	0.50	3.0			
VH RIGHT EYE												
BSL VALUE	PLO	55	0.20	0.247	0.0	0.00	0.00	0.50	0.5			
	ADA	64	0.18	0.242	0.0	0.00	0.00	0.50	0.5			
	TOT	119	0.19	0.243	0.0	0.00	0.00	0.50	0.5			
FINAL/ET VALUE	PLO	55	0.52	0.751	0.0	0.00	0.00	1.00	3.0			
	ADA	64	0.31	0.581	0.0	0.00	0.00	0.50	2.0			
	TOT	119	0.41	0.670	0.0	0.00	0.00	0.50	3.0			
CHG FROM BSL	PLO	55	0.32	0.735	-0.5	0.00	0.00	0.50	2.5			
	ADA	64	0.13	0.599	-0.5	0.00	0.00	0.00	2.0			
	TOT	119	0.22	0.669	-0.5	0.00	0.00	0.50	2.5			
										-0.21	(-0.42, 0.00)	0.055A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.38.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
LOGMAR LEFT EYE												
BSL VALUE	PLO	55	0.13	0.253	-0.26	0.00	0.10	0.16	1.24			
	ADA	64	0.14	0.274	-0.28	-0.02	0.06	0.24	1.04			
	TOT	119	0.14	0.264	-0.28	-0.02	0.08	0.22	1.24			
FINAL/ET VALUE	PLO	55	0.15	0.286	-0.30	-0.06	0.10	0.28	1.24			
	ADA	64	0.15	0.359	-0.30	-0.06	0.04	0.24	2.08			
	TOT	119	0.15	0.326	-0.30	-0.06	0.06	0.26	2.08			
CHG FROM BSL	PLO	55	0.02	0.179	-0.64	-0.06	0.00	0.06	0.54			
	ADA	64	0.01	0.285	-0.58	-0.08	-0.02	0.02	1.98			
	TOT	119	0.01	0.241	-0.64	-0.06	-0.02	0.04	1.98			
LOGMAR RIGHT EYE												
BSL VALUE	PLO	55	0.16	0.267	-0.16	0.00	0.10	0.26	1.00			
	ADA	64	0.10	0.216	-0.24	-0.03	0.04	0.17	1.16			
	TOT	119	0.13	0.242	-0.24	-0.02	0.04	0.18	1.16			
FINAL/ET VALUE	PLO	55	0.16	0.249	-0.20	0.00	0.12	0.30	1.06			
	ADA	64	0.08	0.265	-0.28	-0.06	0.00	0.20	1.48			
	TOT	119	0.12	0.260	-0.28	-0.06	0.04	0.24	1.48			
CHG FROM BSL	PLO	55	0.00	0.168	-0.52	-0.08	0.00	0.08	0.36			
	ADA	64	-0.01	0.150	-0.42	-0.09	-0.02	0.07	0.40			
	TOT	119	-0.01	0.158	-0.52	-0.08	0.00	0.08	0.40			
										-0.02	(-0.07, 0.04)	0.585A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR
ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.2.1.1.38.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT (LEFT/RIGHT EYE)
IN ANTERIOR CHAMBER CELL GRADE, VITREOUS HAZE GRADE, CENTRAL RETINAL THICKNESS AND LOG(MAR) BCVA (LOCF)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
CRT LEFT EYE												
%CHG FROM BSL	PLO	54	5.4	17.70	-27.5	-2.2	0.5	8.3	69.7			
	ADA	63	3.0	29.81	-61.7	-7.8	-2.0	2.8	136.9			
	TOT	117	4.1	24.89	-61.7	-4.1	-0.4	5.1	136.9			
CRT RIGHT EYE												
%CHG FROM BSL	PLO	54	8.4	35.62	-40.4	-3.0	2.0	9.4	232.5			
	ADA	63	4.6	28.91	-59.3	-4.3	0.0	4.5	140.9			
	TOT	117	6.4	32.09	-59.3	-3.9	0.5	6.8	232.5			
										-3.8	(-12.5, 5.0)	0.394A

NOTE: ONLY SUBJECTS WITH BOTH BSL AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: ANALYSIS OF CRT DONE EXCLUDING SUBJECTS WITH MACULAR HOLE AND/OR RETINAL DETACHMENT.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
AC=ANTERIOR CHAMBER CELL GRADE, VH=VITREOUS HAZE GRADE, CRT=CENTRAL RETINAL THICKNESS,
LOG(MAR) = LOG(MAR) BEST CORRECTED VISUAL ACUITY.
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AND OCT
MACHINE AS FACTORS ADJUSTED FOR CLUSTERED OBSERVATIONS.

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.1.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=MALE)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	38	7	(18.4)	31	(81.6)	*	*	*			
ADALIMUMAB	41	5	(12.2)	36	(87.8)	*	*	*			
TOTAL	79	12	(15.2)	67	(84.8)	*	*	*	0.46	(0.14, 1.46)	0.176

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.2.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=FEMALE)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	68	9	(13.2)	59	(86.8)	*	*	*			
ADALIMUMAB	61	7	(11.5)	54	(88.5)	*	*	*			
TOTAL	129	16	(12.4)	113	(87.6)	*	*	*	0.78	(0.29, 2.08)	0.612

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.3.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE < 30 YEARS)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH
PLACEBO	23	3	(13.0)	20	(87.0)	*	*	*
ADALIMUMAB	16	3	(18.8)	13	(81.3)	*	*	*
TOTAL	39	6	(15.4)	33	(84.6)	*	*	*

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.4.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	52	8	(15.4)	44	(84.6)	*	*	*			
ADALIMUMAB	56	6	(10.7)	50	(89.3)	*	*	*			
TOTAL	108	14	(13.0)	94	(87.0)	*	*	*	0.50	(0.17, 1.44)	0.188

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.5.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	31	5	(16.1)	26	(83.9)	*	*	*			
ADALIMUMAB	30	3	(10.0)	27	(90.0)	*	*	*			
TOTAL	61	8	(13.1)	53	(86.9)	*	*	*	0.55	(0.13, 2.29)	0.401

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.6.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	80	13	(16.3)	67	(83.8)	*	*	*			
ADALIMUMAB	75	10	(13.3)	65	(86.7)	*	*	*			
TOTAL	155	23	(14.8)	132	(85.2)	*	*	*	0.66	(0.29, 1.51)	0.317

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.7.1.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	26	3	(11.5)	23	(88.5)	*	*	*			
ADALIMUMAB	27	2	(7.4)	25	(92.6)	*	*	*			
TOTAL	53	5	(9.4)	48	(90.6)	*	*	*	0.54	(0.09, 3.26)	0.499

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.7.2.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH
PLACEBO	7	0		7	(100)	*	*	*
ADALIMUMAB	5	1	(20.0)	4	(80.0)	*	*	*
TOTAL	12	1	(8.3)	11	(91.7)	*	*	*

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.7.3.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH
PLACEBO	14	3	(21.4)	11	(78.6)	3.7	*	*
ADALIMUMAB	15	1	(6.7)	14	(93.3)	*	*	*
TOTAL	29	4	(13.8)	25	(86.2)	*	*	*

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.7.4.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

TREATMENT	N	EVIDENCE OF EDEMA N (%)	CENSORED N (%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH
PLACEBO	1	0	1 (100)	*	*	*
ADALIMUMAB	0					
TOTAL	1	0	1 (100)	*	*	*

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.7.5.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER)

TREATMENT	N	EVIDENCE OF EDEMA N (%)	CENSORED N (%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH
PLACEBO	0					
ADALIMUMAB	0					
TOTAL	0					

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.7.6.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH
PLACEBO	3	0		3	(100)	*	*	*
ADALIMUMAB	6	0		6	(100)	*	*	*
TOTAL	9	0		9	(100)	*	*	*

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.7.7.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH
PLACEBO	1	0		1	(100)	*	*	*
ADALIMUMAB	1	0		1	(100)	*	*	*
TOTAL	2	0		2	(100)	*	*	*

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.
* NOT ESTIMABLE

Program Source Code: [redacted]

[redacted]
ADALIMUMAB (UVEITIS)
CLINICAL SUMMARY OF EFFICACY (JAPAN)
R&D/15/0714 - CLINICAL/STATISTICAL

TABLE 14.2__2000.3.1.1.8.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	22	2	(9.1)	20	(90.9)	*	*	*			
ADALIMUMAB	20	0		20	(100)	*	*	*			
TOTAL	42	2	(4.8)	40	(95.2)	*	*	*	*	(0.00,)	0.167

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.9.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	84	14	(16.7)	70	(83.3)	*	*	*			
ADALIMUMAB	82	12	(14.6)	70	(85.4)	*	*	*			
TOTAL	166	26	(15.7)	140	(84.3)	*	*	*	0.72	(0.33, 1.55)	0.396

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.10.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH
PLACEBO	25	4	(16.0)	21	(84.0)	*	*	*
ADALIMUMAB	14	3	(21.4)	11	(78.6)	7.4	*	*
TOTAL	39	7	(17.9)	32	(82.1)	7.4	*	*

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.11.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	31	3	(9.7)	28	(90.3)	*	*	*			
ADALIMUMAB	34	6	(17.6)	28	(82.4)	12.9	*	*			
TOTAL	65	9	(13.8)	56	(86.2)	*	*	*	1.94	(0.48, 7.78)	0.339

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.12.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	49	9	(18.4)	40	(81.6)	*	*	*			
ADALIMUMAB	53	3	(5.7)	50	(94.3)	*	*	*			
TOTAL	102	12	(11.8)	90	(88.2)	*	*	*	0.24	(0.07, 0.91)	0.023

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.13.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	42	7	(16.7)	35	(83.3)	*	*	*			
ADALIMUMAB	35	5	(14.3)	30	(85.7)	*	*	*			
TOTAL	77	12	(15.6)	65	(84.4)	*	*	*	0.63	(0.20, 2.03)	0.438

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.14.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH
PLACEBO	14	1	(7.1)	13	(92.9)	*	*	*
ADALIMUMAB	13	2	(15.4)	11	(84.6)	*	*	*
TOTAL	27	3	(11.1)	24	(88.9)	*	*	*

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.15.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH
PLACEBO	2	1	(50.0)	1	(50.0)	1.0	*	*
ADALIMUMAB	3	0		3	(100)	*	*	*
TOTAL	5	1	(20.0)	4	(80.0)	*	*	*

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.
* NOT ESTIMABLE

Program Source Code: [redacted]

[redacted]
ADALIMUMAB (UVEITIS)
CLINICAL SUMMARY OF EFFICACY (JAPAN)
R&D/15/0714 - CLINICAL/STATISTICAL

TABLE 14.2__2000.3.1.1.16.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	28	3	(10.7)	25	(89.3)	*	*	*			
ADALIMUMAB	29	3	(10.3)	26	(89.7)	*	*	*			
TOTAL	57	6	(10.5)	51	(89.5)	*	*	*	0.84	(0.17, 4.19)	0.833

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.17.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

TREATMENT	N	EVIDENCE OF EDEMA N	EVIDENCE OF EDEMA (%)	CENSORED N	CENSORED (%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH
PLACEBO	14	2	(14.3)	12	(85.7)	*	*	*
ADALIMUMAB	13	1	(7.7)	12	(92.3)	*	*	*
TOTAL	27	3	(11.1)	24	(88.9)	*	*	*

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.18.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH
PLACEBO	6	2	(33.3)	4	(66.7)	2.4	*	*
ADALIMUMAB	9	1	(11.1)	8	(88.9)	*	*	*
TOTAL	15	3	(20.0)	12	(80.0)	12.9	*	*

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.19.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=0-1)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	45	8	(17.8)	37	(82.2)	*	*	*			
ADALIMUMAB	48	8	(16.7)	40	(83.3)	*	*	*			
TOTAL	93	16	(17.2)	77	(82.8)	*	*	*	0.83	(0.31, 2.20)	0.701

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.20.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	34	5	(14.7)	29	(85.3)	*	*	*			
ADALIMUMAB	34	3	(8.8)	31	(91.2)	*	*	*			
TOTAL	68	8	(11.8)	60	(88.2)	*	*	*	0.58	(0.14, 2.45)	0.453

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.21.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	27	3	(11.1)	24	(88.9)	*	*	*			
ADALIMUMAB	20	1	(5.0)	19	(95.0)	*	*	*			
TOTAL	47	4	(8.5)	43	(91.5)	*	*	*	0.24	(0.02, 2.45)	0.196

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.22.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	73	10	(13.7)	63	(86.3)	*	*	*			
ADALIMUMAB	65	8	(12.3)	57	(87.7)	*	*	*			
TOTAL	138	18	(13.0)	120	(87.0)	*	*	*	0.68	(0.27, 1.74)	0.418

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.23.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	33	6	(18.2)	27	(81.8)	*	*	*			
ADALIMUMAB	37	4	(10.8)	33	(89.2)	*	*	*			
TOTAL	70	10	(14.3)	60	(85.7)	*	*	*	0.53	(0.15, 1.90)	0.323

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

[redacted]
ADALIMUMAB (UVEITIS)
CLINICAL SUMMARY OF EFFICACY (JAPAN)
R&D/15/0714 - CLINICAL/STATISTICAL

TABLE 14.2__2000.3.1.1.24.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	79	16	(20.3)	63	(79.7)	*	*	*			
ADALIMUMAB	81	11	(13.6)	70	(86.4)	*	*	*			
TOTAL	160	27	(16.9)	133	(83.1)	*	*	*	0.60	(0.28, 1.29)	0.184

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.25.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH
PLACEBO	24	0		24	(100)	*	*	*
ADALIMUMAB	15	1	(6.7)	14	(93.3)	*	*	*
TOTAL	39	1	(2.6)	38	(97.4)	*	*	*

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.26.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH
PLACEBO	3	0		3	(100)	*	*	*
ADALIMUMAB	6	0		6	(100)	*	*	*
TOTAL	9	0		9	(100)	*	*	*

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.27.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=YES)

TREATMENT	N	EVIDENCE OF EDEMA N (%)	CENSORED N (%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH
PLACEBO	0					
ADALIMUMAB	0					
TOTAL	0					

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.
* NOT ESTIMABLE

Program Source Code: [redacted]

[redacted]
ADALIMUMAB (UVEITIS)
CLINICAL SUMMARY OF EFFICACY (JAPAN)
R&D/15/0714 - CLINICAL/STATISTICAL
TABLE PAGE 1 OF 1

TABLE 14.2__2000.3.1.1.28.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: OCT EVIDENCE OF MACULAR EDEMA BASED ON CRT AT BASELINE=NO)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	106	16	(15.1)	90	(84.9)	*	*	*			
ADALIMUMAB	102	12	(11.8)	90	(88.2)	*	*	*			
TOTAL	208	28	(13.5)	180	(86.5)	*	*	*	0.64	(0.30, 1.35)	0.232

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.29.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=YES)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	48	10	(20.8)	38	(79.2)	4.4	*	*			
ADALIMUMAB	45	6	(13.3)	39	(86.7)	*	*	*			
TOTAL	93	16	(17.2)	77	(82.8)	*	*	*	0.51	(0.19, 1.42)	0.190

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

[redacted]
ADALIMUMAB (UVEITIS)
CLINICAL SUMMARY OF EFFICACY (JAPAN)
R&D/15/0714 - CLINICAL/STATISTICAL
TABLE PAGE 1 OF 1

TABLE 14.2__2000.3.1.1.30.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: IMM USAGE AT BASELINE=NO)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	58	6	(10.3)	52	(89.7)	*	*	*			
ADALIMUMAB	57	6	(10.5)	51	(89.5)	*	*	*			
TOTAL	115	12	(10.4)	103	(89.6)	*	*	*	0.85	(0.27, 2.65)	0.779

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.31.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE >20 MG/DAY)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH
PLACEBO	21	1	(4.8)	20	(95.2)	*	*	*
ADALIMUMAB	16	1	(6.3)	15	(93.8)	*	*	*
TOTAL	37	2	(5.4)	35	(94.6)	*	*	*

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.
* NOT ESTIMABLE

Program Source Code: [redacted]

[redacted]
ADALIMUMAB (UVEITIS)
CLINICAL SUMMARY OF EFFICACY (JAPAN)
R&D/15/0714 - CLINICAL/STATISTICAL

TABLE 14.2__2000.3.1.1.32.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: ORAL PREDNISONE USAGE AT BASELINE <=20 MG/DAY)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	85	15	(17.6)	70	(82.4)	*	*	*			
ADALIMUMAB	86	11	(12.8)	75	(87.2)	*	*	*			
TOTAL	171	26	(15.2)	145	(84.8)	*	*	*	0.62	(0.28, 1.35)	0.224

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

[redacted]
ADALIMUMAB (UVEITIS)
CLINICAL SUMMARY OF EFFICACY (JAPAN)
R&D/15/0714 - CLINICAL/STATISTICAL

TABLE 14.2__2000.3.1.1.33.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=YES)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	32	6	(18.8)	26	(81.3)	3.9	*	*			
ADALIMUMAB	25	4	(16.0)	21	(84.0)	7.2	*	*			
TOTAL	57	10	(17.5)	47	(82.5)	7.2	*	*	0.54	(0.15, 1.94)	0.330

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.34.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TOPICAL STEROIDS AT BASELINE=NO)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	74	10	(13.5)	64	(86.5)	*	*	*			
ADALIMUMAB	77	8	(10.4)	69	(89.6)	*	*	*			
TOTAL	151	18	(11.9)	133	(88.1)	*	*	*	0.67	(0.26, 1.70)	0.393

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.35.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=YES)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH
PLACEBO	1	0		1	(100)	*	*	*
ADALIMUMAB	3	0		3	(100)	*	*	*
TOTAL	4	0		4	(100)	*	*	*

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.
* NOT ESTIMABLE

Program Source Code: [redacted]

[redacted]
ADALIMUMAB (UVEITIS)
CLINICAL SUMMARY OF EFFICACY (JAPAN)
R&D/15/0714 - CLINICAL/STATISTICAL
TABLE PAGE 1 OF 1

TABLE 14.2__2000.3.1.1.36.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PROTOCOL DEVIATION 'WRONG TREATMENT/INCORRECT DOSE REGARDING PREDNISONE'=NO)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	105	16	(15.2)	89	(84.8)	*	*	*			
ADALIMUMAB	99	12	(12.1)	87	(87.9)	*	*	*			
TOTAL	204	28	(13.7)	176	(86.3)	*	*	*	0.65	(0.31, 1.38)	0.261

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.3.1.1.37.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=NORTH AMERICA)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	30	2	(6.7)	28	(93.3)	*	*	*			
ADALIMUMAB	26	2	(7.7)	24	(92.3)	*	*	*			
TOTAL	56	4	(7.1)	52	(92.9)	*	*	*	0.87	(0.12, 6.32)	0.888

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

[redacted]
ADALIMUMAB (UVEITIS)
CLINICAL SUMMARY OF EFFICACY (JAPAN)
R&D/15/0714 - CLINICAL/STATISTICAL
TABLE PAGE 1 OF 1

TABLE 14.2__2000.3.1.1.38.I

TIME TO OCT EVIDENCE OF MACULAR EDEMA AT OR AFTER WEEK 2 - BASED ON CRT (WITHOUT MACULAR HOLE AND/OR RETINAL DETACHMENT)
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880, ONLY IN SUBJECTS WITHOUT MACULAR EDEMA BASED ON CRT AT BASELINE)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GEOGRAPHIC REGION=WESTERN AND EASTERN EUROPE)

TREATMENT	N	EVIDENCE OF EDEMA N	(%)	CENSORED N	(%)	TIME TO MACULAR EDEMA (MONTHS) 25TH	MEDIAN	75TH	HAZARD RATIO$	CI 95%#	P-VALUE@
PLACEBO	49	9	(18.4)	40	(81.6)	*	*	*			
ADALIMUMAB	49	4	(8.2)	45	(91.8)	*	*	*			
TOTAL	98	13	(13.3)	85	(86.7)	*	*	*	0.40	(0.12, 1.29)	0.112

NOTE: OCCURENCE OF MACULA EDEMA AT OR AFTER WEEK 2 WAS COUNTED AS EVENT. DROP OUTS DUE TO REASONS OTHER THAN MACULA EDEMA AT OR AFTER WEEK 2 WERE CENSORED AT THE TIME OF DROPPING OUT.
$ HAZARD RATIO OF ADALIMUMAB VS PLACEBO FROM PROPORTIONAL HAZARDS REGRESSION WITH TREATMENT AS FACTOR.
# 95% CONFIDENCE INTERVAL FOR HAZARD RATIO.
@ TWO-SIDED P-VALUE FROM LOG RANK TEST.
* NOT ESTIMABLE

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=MALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	45	53.33	25.339	0.0	25.00	50.00	75.00	100.0			
	ADA	56	58.93	21.013	25.0	50.00	50.00	75.00	100.0			
	TOT	101	56.44	23.090	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	45	51.67	25.226	0.0	50.00	50.00	75.00	100.0			
	ADA	56	60.27	24.086	0.0	50.00	62.50	75.00	100.0			
	TOT	101	56.44	24.850	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	45	-1.67	21.585	-75.0	0.00	0.00	0.00	50.0			
	ADA	56	1.34	19.754	-50.0	0.00	0.00	25.00	50.0			
	TOT	101	0.00	20.540	-75.0	0.00	0.00	12.50	50.0			
										3.01	(-5.17, 11.18)	0.468A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=MALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	45	64.44	16.453	20.0	60.00	60.00	80.00	80.0			
	ADA	55	68.00	15.202	40.0	60.00	60.00	80.00	100.0			
	TOT	100	66.40	15.797	20.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	45	62.22	19.175	20.0	40.00	60.00	80.00	80.0			
	ADA	55	70.00	20.276	20.0	60.00	80.00	80.00	100.0			
	TOT	100	66.50	20.069	20.0	60.00	80.00	80.00	100.0			
CHG FROM BSL	PLO	45	-2.22	14.907	-40.0	0.00	0.00	0.00	20.0			
	ADA	55	2.00	18.196	-40.0	0.00	0.00	20.00	40.0			
	TOT	100	0.10	16.847	-40.0	0.00	0.00	15.00	40.0			
										4.22	(-2.48, 10.92)	0.214A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=MALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	45	78.06	21.011	25.0	62.50	75.00	100.00	100.0			
	ADA	56	83.93	16.116	50.0	75.00	87.50	100.00	100.0			
	TOT	101	81.31	18.593	25.0	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	45	82.50	17.957	50.0	75.00	75.00	100.00	100.0			
	ADA	56	83.48	18.480	37.5	75.00	87.50	100.00	100.0			
	TOT	101	83.04	18.165	37.5	75.00	87.50	100.00	100.0			
CHG FROM BSL	PLO	45	4.44	11.038	-12.5	0.00	0.00	12.50	50.0			
	ADA	56	-0.45	20.080	-62.5	-6.25	0.00	12.50	50.0			
	TOT	101	1.73	16.773	-62.5	0.00	0.00	12.50	50.0			
										-4.89	(-11.52, 1.73)	0.146A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=MALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	45	70.00	25.025	16.7	50.00	75.00	91.67	100.0			
	ADA	56	80.13	17.943	33.3	66.67	83.33	97.92	100.0			
	TOT	101	75.62	21.869	16.7	66.67	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	45	73.98	24.892	16.7	58.33	83.33	100.00	100.0			
	ADA	56	81.62	20.746	0.0	75.00	83.33	100.00	100.0			
	TOT	101	78.22	22.889	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	45	3.98	14.757	-33.3	0.00	0.00	16.67	41.7			
	ADA	56	1.49	18.556	-58.3	-6.25	0.00	12.50	50.0			
	TOT	101	2.60	16.934	-58.3	0.00	0.00	16.67	50.0			
										-2.49	(-9.24, 4.25)	0.465A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=MALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	45	78.52	23.869	8.3	58.33	83.33	100.00	100.0			
	ADA	56	81.47	19.035	25.0	75.00	83.33	100.00	100.0			
	TOT	101	80.16	21.263	8.3	66.67	83.33	100.00	100.0			
FINAL/ET VALUE	PLO	45	77.59	23.491	8.3	66.67	83.33	100.00	100.0			
	ADA	56	82.22	20.757	25.0	66.67	89.58	100.00	100.0			
	TOT	101	80.16	22.025	8.3	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	45	-0.93	13.083	-33.3	-8.33	0.00	8.33	25.0			
	ADA	56	0.74	15.182	-37.5	-8.33	0.00	8.33	41.7			
	TOT	101	0.00	14.240	-37.5	-8.33	0.00	8.33	41.7			
										1.67	(-4.01, 7.35)	0.561A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=MALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	45	89.72	17.124	37.5	75.00	100.00	100.00	100.0			
	ADA	56	90.40	14.100	50.0	81.25	100.00	100.00	100.0			
	TOT	101	90.10	15.443	37.5	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	45	86.53	16.853	50.0	75.00	93.75	100.00	100.0			
	ADA	56	89.62	14.659	50.0	75.00	100.00	100.00	100.0			
	TOT	101	88.24	15.670	50.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	45	-3.19	10.375	-37.5	-12.50	0.00	0.00	25.0			
	ADA	56	-0.78	13.696	-25.0	0.00	0.00	0.00	37.5			
	TOT	101	-1.86	12.328	-37.5	-6.25	0.00	0.00	37.5			
										2.41	(-2.49, 7.31)	0.331A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=MALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	45	65.00	24.512	12.5	37.50	75.00	81.25	100.0			
	ADA	56	71.95	18.886	18.8	62.50	75.00	87.50	100.0			
	TOT	101	68.85	21.739	12.5	56.25	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	45	69.86	27.350	12.5	50.00	81.25	93.75	100.0			
	ADA	56	77.90	20.013	25.0	68.75	81.25	93.75	100.0			
	TOT	101	74.32	23.781	12.5	56.25	81.25	93.75	100.0			
CHG FROM BSL	PLO	45	4.86	11.608	-37.5	0.00	6.25	12.50	25.0			
	ADA	56	5.95	16.140	-37.5	-3.13	6.25	12.50	37.5			
	TOT	101	5.47	14.243	-37.5	0.00	6.25	12.50	37.5			
										1.09	(-4.59, 6.77)	0.704A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=MALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	45	69.17	26.730	12.5	50.00	75.00	100.00	100.0			
	ADA	56	75.45	22.609	25.0	56.25	75.00	100.00	100.0			
	TOT	101	72.65	24.604	12.5	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	45	72.22	28.190	25.0	50.00	75.00	100.00	100.0			
	ADA	56	79.69	22.558	25.0	75.00	75.00	100.00	100.0			
	TOT	101	76.36	25.366	25.0	62.50	75.00	100.00	100.0			
CHG FROM BSL	PLO	45	3.06	16.888	-37.5	0.00	0.00	12.50	50.0			
	ADA	56	4.24	21.752	-50.0	0.00	0.00	12.50	75.0			
	TOT	101	3.71	19.649	-50.0	0.00	0.00	12.50	75.0			
										1.19	(-6.66, 9.03)	0.765A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=MALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	44	83.90	26.192	0.0	75.00	100.00	100.00	100.0			
	ADA	56	91.82	16.552	8.3	87.50	100.00	100.00	100.0			
	TOT	100	88.33	21.582	0.0	83.33	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	44	84.09	26.280	0.0	75.00	100.00	100.00	100.0			
	ADA	56	89.73	16.205	41.7	83.33	100.00	100.00	100.0			
	TOT	100	87.25	21.302	0.0	83.33	100.00	100.00	100.0			
CHG FROM BSL	PLO	44	0.19	11.004	-41.7	0.00	0.00	0.00	25.0			
	ADA	56	-2.08	16.380	-50.0	0.00	0.00	0.00	58.3			
	TOT	100	-1.08	14.246	-50.0	0.00	0.00	0.00	58.3			
										-2.27	(-7.98, 3.43)	0.431A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=MALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	42	72.42	32.274	0.0	58.33	83.33	91.67	100.0			
	ADA	50	76.58	29.939	0.0	66.67	83.33	100.00	100.0			
	TOT	92	74.68	30.924	0.0	66.67	83.33	100.00	100.0			
FINAL/ET VALUE	PLO	42	69.84	31.219	0.0	58.33	83.33	91.67	100.0			
	ADA	50	77.50	28.497	0.0	66.67	83.33	100.00	100.0			
	TOT	92	74.00	29.851	0.0	62.50	83.33	100.00	100.0			
CHG FROM BSL	PLO	42	-2.58	12.783	-41.7	-4.17	0.00	0.00	25.0			
	ADA	50	0.92	26.086	-58.3	-8.33	0.00	0.00	100.0			
	TOT	92	-0.68	21.050	-58.3	-8.33	0.00	0.00	100.0			
										3.50	(-5.28, 12.27)	0.431A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=MALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	44	92.61	17.537	25.0	100.00	100.00	100.00	100.0			
	ADA	56	96.88	10.726	50.0	100.00	100.00	100.00	100.0			
	TOT	100	95.00	14.213	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	44	88.92	18.127	25.0	75.00	100.00	100.00	100.0			
	ADA	56	96.65	9.680	50.0	100.00	100.00	100.00	100.0			
	TOT	100	93.25	14.480	25.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	44	-3.69	12.810	-50.0	0.00	0.00	0.00	25.0			
	ADA	56	-0.22	9.680	-25.0	0.00	0.00	0.00	50.0			
	TOT	100	-1.75	11.239	-50.0	0.00	0.00	0.00	50.0			
										3.47	(-0.99, 7.93)	0.126A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=MALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	45	78.89	25.537	0.0	75.00	75.00	100.00	100.0			
	ADA	55	83.64	21.092	25.0	75.00	100.00	100.00	100.0			
	TOT	100	81.50	23.198	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	45	80.28	24.205	25.0	75.00	100.00	100.00	100.0			
	ADA	55	85.00	19.003	25.0	75.00	100.00	100.00	100.0			
	TOT	100	82.88	21.516	25.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	45	1.39	17.317	-50.0	0.00	0.00	0.00	50.0			
	ADA	55	1.36	17.624	-25.0	0.00	0.00	0.00	50.0			
	TOT	100	1.38	17.398	-50.0	0.00	0.00	0.00	50.0			
										-0.03	(-7.00, 6.95)	0.994A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=MALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	45	76.61	19.379	25.3	67.65	85.76	90.04	97.6			
	ADA	56	81.91	12.117	48.1	76.16	82.25	92.03	99.4			
	TOT	101	79.55	15.906	25.3	73.83	83.30	90.61	99.4			
FINAL/ET VALUE	PLO	45	77.06	20.085	27.9	62.73	86.63	93.45	98.2			
	ADA	56	83.00	15.155	33.1	74.96	86.04	97.33	100.0			
	TOT	101	80.36	17.681	27.9	70.49	86.40	95.15	100.0			
CHG FROM BSL	PLO	45	0.45	8.502	-28.3	-2.65	2.77	5.38	11.2			
	ADA	56	1.09	12.018	-33.6	-3.32	1.70	6.52	37.0			
	TOT	101	0.81	10.552	-33.6	-3.22	2.35	6.17	37.0			
										0.64	(-3.57, 4.85)	0.765A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=FEMALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	80	52.19	25.530	0.0	25.00	50.00	75.00	100.0			
	ADA	75	55.00	21.748	0.0	50.00	50.00	75.00	100.0			
	TOT	155	53.55	23.741	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	80	51.41	22.501	0.0	25.00	50.00	75.00	100.0			
	ADA	75	53.00	23.596	0.0	50.00	50.00	75.00	100.0			
	TOT	155	52.18	22.976	0.0	25.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	80	-0.78	17.604	-50.0	0.00	0.00	0.00	25.0			
	ADA	75	-2.00	20.860	-50.0	-25.00	0.00	0.00	50.0			
	TOT	155	-1.37	19.195	-50.0	-25.00	0.00	0.00	50.0			
										-1.22	(-7.33, 4.89)	0.694A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=FEMALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	80	69.88	16.649	40.0	60.00	80.00	80.00	100.0			
	ADA	75	67.20	15.986	40.0	60.00	60.00	80.00	100.0			
	TOT	155	68.58	16.334	40.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	80	65.25	18.485	20.0	60.00	60.00	80.00	100.0			
	ADA	75	69.60	18.413	20.0	60.00	80.00	80.00	100.0			
	TOT	155	67.35	18.519	20.0	60.00	60.00	80.00	100.0			
CHG FROM BSL	PLO	80	-4.63	16.377	-40.0	-20.00	0.00	0.00	40.0			
	ADA	75	2.40	14.317	-40.0	0.00	0.00	20.00	40.0			
	TOT	155	-1.23	15.763	-40.0	0.00	0.00	0.00	40.0			
										7.03	(2.13, 11.92)	0.005A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=FEMALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	80	74.84	23.658	12.5	62.50	75.00	100.00	100.0			
	ADA	75	74.58	22.659	25.0	50.00	75.00	87.50	100.0			
	TOT	155	74.72	23.105	12.5	62.50	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	80	76.41	21.877	25.0	62.50	75.00	100.00	100.0			
	ADA	75	78.67	21.531	12.5	62.50	75.00	100.00	100.0			
	TOT	155	77.50	21.669	12.5	62.50	75.00	100.00	100.0			
CHG FROM BSL	PLO	80	1.56	20.025	-50.0	-12.50	0.00	12.50	62.5			
	ADA	75	4.08	22.756	-50.0	-12.50	0.00	12.50	62.5			
	TOT	155	2.78	21.357	-50.0	-12.50	0.00	12.50	62.5			
										2.52	(-4.27, 9.31)	0.465A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=FEMALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	80	72.34	24.379	0.0	58.33	75.00	91.67	100.0			
	ADA	75	72.39	22.737	8.3	58.33	75.00	91.67	100.0			
	TOT	155	72.37	23.522	0.0	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	80	75.94	20.669	25.0	58.33	75.00	91.67	100.0			
	ADA	75	76.33	26.917	0.0	66.67	83.33	100.00	100.0			
	TOT	155	76.13	23.819	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	80	3.59	18.477	-33.3	-8.33	0.00	12.50	75.0			
	ADA	75	3.94	21.908	-75.0	-8.33	0.00	16.67	41.7			
	TOT	155	3.76	20.144	-75.0	-8.33	0.00	16.67	75.0			
										0.35	(-6.07, 6.77)	0.914A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=FEMALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	80	71.56	22.992	16.7	54.17	75.00	91.67	100.0			
	ADA	75	71.28	20.963	8.3	58.33	75.00	91.67	100.0			
	TOT	155	71.42	21.963	8.3	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	80	73.02	22.384	16.7	58.33	75.00	91.67	100.0			
	ADA	75	75.89	25.208	0.0	58.33	83.33	91.67	100.0			
	TOT	155	74.41	23.758	0.0	58.33	83.33	91.67	100.0			
CHG FROM BSL	PLO	80	1.46	17.416	-41.7	-8.33	0.00	8.33	50.0			
	ADA	75	4.61	18.362	-50.0	0.00	8.33	16.67	75.0			
	TOT	155	2.98	17.892	-50.0	-8.33	0.00	8.33	75.0			
										3.15	(-2.52, 8.83)	0.274A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=FEMALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	80	86.25	19.548	25.0	75.00	100.00	100.00	100.0			
	ADA	75	86.00	21.451	0.0	75.00	100.00	100.00	100.0			
	TOT	155	86.13	20.424	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	80	86.56	20.479	6.3	75.00	100.00	100.00	100.0			
	ADA	75	87.83	21.254	12.5	75.00	100.00	100.00	100.0			
	TOT	155	87.18	20.800	6.3	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	80	0.31	14.373	-43.8	0.00	0.00	0.00	37.5			
	ADA	75	1.83	15.058	-50.0	0.00	0.00	12.50	50.0			
	TOT	155	1.05	14.680	-50.0	0.00	0.00	12.50	50.0			
										1.52	(-3.15, 6.19)	0.521A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=FEMALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	80	63.65	24.323	0.0	50.00	68.75	81.25	100.0			
	ADA	75	61.03	24.780	0.0	43.75	68.75	81.25	93.8			
	TOT	155	62.38	24.500	0.0	50.00	68.75	81.25	100.0			
FINAL/ET VALUE	PLO	80	67.73	25.979	0.0	50.00	75.00	87.50	100.0			
	ADA	75	73.00	26.480	0.0	62.50	81.25	93.75	100.0			
	TOT	155	70.28	26.270	0.0	56.25	75.00	93.75	100.0			
CHG FROM BSL	PLO	80	4.09	20.961	-56.3	-6.25	6.25	12.50	68.8			
	ADA	75	11.97	18.894	-37.5	0.00	12.50	25.00	62.5			
	TOT	155	7.90	20.311	-56.3	0.00	6.25	18.75	68.8			
										7.88	(1.54, 14.23)	0.015A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=FEMALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	80	67.34	26.197	0.0	50.00	68.75	93.75	100.0			
	ADA	75	66.00	28.068	0.0	50.00	75.00	87.50	100.0			
	TOT	155	66.69	27.039	0.0	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	80	69.06	28.055	0.0	50.00	75.00	100.00	100.0			
	ADA	75	75.00	26.636	0.0	50.00	87.50	100.00	100.0			
	TOT	155	71.94	27.451	0.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	80	1.72	23.511	-62.5	-12.50	0.00	12.50	62.5			
	ADA	75	9.00	20.505	-37.5	0.00	0.00	12.50	62.5			
	TOT	155	5.24	22.337	-62.5	0.00	0.00	12.50	62.5			
										7.28	(0.26, 14.30)	0.042A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=FEMALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	80	81.09	26.410	0.0	66.67	91.67	100.00	100.0			
	ADA	75	80.89	24.954	8.3	66.67	91.67	100.00	100.0			
	TOT	155	80.99	25.633	0.0	66.67	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	80	81.67	26.598	0.0	70.83	91.67	100.00	100.0			
	ADA	75	84.78	25.386	8.3	75.00	100.00	100.00	100.0			
	TOT	155	83.17	25.981	0.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	80	0.57	19.886	-83.3	0.00	0.00	8.33	75.0			
	ADA	75	3.89	16.629	-50.0	0.00	0.00	8.33	58.3			
	TOT	155	2.18	18.398	-83.3	0.00	0.00	8.33	75.0			
										3.32	(-2.52, 9.15)	0.263A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=FEMALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	62	68.01	25.224	0.0	50.00	75.00	83.33	100.0			
	ADA	50	61.25	34.238	0.0	41.67	70.83	91.67	100.0			
	TOT	112	64.99	29.640	0.0	50.00	75.00	83.33	100.0			
FINAL/ET VALUE	PLO	62	64.31	25.536	0.0	50.00	68.75	83.33	100.0			
	ADA	50	62.67	33.386	0.0	50.00	75.00	83.33	100.0			
	TOT	112	63.58	29.173	0.0	50.00	75.00	83.33	100.0			
CHG FROM BSL	PLO	62	-3.70	17.040	-41.7	-16.67	0.00	0.00	66.7			
	ADA	50	1.42	15.096	-41.7	0.00	0.00	8.33	41.7			
	TOT	112	-1.41	16.331	-41.7	-8.33	0.00	8.33	66.7			
										5.11	(-0.99, 11.22)	0.100A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=FEMALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	79	88.29	18.706	25.0	75.00	100.00	100.00	100.0			
	ADA	74	92.57	16.412	25.0	100.00	100.00	100.00	100.0			
	TOT	153	90.36	17.707	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	79	91.46	15.445	50.0	75.00	100.00	100.00	100.0			
	ADA	74	91.55	20.804	0.0	100.00	100.00	100.00	100.0			
	TOT	153	91.50	18.174	0.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	79	3.16	12.890	-25.0	0.00	0.00	0.00	50.0			
	ADA	74	-1.01	13.996	-50.0	0.00	0.00	0.00	50.0			
	TOT	153	1.14	13.554	-50.0	0.00	0.00	0.00	50.0			
										-4.18	(-8.47, 0.12)	0.056A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=FEMALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	78	74.04	24.323	25.0	50.00	75.00	100.00	100.0			
	ADA	74	76.35	23.732	0.0	50.00	75.00	100.00	100.0			
	TOT	152	75.16	23.985	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	78	80.13	20.588	25.0	75.00	75.00	100.00	100.0			
	ADA	74	80.41	25.931	0.0	75.00	100.00	100.00	100.0			
	TOT	152	80.26	23.265	0.0	75.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	78	6.09	19.712	-25.0	0.00	0.00	25.00	50.0			
	ADA	74	4.05	21.111	-75.0	0.00	0.00	25.00	50.0			
	TOT	152	5.10	20.363	-75.0	0.00	0.00	25.00	50.0			
										-2.04	(-8.58, 4.51)	0.540A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: GENDER=FEMALE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	80	74.15	17.299	33.0	61.82	77.42	89.05	96.0			
	ADA	75	73.79	16.674	15.4	65.49	77.88	87.39	95.9			
	TOT	155	73.98	16.946	15.4	62.92	77.88	87.77	96.0			
FINAL/ET VALUE	PLO	80	75.46	17.361	28.7	64.61	78.66	87.71	100.0			
	ADA	75	77.85	20.431	12.4	66.83	86.55	92.50	99.4			
	TOT	155	76.61	18.884	12.4	65.68	83.92	90.68	100.0			
CHG FROM BSL	PLO	80	1.30	11.117	-30.9	-5.74	1.86	6.46	29.4			
	ADA	75	4.06	11.941	-31.3	-0.57	4.36	11.17	42.0			
	TOT	155	2.64	11.568	-31.3	-3.03	3.03	9.66	42.0			
										2.75	(-0.91, 6.41)	0.139A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE < 30 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	27	54.63	24.056	0.0	50.00	50.00	75.00	100.0			
	ADA	21	58.33	19.896	25.0	50.00	50.00	75.00	100.0			
	TOT	48	56.25	22.182	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	27	53.70	24.713	0.0	25.00	50.00	75.00	100.0			
	ADA	21	60.71	18.661	25.0	50.00	50.00	75.00	100.0			
	TOT	48	56.77	22.325	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	27	-0.93	16.234	-25.0	0.00	0.00	0.00	25.0			
	ADA	21	2.38	19.211	-25.0	0.00	0.00	25.00	25.0			
	TOT	48	0.52	17.481	-25.0	0.00	0.00	12.50	25.0			
										3.31	(-7.00, 13.61)	0.521A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE < 30 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	27	71.85	14.945	40.0	60.00	80.00	80.00	100.0			
	ADA	21	66.67	13.166	40.0	60.00	60.00	80.00	80.0			
	TOT	48	69.58	14.286	40.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	27	68.15	18.613	20.0	60.00	80.00	80.00	100.0			
	ADA	21	70.48	14.992	40.0	60.00	60.00	80.00	100.0			
	TOT	48	69.17	16.990	20.0	60.00	70.00	80.00	100.0			
CHG FROM BSL	PLO	27	-3.70	16.675	-40.0	-20.00	0.00	0.00	40.0			
	ADA	21	3.81	16.272	-20.0	0.00	0.00	20.00	40.0			
	TOT	48	-0.42	16.753	-40.0	-20.00	0.00	0.00	40.0			
										7.51	(-2.15, 17.18)	0.124A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE < 30 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	27	76.85	22.389	25.0	62.50	87.50	100.00	100.0			
	ADA	21	76.79	19.877	37.5	62.50	75.00	100.00	100.0			
	TOT	48	76.82	21.105	25.0	62.50	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	27	78.70	21.319	37.5	62.50	75.00	100.00	100.0			
	ADA	21	79.17	23.162	37.5	62.50	87.50	100.00	100.0			
	TOT	48	78.91	21.903	37.5	62.50	75.00	100.00	100.0			
CHG FROM BSL	PLO	27	1.85	13.739	-25.0	0.00	0.00	12.50	37.5			
	ADA	21	2.38	21.146	-62.5	0.00	0.00	12.50	50.0			
	TOT	48	2.08	17.169	-62.5	0.00	0.00	12.50	50.0			
										0.53	(-9.63, 10.69)	0.917A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE < 30 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	27	79.01	25.040	16.7	66.67	91.67	100.00	100.0			
	ADA	21	77.78	17.546	50.0	66.67	75.00	91.67	100.0			
	TOT	48	78.47	21.868	16.7	66.67	87.50	95.83	100.0			
FINAL/ET VALUE	PLO	27	83.02	22.347	16.7	75.00	91.67	100.00	100.0			
	ADA	21	79.76	21.176	25.0	75.00	83.33	100.00	100.0			
	TOT	48	81.60	21.673	16.7	75.00	91.67	100.00	100.0			
CHG FROM BSL	PLO	27	4.01	18.971	-25.0	-8.33	0.00	8.33	75.0			
	ADA	21	1.98	17.659	-41.7	-8.33	0.00	16.67	25.0			
	TOT	48	3.13	18.243	-41.7	-8.33	0.00	12.50	75.0			
										-2.03	(-12.81, 8.75)	0.707A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE < 30 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	27	75.62	23.448	8.3	58.33	83.33	91.67	100.0			
	ADA	21	77.98	18.780	37.5	66.67	83.33	91.67	100.0			
	TOT	48	76.65	21.345	8.3	62.50	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	27	77.78	22.408	8.3	66.67	83.33	91.67	100.0			
	ADA	21	80.95	20.094	33.3	75.00	83.33	100.00	100.0			
	TOT	48	79.17	21.263	8.3	66.67	83.33	95.83	100.0			
CHG FROM BSL	PLO	27	2.16	17.077	-33.3	-8.33	0.00	8.33	50.0			
	ADA	21	2.98	15.542	-41.7	-4.17	0.00	8.33	25.0			
	TOT	48	2.52	16.257	-41.7	-8.33	0.00	8.33	50.0			
										0.82	(-8.81, 10.44)	0.865A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE < 30 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	27	89.35	16.879	50.0	75.00	100.00	100.00	100.0			
	ADA	21	88.10	17.445	50.0	75.00	100.00	100.00	100.0			
	TOT	48	88.80	16.956	50.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	27	89.12	14.870	50.0	75.00	100.00	100.00	100.0			
	ADA	21	87.50	18.114	50.0	75.00	100.00	100.00	100.0			
	TOT	48	88.41	16.205	50.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	27	-0.23	13.028	-37.5	-6.25	0.00	0.00	25.0			
	ADA	21	-0.60	15.040	-50.0	0.00	0.00	0.00	25.0			
	TOT	48	-0.39	13.790	-50.0	0.00	0.00	0.00	25.0			
										-0.36	(-8.53, 7.80)	0.929A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE < 30 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	27	62.50	23.957	6.3	43.75	68.75	81.25	93.8			
	ADA	21	65.58	19.180	25.0	56.25	68.75	81.25	93.8			
	TOT	48	63.85	21.827	6.3	50.00	68.75	81.25	93.8			
FINAL/ET VALUE	PLO	27	70.14	26.308	18.8	43.75	75.00	87.50	100.0			
	ADA	21	73.81	26.117	12.5	50.00	87.50	93.75	100.0			
	TOT	48	71.74	26.010	12.5	50.00	78.13	93.75	100.0			
CHG FROM BSL	PLO	27	7.64	15.729	-37.5	-6.25	6.25	18.75	37.5			
	ADA	21	8.23	21.515	-31.3	-12.50	12.50	25.00	41.7			
	TOT	48	7.90	18.273	-37.5	-6.25	6.25	21.88	41.7			
										0.60	(-10.22, 11.41)	0.912A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE < 30 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	27	65.28	25.789	12.5	50.00	62.50	87.50	100.0			
	ADA	21	69.64	23.575	25.0	50.00	75.00	87.50	100.0			
	TOT	48	67.19	24.682	12.5	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	27	68.06	28.448	25.0	37.50	75.00	100.00	100.0			
	ADA	21	81.55	24.565	25.0	75.00	87.50	100.00	100.0			
	TOT	48	73.96	27.390	25.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	27	2.78	17.450	-37.5	0.00	0.00	12.50	50.0			
	ADA	21	11.90	25.148	-25.0	0.00	0.00	25.00	62.5			
	TOT	48	6.77	21.413	-37.5	0.00	0.00	12.50	62.5			
										9.13	(-3.26, 21.51)	0.145A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE < 30 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	27	84.57	25.287	0.0	83.33	100.00	100.00	100.0			
	ADA	21	78.57	24.801	16.7	58.33	91.67	100.00	100.0			
	TOT	48	81.94	24.990	0.0	66.67	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	27	84.88	23.461	16.7	66.67	100.00	100.00	100.0			
	ADA	21	84.52	21.616	16.7	75.00	100.00	100.00	100.0			
	TOT	48	84.72	22.435	16.7	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	27	0.31	14.886	-50.0	0.00	0.00	8.33	16.7			
	ADA	21	5.95	19.745	-33.3	0.00	0.00	8.33	50.0			
	TOT	48	2.78	17.219	-50.0	0.00	0.00	8.33	50.0			
										5.64	(-4.41, 15.70)	0.264A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE < 30 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	20	78.75	22.858	0.0	75.00	83.33	91.67	100.0			
	ADA	12	75.00	29.729	0.0	62.50	83.33	95.83	100.0			
	TOT	32	77.34	25.244	0.0	70.83	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	20	68.96	24.049	0.0	58.33	75.00	83.33	100.0			
	ADA	12	75.69	28.528	0.0	66.67	83.33	95.83	100.0			
	TOT	32	71.48	25.578	0.0	58.33	79.17	83.33	100.0			
CHG FROM BSL	PLO	20	-9.79	12.844	-25.0	-22.92	-8.33	0.00	16.7			
	ADA	12	0.69	21.748	-33.3	-12.50	0.00	16.67	41.7			
	TOT	32	-5.86	17.191	-33.3	-20.83	-2.08	0.00	41.7			
										10.49	(-1.95, 22.92)	0.095A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE < 30 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	27	90.74	19.792	25.0	100.00	100.00	100.00	100.0			
	ADA	21	94.05	15.622	50.0	100.00	100.00	100.00	100.0			
	TOT	48	92.19	17.981	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	27	92.59	16.720	25.0	100.00	100.00	100.00	100.0			
	ADA	21	94.05	22.227	0.0	100.00	100.00	100.00	100.0			
	TOT	48	93.23	19.116	0.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	27	1.85	11.860	-25.0	0.00	0.00	0.00	25.0			
	ADA	21	0.00	17.678	-50.0	0.00	0.00	0.00	50.0			
	TOT	48	1.04	14.548	-50.0	0.00	0.00	0.00	50.0			
										-1.85	(-10.45, 6.74)	0.667A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE < 30 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	27	78.70	21.599	25.0	75.00	75.00	100.00	100.0			
	ADA	20	76.25	23.613	25.0	50.00	75.00	100.00	100.0			
	TOT	47	77.66	22.260	25.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	27	83.80	18.284	25.0	75.00	75.00	100.00	100.0			
	ADA	20	80.00	25.131	25.0	75.00	87.50	100.00	100.0			
	TOT	47	82.18	21.294	25.0	75.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	27	5.09	22.537	-25.0	-12.50	0.00	25.00	50.0			
	ADA	20	3.75	24.702	-50.0	0.00	0.00	25.00	50.0			
	TOT	47	4.52	23.229	-50.0	0.00	0.00	25.00	50.0			
										-1.34	(-15.29, 12.61)	0.847A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE < 30 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	27	77.32	18.505	25.3	63.03	85.87	91.55	95.5			
	ADA	21	76.76	14.719	47.5	69.13	81.40	87.77	93.5			
	TOT	48	77.08	16.784	25.3	66.82	83.72	88.90	95.5			
FINAL/ET VALUE	PLO	27	78.60	17.581	27.9	62.73	84.17	92.88	99.6			
	ADA	21	80.09	16.937	40.6	66.42	84.33	91.63	100.0			
	TOT	48	79.25	17.136	27.9	65.13	84.25	92.25	100.0			
CHG FROM BSL	PLO	27	1.28	10.204	-25.7	-5.49	0.92	6.67	29.4			
	ADA	21	3.33	12.496	-30.8	-2.71	6.48	9.66	22.7			
	TOT	48	2.17	11.185	-30.8	-3.74	3.07	8.43	29.4			
										2.05	(-4.54, 8.64)	0.535A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	57	51.75	24.937	0.0	25.00	50.00	75.00	100.0			
	ADA	64	57.42	21.213	25.0	50.00	50.00	75.00	100.0			
	TOT	121	54.75	23.120	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	57	50.44	24.317	0.0	25.00	50.00	75.00	100.0			
	ADA	64	58.59	25.284	0.0	50.00	50.00	75.00	100.0			
	TOT	121	54.75	25.065	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	57	-1.32	21.350	-75.0	0.00	0.00	0.00	50.0			
	ADA	64	1.17	22.462	-50.0	0.00	0.00	25.00	50.0			
	TOT	121	0.00	21.890	-75.0	0.00	0.00	25.00	50.0			
										2.49	(-5.43, 10.40)	0.535A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	57	67.72	16.799	20.0	60.00	60.00	80.00	100.0			
	ADA	63	68.57	17.120	40.0	60.00	80.00	80.00	100.0			
	TOT	120	68.17	16.902	20.0	60.00	70.00	80.00	100.0			
FINAL/ET VALUE	PLO	57	63.86	19.063	20.0	60.00	60.00	80.00	100.0			
	ADA	63	73.33	19.344	20.0	60.00	80.00	80.00	100.0			
	TOT	120	68.83	19.712	20.0	60.00	80.00	80.00	100.0			
CHG FROM BSL	PLO	57	-3.86	15.324	-40.0	-20.00	0.00	0.00	20.0			
	ADA	63	4.76	15.539	-40.0	0.00	0.00	20.00	40.0			
	TOT	120	0.67	15.969	-40.0	0.00	0.00	10.00	40.0			
										8.62	(3.03, 14.21)	0.003A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	57	71.93	22.069	25.0	50.00	75.00	87.50	100.0			
	ADA	64	79.10	20.661	25.0	68.75	87.50	100.00	100.0			
	TOT	121	75.72	21.548	25.0	62.50	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	57	77.19	21.923	25.0	62.50	75.00	100.00	100.0			
	ADA	64	79.88	20.608	37.5	62.50	81.25	100.00	100.0			
	TOT	121	78.62	21.191	25.0	62.50	75.00	100.00	100.0			
CHG FROM BSL	PLO	57	5.26	19.757	-50.0	0.00	0.00	12.50	62.5			
	ADA	64	0.78	21.231	-50.0	-12.50	0.00	12.50	62.5			
	TOT	121	2.89	20.588	-50.0	0.00	0.00	12.50	62.5			
										-4.48	(-11.89, 2.93)	0.233A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	57	71.27	23.854	12.5	58.33	75.00	91.67	100.0			
	ADA	64	78.71	21.505	8.3	66.67	83.33	97.92	100.0			
	TOT	121	75.21	22.853	8.3	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	57	76.24	21.245	25.0	66.67	75.00	100.00	100.0			
	ADA	64	82.49	21.092	0.0	75.00	83.33	100.00	100.0			
	TOT	121	79.55	21.307	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	57	4.97	14.825	-25.0	0.00	0.00	16.67	62.5			
	ADA	64	3.78	17.890	-41.7	-8.33	0.00	8.33	50.0			
	TOT	121	4.34	16.461	-41.7	-4.17	0.00	8.33	62.5			
										-1.19	(-7.15, 4.76)	0.692A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	57	75.29	24.345	16.7	58.33	83.33	100.00	100.0			
	ADA	64	77.54	21.639	25.0	66.67	83.33	93.75	100.0			
	TOT	121	76.48	22.884	16.7	66.67	83.33	100.00	100.0			
FINAL/ET VALUE	PLO	57	75.00	23.975	25.0	58.33	75.00	100.00	100.0			
	ADA	64	80.73	23.235	0.0	70.83	87.50	100.00	100.0			
	TOT	121	78.03	23.662	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	57	-0.29	14.236	-41.7	-8.33	0.00	8.33	33.3			
	ADA	64	3.19	17.952	-37.5	-4.17	0.00	10.42	75.0			
	TOT	121	1.55	16.335	-41.7	-8.33	0.00	8.33	75.0			
										3.48	(-2.40, 9.36)	0.243A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	57	86.84	20.241	25.0	75.00	100.00	100.00	100.0			
	ADA	64	90.63	16.214	25.0	87.50	100.00	100.00	100.0			
	TOT	121	88.84	18.243	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	57	86.18	19.755	6.3	75.00	100.00	100.00	100.0			
	ADA	64	91.21	17.349	12.5	87.50	100.00	100.00	100.0			
	TOT	121	88.84	18.614	6.3	87.50	100.00	100.00	100.0			
CHG FROM BSL	PLO	57	-0.66	12.649	-43.8	0.00	0.00	0.00	37.5			
	ADA	64	0.59	14.845	-50.0	0.00	0.00	0.00	50.0			
	TOT	121	0.00	13.811	-50.0	0.00	0.00	0.00	50.0			
										1.24	(-3.75, 6.24)	0.623A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	57	64.04	26.993	0.0	50.00	75.00	87.50	100.0			
	ADA	64	65.10	24.437	0.0	50.00	68.75	85.42	100.0			
	TOT	121	64.60	25.570	0.0	50.00	68.75	87.50	100.0			
FINAL/ET VALUE	PLO	57	70.50	27.005	0.0	56.25	81.25	93.75	100.0			
	ADA	64	74.90	22.835	0.0	62.50	81.25	93.75	100.0			
	TOT	121	72.83	24.879	0.0	62.50	81.25	93.75	100.0			
CHG FROM BSL	PLO	57	6.47	16.064	-31.3	0.00	6.25	12.50	68.8			
	ADA	64	9.80	18.488	-37.5	0.00	6.25	18.75	62.5			
	TOT	121	8.23	17.397	-37.5	0.00	6.25	12.50	68.8			
										3.33	(-2.94, 9.60)	0.295A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	57	69.96	28.334	12.5	50.00	75.00	100.00	100.0			
	ADA	64	71.48	27.501	0.0	50.00	75.00	100.00	100.0			
	TOT	121	70.76	27.790	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	57	73.25	29.828	12.5	50.00	87.50	100.00	100.0			
	ADA	64	77.93	25.074	0.0	62.50	75.00	100.00	100.0			
	TOT	121	75.72	27.400	0.0	50.00	87.50	100.00	100.0			
CHG FROM BSL	PLO	57	3.29	24.036	-62.5	0.00	0.00	12.50	62.5			
	ADA	64	6.45	19.415	-37.5	0.00	0.00	12.50	62.5			
	TOT	121	4.96	21.679	-62.5	0.00	0.00	12.50	62.5			
										3.16	(-4.67, 10.99)	0.426A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	57	77.85	31.192	0.0	58.33	100.00	100.00	100.0			
	ADA	64	86.20	22.381	8.3	83.33	100.00	100.00	100.0			
	TOT	121	82.27	27.102	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	57	81.73	29.439	0.0	75.00	100.00	100.00	100.0			
	ADA	64	88.67	19.774	8.3	83.33	100.00	100.00	100.0			
	TOT	121	85.40	24.937	0.0	83.33	100.00	100.00	100.0			
CHG FROM BSL	PLO	57	3.87	16.019	-41.7	0.00	0.00	0.00	75.0			
	ADA	64	2.47	17.422	-41.7	0.00	0.00	0.00	58.3			
	TOT	121	3.13	16.721	-41.7	0.00	0.00	0.00	75.0			
										-1.40	(-7.45, 4.65)	0.648A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	47	68.26	31.500	0.0	50.00	75.00	91.67	100.0			
	ADA	51	71.00	33.881	0.0	58.33	83.33	100.00	100.0			
	TOT	98	69.69	32.621	0.0	58.33	83.33	100.00	100.0			
FINAL/ET VALUE	PLO	47	65.43	31.481	0.0	50.00	75.00	91.67	100.0			
	ADA	51	72.06	31.834	0.0	58.33	83.33	100.00	100.0			
	TOT	98	68.88	31.677	0.0	58.33	75.00	100.00	100.0			
CHG FROM BSL	PLO	47	-2.84	13.463	-41.7	-8.33	0.00	0.00	25.0			
	ADA	51	1.06	19.980	-41.7	-8.33	0.00	0.00	100.0			
	TOT	98	-0.81	17.192	-41.7	-8.33	0.00	0.00	100.0			
										3.90	(-2.99, 10.79)	0.264A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	55	91.36	17.492	25.0	100.00	100.00	100.00	100.0			
	ADA	64	96.48	10.789	50.0	100.00	100.00	100.00	100.0			
	TOT	119	94.12	14.448	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	55	92.05	14.306	50.0	75.00	100.00	100.00	100.0			
	ADA	64	96.29	12.536	25.0	100.00	100.00	100.00	100.0			
	TOT	119	94.33	13.493	25.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	55	0.68	13.697	-25.0	0.00	0.00	0.00	50.0			
	ADA	64	-0.20	11.022	-25.0	0.00	0.00	0.00	50.0			
	TOT	119	0.21	12.284	-25.0	0.00	0.00	0.00	50.0			
										-0.88	(-5.37, 3.61)	0.700A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	55	77.27	26.031	0.0	50.00	75.00	100.00	100.0			
	ADA	64	83.20	20.919	25.0	75.00	100.00	100.00	100.0			
	TOT	119	80.46	23.506	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	55	80.45	22.278	25.0	75.00	75.00	100.00	100.0			
	ADA	64	85.16	18.213	25.0	75.00	100.00	100.00	100.0			
	TOT	119	82.98	20.243	25.0	75.00	87.50	100.00	100.0			
CHG FROM BSL	PLO	55	3.18	15.065	-25.0	0.00	0.00	0.00	50.0			
	ADA	64	1.95	16.847	-25.0	0.00	0.00	0.00	50.0			
	TOT	119	2.52	15.993	-25.0	0.00	0.00	0.00	50.0			
										-1.23	(-7.07, 4.62)	0.678A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	57	74.63	19.275	26.6	64.36	82.65	90.04	97.6			
	ADA	64	79.04	15.096	35.5	73.22	81.14	90.51	99.4			
	TOT	121	76.96	17.260	26.6	70.53	81.70	90.42	99.4			
FINAL/ET VALUE	PLO	57	76.43	19.211	31.7	65.30	84.13	92.77	100.0			
	ADA	64	82.23	16.459	20.4	74.96	86.82	92.69	100.0			
	TOT	121	79.50	17.969	20.4	70.80	86.33	92.77	100.0			
CHG FROM BSL	PLO	57	1.80	9.770	-30.9	-3.79	2.54	5.48	21.5			
	ADA	64	3.19	11.644	-24.9	-2.18	3.07	9.56	42.0			
	TOT	121	2.54	10.780	-30.9	-2.27	2.73	8.56	42.0			
										1.39	(-2.51, 5.29)	0.481A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.5.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	41	52.44	27.275	0.0	25.00	50.00	75.00	100.0			
	ADA	46	54.89	22.742	0.0	50.00	50.00	75.00	100.0			
	TOT	87	53.74	24.863	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	41	51.52	21.686	0.0	50.00	50.00	75.00	100.0			
	ADA	46	50.54	23.711	0.0	25.00	50.00	75.00	100.0			
	TOT	87	51.01	22.653	0.0	25.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	41	-0.91	17.764	-50.0	0.00	0.00	0.00	25.0			
	ADA	46	-4.35	17.523	-50.0	-25.00	0.00	0.00	25.0			
	TOT	87	-2.73	17.619	-50.0	-25.00	0.00	0.00	25.0			
										-3.43	(-10.96, 4.10)	0.367A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.5.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	41	65.61	17.614	40.0	60.00	60.00	80.00	100.0			
	ADA	46	66.52	14.639	40.0	60.00	60.00	80.00	100.0			
	TOT	87	66.09	16.020	40.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	41	61.95	18.333	20.0	40.00	60.00	80.00	100.0			
	ADA	46	64.57	19.744	20.0	60.00	60.00	80.00	100.0			
	TOT	87	63.33	19.027	20.0	40.00	60.00	80.00	100.0			
CHG FROM BSL	PLO	41	-3.66	16.395	-40.0	-20.00	0.00	0.00	20.0			
	ADA	46	-1.96	16.003	-40.0	0.00	0.00	0.00	20.0			
	TOT	87	-2.76	16.117	-40.0	0.00	0.00	0.00	20.0			
										1.70	(-5.21, 8.61)	0.626A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.5.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	41	81.10	23.238	12.5	62.50	87.50	100.00	100.0			
	ADA	46	78.67	21.188	25.0	75.00	87.50	100.00	100.0			
	TOT	87	79.81	22.081	12.5	62.50	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	41	80.49	18.760	50.0	62.50	87.50	100.00	100.0			
	ADA	46	82.61	18.907	12.5	75.00	87.50	100.00	100.0			
	TOT	87	81.61	18.759	12.5	75.00	87.50	100.00	100.0			
CHG FROM BSL	PLO	41	-0.61	15.550	-50.0	0.00	0.00	0.00	50.0			
	ADA	46	3.94	22.873	-50.0	-12.50	0.00	12.50	62.5			
	TOT	87	1.80	19.785	-50.0	-12.50	0.00	12.50	62.5			
										4.55	(-3.89, 12.99)	0.287A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.5.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	41	66.87	24.544	0.0	50.00	75.00	83.33	100.0			
	ADA	46	70.56	21.452	12.5	58.33	75.00	83.33	100.0			
	TOT	87	68.82	22.900	0.0	50.00	75.00	83.33	100.0			
FINAL/ET VALUE	PLO	41	68.70	22.031	25.0	50.00	66.67	83.33	100.0			
	ADA	46	72.64	29.274	0.0	58.33	83.33	91.67	100.0			
	TOT	87	70.79	26.040	0.0	50.00	75.00	91.67	100.0			
CHG FROM BSL	PLO	41	1.83	19.141	-33.3	-8.33	0.00	16.67	50.0			
	ADA	46	2.08	25.012	-75.0	-4.17	8.33	16.67	41.7			
	TOT	87	1.96	22.310	-75.0	-8.33	0.00	16.67	50.0			
										0.25	(-9.33, 9.84)	0.958A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.5.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	41	71.34	22.519	25.0	50.00	75.00	91.67	100.0			
	ADA	46	71.92	20.135	8.3	58.33	75.00	91.67	100.0			
	TOT	87	71.65	21.168	8.3	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	41	72.15	21.619	16.7	58.33	66.67	91.67	100.0			
	ADA	46	74.55	25.280	0.0	58.33	83.33	91.67	100.0			
	TOT	87	73.42	23.521	0.0	58.33	75.00	91.67	100.0			
CHG FROM BSL	PLO	41	0.81	17.757	-33.3	-8.33	0.00	8.33	50.0			
	ADA	46	2.63	16.973	-50.0	-4.17	4.17	8.33	41.7			
	TOT	87	1.77	17.269	-50.0	-8.33	0.00	8.33	50.0			
										1.81	(-5.59, 9.22)	0.628A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.5.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	41	87.20	18.003	37.5	75.00	100.00	100.00	100.0			
	ADA	46	83.97	21.995	0.0	75.00	87.50	100.00	100.0			
	TOT	87	85.49	20.162	0.0	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	41	85.37	21.084	25.0	75.00	100.00	100.00	100.0			
	ADA	46	85.46	20.500	25.0	75.00	100.00	100.00	100.0			
	TOT	87	85.42	20.656	25.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	41	-1.83	14.131	-37.5	-12.50	0.00	0.00	25.0			
	ADA	46	1.49	14.018	-25.0	0.00	0.00	12.50	25.0			
	TOT	87	-0.07	14.089	-37.5	0.00	0.00	12.50	25.0			
										3.32	(-2.69, 9.33)	0.275A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.5.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	41	65.35	20.837	25.0	50.00	62.50	81.25	93.8			
	ADA	46	66.58	23.019	12.5	50.00	75.00	81.25	100.0			
	TOT	87	66.00	21.900	12.5	50.00	68.75	81.25	100.0			
FINAL/ET VALUE	PLO	41	64.63	25.793	0.0	50.00	62.50	87.50	100.0			
	ADA	46	75.95	24.999	12.5	62.50	81.25	93.75	100.0			
	TOT	87	70.62	25.859	0.0	50.00	75.00	93.75	100.0			
CHG FROM BSL	PLO	41	-0.71	21.315	-56.3	-12.50	6.25	12.50	37.5			
	ADA	46	9.38	15.687	-37.5	0.00	12.50	18.75	43.8			
	TOT	87	4.62	19.124	-56.3	0.00	6.25	18.75	43.8			
										10.09	(2.16, 18.01)	0.013A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.5.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	41	67.07	24.005	0.0	50.00	62.50	87.50	100.0			
	ADA	46	68.21	25.915	12.5	50.00	75.00	87.50	100.0			
	TOT	87	67.67	24.895	0.0	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	41	67.38	25.292	0.0	50.00	75.00	87.50	100.0			
	ADA	46	73.64	25.170	25.0	50.00	75.00	100.00	100.0			
	TOT	87	70.69	25.277	0.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	41	0.30	19.860	-50.0	-12.50	0.00	12.50	50.0			
	ADA	46	5.43	21.514	-50.0	0.00	0.00	12.50	75.0			
	TOT	87	3.02	20.792	-50.0	-12.50	0.00	12.50	75.0			
										5.13	(-3.73, 13.99)	0.253A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.5.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	40	86.46	17.366	33.3	75.00	91.67	100.00	100.0			
	ADA	46	87.86	20.987	8.3	83.33	100.00	100.00	100.0			
	TOT	86	87.21	19.289	8.3	83.33	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	40	82.08	24.134	16.7	75.00	91.67	100.00	100.0			
	ADA	46	85.51	25.181	8.3	83.33	100.00	100.00	100.0			
	TOT	86	83.91	24.614	8.3	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	40	-4.38	19.428	-83.3	0.00	0.00	0.00	25.0			
	ADA	46	-2.36	13.570	-50.0	0.00	0.00	0.00	25.0			
	TOT	86	-3.29	16.483	-83.3	0.00	0.00	0.00	25.0			
										2.02	(-5.10, 9.14)	0.574A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.5.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	37	66.89	26.038	0.0	58.33	66.67	83.33	100.0			
	ADA	37	64.08	32.740	0.0	58.33	75.00	83.33	100.0			
	TOT	74	65.48	29.410	0.0	58.33	75.00	83.33	100.0			
FINAL/ET VALUE	PLO	37	66.67	25.685	0.0	50.00	66.67	83.33	100.0			
	ADA	37	65.54	32.891	0.0	58.33	79.17	83.33	100.0			
	TOT	74	66.10	29.312	0.0	50.00	75.00	83.33	100.0			
CHG FROM BSL	PLO	37	-0.23	18.081	-41.7	-8.33	0.00	8.33	66.7			
	ADA	37	1.46	23.183	-58.3	-8.33	0.00	8.33	100.0			
	TOT	74	0.62	20.663	-58.3	-8.33	0.00	8.33	100.0			
										1.69	(-7.95, 11.32)	0.728A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.5.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	41	87.20	18.643	50.0	75.00	100.00	100.00	100.0			
	ADA	45	91.67	17.678	25.0	100.00	100.00	100.00	100.0			
	TOT	86	89.53	18.176	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	41	87.20	18.643	50.0	75.00	100.00	100.00	100.0			
	ADA	45	90.00	19.511	25.0	100.00	100.00	100.00	100.0			
	TOT	86	88.66	19.042	25.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	41	0.00	13.693	-50.0	0.00	0.00	0.00	25.0			
	ADA	45	-1.67	11.180	-50.0	0.00	0.00	0.00	25.0			
	TOT	86	-0.87	12.395	-50.0	0.00	0.00	0.00	25.0			
										-1.67	(-7.01, 3.67)	0.537A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.5.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	41	71.95	25.122	25.0	50.00	75.00	100.00	100.0			
	ADA	45	75.56	24.708	0.0	50.00	75.00	100.00	100.0			
	TOT	86	73.84	24.825	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	41	77.44	23.588	25.0	50.00	75.00	100.00	100.0			
	ADA	45	79.44	28.349	0.0	75.00	100.00	100.00	100.0			
	TOT	86	78.49	26.055	0.0	50.00	87.50	100.00	100.0			
CHG FROM BSL	PLO	41	5.49	21.296	-50.0	0.00	0.00	25.00	50.0			
	ADA	45	3.89	21.290	-75.0	0.00	0.00	25.00	50.0			
	TOT	86	4.65	21.183	-75.0	0.00	0.00	25.00	50.0			
										-1.60	(-10.74, 7.54)	0.729A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.5.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	41	74.10	16.159	40.3	62.65	75.83	88.14	95.6			
	ADA	46	75.02	16.081	15.4	68.90	79.99	85.08	98.9			
	TOT	87	74.59	16.031	15.4	66.52	78.86	87.08	98.9			
FINAL/ET VALUE	PLO	41	73.79	17.705	28.7	60.19	73.94	87.77	98.2			
	ADA	46	77.00	21.519	12.4	66.83	85.30	93.64	100.0			
	TOT	87	75.49	19.766	12.4	63.98	76.67	92.50	100.0			
CHG FROM BSL	PLO	41	-0.31	10.958	-28.3	-5.80	2.46	6.04	25.0			
	ADA	46	1.98	12.531	-33.6	-0.57	3.39	9.58	24.4			
	TOT	87	0.90	11.804	-33.6	-3.22	2.65	7.58	25.0			
										2.29	(-2.76, 7.33)	0.370A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	92	53.80	25.119	0.0	37.50	50.00	75.00	100.0			
	ADA	96	59.11	21.188	0.0	50.00	50.00	75.00	100.0			
	TOT	188	56.52	23.285	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	92	52.85	21.460	0.0	50.00	50.00	75.00	100.0			
	ADA	96	59.51	21.820	0.0	50.00	56.25	75.00	100.0			
	TOT	188	56.25	21.843	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	92	-0.95	18.179	-50.0	0.00	0.00	0.00	50.0			
	ADA	96	0.39	19.740	-50.0	-12.50	0.00	6.25	50.0			
	TOT	188	-0.27	18.953	-50.0	0.00	0.00	0.00	50.0			
										1.34	(-4.12, 6.81)	0.629A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	92	69.02	16.446	20.0	60.00	80.00	80.00	100.0			
	ADA	95	69.89	13.952	40.0	60.00	80.00	80.00	100.0			
	TOT	187	69.47	15.195	20.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	92	65.43	17.315	20.0	60.00	60.00	80.00	100.0			
	ADA	95	71.89	17.582	20.0	60.00	80.00	80.00	100.0			
	TOT	187	68.72	17.703	20.0	60.00	80.00	80.00	100.0			
CHG FROM BSL	PLO	92	-3.59	16.007	-40.0	-20.00	0.00	0.00	40.0			
	ADA	95	2.00	16.019	-40.0	0.00	0.00	20.00	40.0			
	TOT	187	-0.75	16.213	-40.0	0.00	0.00	0.00	40.0			
										5.59	(0.97, 10.21)	0.018A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	92	74.05	23.384	12.5	62.50	75.00	100.00	100.0			
	ADA	96	78.71	21.143	25.0	62.50	87.50	100.00	100.0			
	TOT	188	76.43	22.331	12.5	62.50	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	92	77.85	20.892	25.0	62.50	75.00	100.00	100.0			
	ADA	96	82.55	20.072	12.5	75.00	87.50	100.00	100.0			
	TOT	188	80.25	20.558	12.5	62.50	81.25	100.00	100.0			
CHG FROM BSL	PLO	92	3.80	17.652	-50.0	0.00	0.00	12.50	62.5			
	ADA	96	3.84	21.733	-62.5	0.00	0.00	12.50	62.5			
	TOT	188	3.82	19.789	-62.5	0.00	0.00	12.50	62.5			
										0.04	(-5.67, 5.75)	0.990A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2.2000.4.1.1.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	92	72.15	24.823	12.5	58.33	75.00	91.67	100.0			
	ADA	96	76.65	20.929	8.3	66.67	83.33	91.67	100.0			
	TOT	188	74.45	22.967	8.3	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	92	76.09	22.073	16.7	58.33	83.33	100.00	100.0			
	ADA	96	79.82	23.402	0.0	75.00	83.33	100.00	100.0			
	TOT	188	77.99	22.777	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	92	3.94	17.853	-33.3	-8.33	0.00	16.67	75.0			
	ADA	96	3.17	17.921	-75.0	-2.08	0.00	16.67	41.7			
	TOT	188	3.55	17.844	-75.0	-8.33	0.00	16.67	75.0			
										-0.77	(-5.92, 4.38)	0.768A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	92	74.18	23.377	8.3	58.33	83.33	91.67	100.0			
	ADA	96	78.86	18.744	25.0	66.67	83.33	91.67	100.0			
	TOT	188	76.57	21.211	8.3	66.67	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	92	75.14	22.395	8.3	62.50	75.00	91.67	100.0			
	ADA	96	80.25	22.703	0.0	75.00	85.42	100.00	100.0			
	TOT	188	77.75	22.638	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	92	0.95	16.963	-41.7	-8.33	0.00	8.33	50.0			
	ADA	96	1.39	17.372	-50.0	-8.33	0.00	8.33	75.0			
	TOT	188	1.17	17.128	-50.0	-8.33	0.00	8.33	75.0			
										0.44	(-4.51, 5.38)	0.861A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	92	87.64	18.852	25.0	75.00	100.00	100.00	100.0			
	ADA	96	89.19	17.360	25.0	75.00	100.00	100.00	100.0			
	TOT	188	88.43	18.074	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	92	86.82	19.313	6.3	75.00	100.00	100.00	100.0			
	ADA	96	89.84	17.614	12.5	87.50	100.00	100.00	100.0			
	TOT	188	88.36	18.477	6.3	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	92	-0.82	13.997	-43.8	0.00	0.00	0.00	37.5			
	ADA	96	0.65	13.617	-50.0	0.00	0.00	0.00	50.0			
	TOT	188	-0.07	13.787	-50.0	0.00	0.00	0.00	50.0			
										1.47	(-2.51, 5.44)	0.468A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	92	63.84	22.902	0.0	50.00	68.75	81.25	93.8			
	ADA	96	65.23	23.317	0.0	50.00	68.75	81.25	100.0			
	TOT	188	64.55	23.064	0.0	50.00	68.75	81.25	100.0			
FINAL/ET VALUE	PLO	92	67.73	25.766	0.0	50.00	75.00	87.50	100.0			
	ADA	96	75.85	24.428	0.0	62.50	81.25	93.75	100.0			
	TOT	188	71.88	25.353	0.0	56.25	81.25	93.75	100.0			
CHG FROM BSL	PLO	92	3.89	17.775	-56.3	0.00	6.25	15.63	43.8			
	ADA	96	10.61	17.980	-31.3	0.00	12.50	18.75	62.5			
	TOT	188	7.32	18.147	-56.3	0.00	6.25	18.75	62.5			
										6.72	(1.57, 11.86)	0.011A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	92	66.58	25.885	0.0	50.00	68.75	87.50	100.0			
	ADA	96	68.36	26.960	0.0	50.00	75.00	87.50	100.0			
	TOT	188	67.49	26.384	0.0	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	92	68.61	28.073	0.0	50.00	75.00	100.00	100.0			
	ADA	96	75.13	26.439	0.0	56.25	75.00	100.00	100.0			
	TOT	188	71.94	27.373	0.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	92	2.04	21.070	-62.5	-12.50	0.00	12.50	62.5			
	ADA	96	6.77	20.988	-50.0	0.00	0.00	12.50	62.5			
	TOT	188	4.45	21.106	-62.5	0.00	0.00	12.50	62.5			
										4.73	(-1.32, 10.79)	0.125A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	91	82.14	25.018	0.0	75.00	91.67	100.00	100.0			
	ADA	96	86.63	20.714	8.3	75.00	100.00	100.00	100.0			
	TOT	187	84.45	22.958	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	91	82.23	25.435	0.0	75.00	91.67	100.00	100.0			
	ADA	96	86.46	22.822	8.3	83.33	100.00	100.00	100.0			
	TOT	187	84.40	24.156	0.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	91	0.09	17.146	-83.3	0.00	0.00	8.33	41.7			
	ADA	96	-0.17	14.609	-50.0	0.00	0.00	0.00	50.0			
	TOT	187	-0.04	15.851	-83.3	0.00	0.00	8.33	50.0			
										-0.27	(-4.85, 4.32)	0.909A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	77	72.29	27.396	0.0	58.33	83.33	91.67	100.0			
	ADA	74	73.76	28.534	0.0	66.67	83.33	91.67	100.0			
	TOT	151	73.01	27.876	0.0	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	77	67.97	27.014	0.0	50.00	75.00	83.33	100.0			
	ADA	74	73.65	26.506	0.0	58.33	83.33	91.67	100.0			
	TOT	151	70.75	26.829	0.0	58.33	75.00	91.67	100.0			
CHG FROM BSL	PLO	77	-4.33	15.858	-41.7	-12.50	0.00	0.00	66.7			
	ADA	74	-0.11	18.811	-41.7	-8.33	0.00	8.33	100.0			
	TOT	151	-2.26	17.439	-41.7	-8.33	0.00	0.00	100.0			
										4.22	(-1.37, 9.80)	0.138A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	90	89.17	19.128	25.0	75.00	100.00	100.00	100.0			
	ADA	95	96.32	11.513	50.0	100.00	100.00	100.00	100.0			
	TOT	185	92.84	16.048	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	90	90.28	16.632	25.0	75.00	100.00	100.00	100.0			
	ADA	95	95.13	14.275	25.0	100.00	100.00	100.00	100.0			
	TOT	185	92.77	15.614	25.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	90	1.11	13.978	-50.0	0.00	0.00	0.00	50.0			
	ADA	95	-1.18	10.951	-50.0	0.00	0.00	0.00	50.0			
	TOT	185	-0.07	12.534	-50.0	0.00	0.00	0.00	50.0			
										-2.30	(-5.93, 1.34)	0.214A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	90	76.67	23.643	25.0	50.00	75.00	100.00	100.0			
	ADA	95	80.53	22.532	25.0	75.00	75.00	100.00	100.0			
	TOT	185	78.65	23.097	25.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	90	81.39	21.952	25.0	75.00	81.25	100.00	100.0			
	ADA	95	82.11	23.254	0.0	75.00	100.00	100.00	100.0			
	TOT	185	81.76	22.571	0.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	90	4.72	19.704	-50.0	0.00	0.00	25.00	50.0			
	ADA	95	1.58	20.567	-75.0	0.00	0.00	0.00	50.0			
	TOT	185	3.11	20.159	-75.0	0.00	0.00	25.00	50.0			
										-3.14	(-8.99, 2.71)	0.290A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	92	75.07	17.757	25.3	63.50	81.73	90.13	97.6			
	ADA	96	78.49	14.427	35.5	71.66	81.27	88.88	99.4			
	TOT	188	76.82	16.190	25.3	68.52	81.55	89.19	99.4			
FINAL/ET VALUE	PLO	92	76.18	17.902	27.9	64.98	80.13	92.47	99.6			
	ADA	96	80.90	18.071	12.4	74.08	86.69	93.67	100.0			
	TOT	188	78.59	18.096	12.4	67.86	84.47	92.88	100.0			
CHG FROM BSL	PLO	92	1.10	10.866	-30.9	-4.98	2.27	6.21	29.4			
	ADA	96	2.41	11.833	-31.3	-2.03	3.16	8.43	42.0			
	TOT	188	1.77	11.358	-31.3	-2.87	2.59	6.83	42.0			
										1.31	(-1.97, 4.58)	0.432A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	33	49.24	26.134	0.0	25.00	50.00	75.00	100.0			
	ADA	35	50.00	21.004	25.0	25.00	50.00	50.00	100.0			
	TOT	68	49.63	23.457	0.0	25.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	33	47.73	28.204	0.0	25.00	50.00	75.00	100.0			
	ADA	35	46.79	27.343	0.0	25.00	50.00	75.00	100.0			
	TOT	68	47.24	27.560	0.0	25.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	33	-1.52	21.596	-75.0	0.00	0.00	0.00	25.0			
	ADA	35	-3.21	22.142	-50.0	-25.00	0.00	12.50	25.0			
	TOT	68	-2.39	21.732	-75.0	-25.00	0.00	6.25	25.0			
										-1.70	(-12.30, 8.90)	0.750A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	33	64.85	17.342	40.0	60.00	60.00	80.00	100.0			
	ADA	35	61.14	18.113	40.0	40.00	60.00	80.00	100.0			
	TOT	68	62.94	17.709	40.0	40.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	33	60.61	22.071	20.0	40.00	60.00	80.00	100.0			
	ADA	35	64.00	22.123	20.0	40.00	60.00	80.00	100.0			
	TOT	68	62.35	21.998	20.0	40.00	60.00	80.00	100.0			
CHG FROM BSL	PLO	33	-4.24	15.619	-40.0	-20.00	0.00	0.00	20.0			
	ADA	35	2.86	16.192	-40.0	0.00	0.00	20.00	40.0			
	TOT	68	-0.59	16.197	-40.0	0.00	0.00	0.00	40.0			
										7.10	(-0.61, 14.81)	0.071A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	33	81.44	20.039	25.0	75.00	87.50	100.00	100.0			
	ADA	35	78.21	19.256	25.0	62.50	87.50	87.50	100.0			
	TOT	68	79.78	19.560	25.0	68.75	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	33	80.68	20.274	37.5	75.00	87.50	100.00	100.0			
	ADA	35	75.71	20.549	37.5	62.50	75.00	100.00	100.0			
	TOT	68	78.13	20.417	37.5	62.50	75.00	100.00	100.0			
CHG FROM BSL	PLO	33	-0.76	16.220	-50.0	-12.50	0.00	12.50	25.0			
	ADA	35	-2.50	21.179	-50.0	-25.00	0.00	12.50	37.5			
	TOT	68	-1.65	18.816	-50.0	-12.50	0.00	12.50	37.5			
										-1.74	(-10.92, 7.43)	0.706A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	33	69.70	24.010	0.0	58.33	75.00	91.67	100.0			
	ADA	35	73.10	21.659	12.5	58.33	75.00	91.67	100.0			
	TOT	68	71.45	22.722	0.0	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	33	72.85	22.729	25.0	58.33	75.00	91.67	100.0			
	ADA	35	75.24	27.452	0.0	66.67	83.33	100.00	100.0			
	TOT	68	74.08	25.112	0.0	58.33	83.33	100.00	100.0			
CHG FROM BSL	PLO	33	3.16	15.346	-25.0	-4.17	0.00	8.33	41.7			
	ADA	35	2.14	26.629	-66.7	-8.33	4.17	16.67	50.0			
	TOT	68	2.63	21.739	-66.7	-8.33	0.00	16.67	50.0			
										-1.01	(-11.62, 9.59)	0.849A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	33	73.74	24.037	25.0	50.00	83.33	100.00	100.0			
	ADA	35	66.79	23.429	8.3	50.00	66.67	91.67	100.0			
	TOT	68	70.16	23.807	8.3	50.00	66.67	91.67	100.0			
FINAL/ET VALUE	PLO	33	73.36	24.205	25.0	58.33	75.00	100.00	100.0			
	ADA	35	74.05	25.467	8.3	58.33	83.33	91.67	100.0			
	TOT	68	73.71	24.679	8.3	58.33	83.33	100.00	100.0			
CHG FROM BSL	PLO	33	-0.38	13.026	-33.3	-8.33	0.00	8.33	25.0			
	ADA	35	7.26	15.861	-25.0	0.00	8.33	16.67	41.7			
	TOT	68	3.55	14.950	-33.3	0.00	0.00	14.58	41.7			
										7.64	(0.59, 14.69)	0.034A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	33	87.12	18.615	37.5	75.00	100.00	100.00	100.0			
	ADA	35	84.29	21.934	0.0	75.00	87.50	100.00	100.0			
	TOT	68	85.66	20.290	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	33	85.80	19.090	25.0	75.00	87.50	100.00	100.0			
	ADA	35	85.18	21.227	25.0	75.00	100.00	100.00	100.0			
	TOT	68	85.48	20.070	25.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	33	-1.33	10.569	-25.0	-6.25	0.00	0.00	37.5			
	ADA	35	0.89	16.889	-50.0	0.00	0.00	12.50	37.5			
	TOT	68	-0.18	14.119	-50.0	0.00	0.00	0.00	37.5			
										2.22	(-4.65, 9.09)	0.521A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	33	64.96	28.209	12.5	31.25	75.00	87.50	100.0			
	ADA	35	66.96	22.462	12.5	56.25	68.75	87.50	93.8			
	TOT	68	65.99	25.241	12.5	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	33	70.64	28.362	12.5	50.00	81.25	93.75	100.0			
	ADA	35	73.04	22.877	12.5	62.50	75.00	93.75	100.0			
	TOT	68	71.88	25.519	12.5	56.25	81.25	93.75	100.0			
CHG FROM BSL	PLO	33	5.68	19.223	-37.5	-6.25	6.25	12.50	68.8			
	ADA	35	6.07	17.709	-37.5	-6.25	6.25	18.75	37.5			
	TOT	68	5.88	18.322	-37.5	-6.25	6.25	12.50	68.8			
										0.39	(-8.55, 9.33)	0.931A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	33	71.97	27.427	25.0	50.00	75.00	100.00	100.0			
	ADA	35	74.64	23.772	12.5	62.50	75.00	100.00	100.0			
	TOT	68	73.35	25.453	12.5	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	33	74.62	27.861	12.5	50.00	87.50	100.00	100.0			
	ADA	35	82.14	19.946	25.0	75.00	87.50	100.00	100.0			
	TOT	68	78.49	24.227	12.5	62.50	87.50	100.00	100.0			
CHG FROM BSL	PLO	33	2.65	22.264	-50.0	-12.50	0.00	12.50	62.5			
	ADA	35	7.50	21.693	-37.5	0.00	0.00	12.50	75.0			
	TOT	68	5.15	21.943	-50.0	0.00	0.00	12.50	75.0			
										4.85	(-5.80, 15.49)	0.366A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	33	81.94	29.841	16.7	75.00	100.00	100.00	100.0			
	ADA	35	82.62	26.458	8.3	83.33	91.67	100.00	100.0			
	TOT	68	82.29	27.940	8.3	79.17	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	33	83.33	29.315	0.0	83.33	100.00	100.00	100.0			
	ADA	35	88.10	19.832	16.7	83.33	100.00	100.00	100.0			
	TOT	68	85.78	24.815	0.0	83.33	100.00	100.00	100.0			
CHG FROM BSL	PLO	33	1.39	17.637	-50.0	0.00	0.00	0.00	75.0			
	ADA	35	5.48	21.192	-50.0	0.00	0.00	8.33	58.3			
	TOT	68	3.49	19.512	-50.0	0.00	0.00	0.00	75.0			
										4.09	(-5.38, 13.56)	0.392A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	27	62.65	29.812	0.0	50.00	66.67	83.33	100.0			
	ADA	26	55.13	40.557	0.0	0.00	62.50	83.33	100.0			
	TOT	53	58.96	35.350	0.0	41.67	66.67	83.33	100.0			
FINAL/ET VALUE	PLO	27	62.50	30.662	0.0	33.33	75.00	83.33	100.0			
	ADA	26	59.94	42.428	0.0	0.00	75.00	100.00	100.0			
	TOT	53	61.24	36.568	0.0	29.17	75.00	91.67	100.0			
CHG FROM BSL	PLO	27	-0.15	13.843	-41.7	-4.17	0.00	8.33	25.0			
	ADA	26	4.81	26.995	-58.3	0.00	0.00	8.33	100.0			
	TOT	53	2.28	21.271	-58.3	0.00	0.00	8.33	100.0			
										4.96	(-6.80, 16.73)	0.401A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	33	91.67	16.137	50.0	100.00	100.00	100.00	100.0			
	ADA	35	89.29	19.446	25.0	75.00	100.00	100.00	100.0			
	TOT	68	90.44	17.825	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	33	91.29	16.082	50.0	87.50	100.00	100.00	100.0			
	ADA	35	90.00	22.849	0.0	100.00	100.00	100.00	100.0			
	TOT	68	90.63	19.720	0.0	93.75	100.00	100.00	100.0			
CHG FROM BSL	PLO	33	-0.38	11.042	-25.0	0.00	0.00	0.00	25.0			
	ADA	35	0.71	15.442	-50.0	0.00	0.00	0.00	50.0			
	TOT	68	0.18	13.399	-50.0	0.00	0.00	0.00	50.0			
										1.09	(-5.44, 7.63)	0.739A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	33	73.48	27.908	0.0	50.00	75.00	100.00	100.0			
	ADA	34	76.47	23.790	0.0	50.00	75.00	100.00	100.0			
	TOT	67	75.00	25.746	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	33	76.89	21.678	25.0	75.00	75.00	100.00	100.0			
	ADA	34	83.09	23.614	25.0	75.00	100.00	100.00	100.0			
	TOT	67	80.04	22.724	25.0	75.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	33	3.41	16.908	-25.0	0.00	0.00	0.00	50.0			
	ADA	34	6.62	16.639	-25.0	0.00	0.00	25.00	50.0			
	TOT	67	5.04	16.722	-25.0	0.00	0.00	25.00	50.0			
										3.21	(-4.98, 11.39)	0.437A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.1.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	33	74.93	19.078	35.2	63.03	83.79	89.09	95.9			
	ADA	35	73.90	17.530	15.4	66.63	77.88	87.65	98.9			
	TOT	68	74.40	18.168	15.4	64.77	79.36	88.43	98.9			
FINAL/ET VALUE	PLO	33	75.63	19.734	31.7	62.73	84.51	90.80	100.0			
	ADA	35	77.72	19.621	25.0	63.48	84.33	92.31	100.0			
	TOT	68	76.71	19.556	25.0	63.11	84.42	91.69	100.0			
CHG FROM BSL	PLO	33	0.70	8.323	-16.9	-4.81	1.82	5.38	19.3			
	ADA	35	3.82	12.631	-33.6	-2.08	7.14	11.17	37.0			
	TOT	68	2.31	10.794	-33.6	-3.66	3.90	8.90	37.0			
										3.12	(-2.09, 8.33)	0.236A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BSL VALUE	PLO	7	50.00	32.275	0.0	25.00	50.00	75.00	100.0
	ADA	6	50.00	15.811	25.0	50.00	50.00	50.00	75.0
	TOT	13	50.00	25.000	0.0	50.00	50.00	50.00	100.0
FINAL/ET VALUE	PLO	7	53.57	30.375	0.0	25.00	75.00	75.00	75.0
	ADA	6	50.00	22.361	25.0	25.00	50.00	75.00	75.0
	TOT	13	51.92	25.944	0.0	25.00	50.00	75.00	75.0
CHG FROM BSL	PLO	7	3.57	17.252	-25.0	0.00	0.00	25.00	25.0
	ADA	6	0.00	22.361	-25.0	-25.00	0.00	25.00	25.0
	TOT	13	1.92	18.989	-25.0	0.00	0.00	25.00	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BSL VALUE	PLO	7	74.29	19.024	60.0	60.00	60.00	100.00	100.0
	ADA	6	60.00	17.889	40.0	40.00	60.00	80.00	80.0
	TOT	13	67.69	19.215	40.0	60.00	60.00	80.00	100.0
FINAL/ET VALUE	PLO	7	74.29	19.024	40.0	60.00	80.00	80.00	100.0
	ADA	6	76.67	8.165	60.0	80.00	80.00	80.00	80.0
	TOT	13	75.38	14.500	40.0	80.00	80.00	80.00	100.0
CHG FROM BSL	PLO	7	0.00	16.330	-20.0	-20.00	0.00	20.00	20.0
	ADA	6	16.67	15.055	0.0	0.00	20.00	20.00	40.0
	TOT	13	7.69	17.394	-20.0	0.00	0.00	20.00	40.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BSL VALUE	PLO	7	83.93	18.700	50.0	75.00	87.50	100.00	100.0
	ADA	6	70.83	23.274	37.5	50.00	75.00	87.50	100.0
	TOT	13	77.88	21.136	37.5	75.00	75.00	100.00	100.0
FINAL/ET VALUE	PLO	7	83.93	23.623	50.0	50.00	100.00	100.00	100.0
	ADA	6	79.17	25.820	37.5	62.50	87.50	100.00	100.0
	TOT	13	81.73	23.726	37.5	62.50	100.00	100.00	100.0
CHG FROM BSL	PLO	7	0.00	16.137	-25.0	-12.50	0.00	12.50	25.0
	ADA	6	8.33	25.820	-37.5	0.00	12.50	25.00	37.5
	TOT	13	3.85	20.656	-37.5	0.00	0.00	12.50	37.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BSL VALUE	PLO	7	73.81	21.207	41.7	50.00	83.33	91.67	91.7
	ADA	6	80.56	34.728	12.5	75.00	97.92	100.00	100.0
	TOT	13	76.92	27.196	12.5	66.67	91.67	95.83	100.0
FINAL/ET VALUE	PLO	7	84.52	13.113	66.7	66.67	91.67	91.67	100.0
	ADA	6	80.56	36.004	8.3	83.33	95.83	100.00	100.0
	TOT	13	82.69	25.107	8.3	83.33	91.67	100.00	100.0
CHG FROM BSL	PLO	7	10.71	10.446	0.0	0.00	16.67	16.67	25.0
	ADA	6	0.00	10.865	-16.7	-4.17	0.00	4.17	16.7
	TOT	13	5.77	11.604	-16.7	0.00	0.00	16.67	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BSL VALUE	PLO	7	69.05	27.936	25.0	41.67	83.33	91.67	100.0
	ADA	6	78.47	34.803	8.3	83.33	91.67	95.83	100.0
	TOT	13	73.40	30.312	8.3	58.33	83.33	91.67	100.0
FINAL/ET VALUE	PLO	7	72.02	22.658	33.3	58.33	75.00	91.67	100.0
	ADA	6	81.94	36.292	8.3	91.67	95.83	100.00	100.0
	TOT	13	76.60	28.844	8.3	62.50	91.67	100.00	100.0
CHG FROM BSL	PLO	7	2.98	14.174	-25.0	0.00	8.33	8.33	20.8
	ADA	6	3.47	8.505	-8.3	0.00	2.08	8.33	16.7
	TOT	13	3.21	11.430	-25.0	0.00	4.17	8.33	20.8

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BSL VALUE	PLO	7	82.14	24.851	37.5	62.50	100.00	100.00	100.0
	ADA	6	79.17	40.052	0.0	75.00	100.00	100.00	100.0
	TOT	13	80.77	31.298	0.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	7	87.50	14.434	62.5	75.00	87.50	100.00	100.0
	ADA	6	87.50	30.619	25.0	100.00	100.00	100.00	100.0
	TOT	13	87.50	22.244	25.0	87.50	100.00	100.00	100.0
CHG FROM BSL	PLO	7	5.36	15.905	-12.5	0.00	0.00	12.50	37.5
	ADA	6	8.33	12.910	0.0	0.00	0.00	25.00	25.0
	TOT	13	6.73	14.083	-12.5	0.00	0.00	12.50	37.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BSL VALUE	PLO	7	57.14	33.547	12.5	25.00	75.00	81.25	100.0
	ADA	6	66.67	28.413	12.5	62.50	75.00	87.50	87.5
	TOT	13	61.54	30.389	12.5	31.25	75.00	81.25	100.0
FINAL/ET VALUE	PLO	7	75.00	28.413	18.8	62.50	87.50	93.75	100.0
	ADA	6	77.08	31.787	18.8	62.50	90.63	100.00	100.0
	TOT	13	75.96	28.737	18.8	62.50	87.50	93.75	100.0
CHG FROM BSL	PLO	7	17.86	30.283	-12.5	-6.25	12.50	50.00	68.8
	ADA	6	10.42	11.637	0.0	0.00	9.38	12.50	31.3
	TOT	13	14.42	23.018	-12.5	0.00	12.50	12.50	68.8

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BSL VALUE	PLO	7	64.29	34.178	25.0	37.50	50.00	100.00	100.0
	ADA	6	70.83	34.157	12.5	50.00	81.25	100.00	100.0
	TOT	13	67.31	32.890	12.5	37.50	75.00	100.00	100.0
FINAL/ET VALUE	PLO	7	83.93	23.623	50.0	50.00	100.00	100.00	100.0
	ADA	6	81.25	29.315	25.0	75.00	93.75	100.00	100.0
	TOT	13	82.69	25.279	25.0	75.00	100.00	100.00	100.0
CHG FROM BSL	PLO	7	19.64	27.817	-12.5	0.00	12.50	50.00	62.5
	ADA	6	10.42	9.410	0.0	0.00	12.50	12.50	25.0
	TOT	13	15.38	21.136	-12.5	0.00	12.50	25.00	62.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BSL VALUE	PLO	7	67.86	40.946	16.7	16.67	100.00	100.00	100.0
	ADA	6	83.33	36.893	8.3	91.67	100.00	100.00	100.0
	TOT	13	75.00	38.339	8.3	41.67	100.00	100.00	100.0
FINAL/ET VALUE	PLO	7	80.95	36.866	0.0	75.00	100.00	100.00	100.0
	ADA	6	86.11	34.021	16.7	100.00	100.00	100.00	100.0
	TOT	13	83.33	34.190	0.0	91.67	100.00	100.00	100.0
CHG FROM BSL	PLO	7	13.10	31.127	-16.7	0.00	0.00	33.33	75.0
	ADA	6	2.78	4.303	0.0	0.00	0.00	8.33	8.3
	TOT	13	8.33	22.822	-16.7	0.00	0.00	8.33	75.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BSL VALUE	PLO	6	58.33	32.489	0.0	41.67	70.83	83.33	83.3
	ADA	6	73.61	39.587	0.0	58.33	91.67	100.00	100.0
	TOT	12	65.97	35.437	0.0	50.00	79.17	91.67	100.0
FINAL/ET VALUE	PLO	6	65.28	34.326	0.0	58.33	75.00	91.67	91.7
	ADA	6	80.56	40.023	0.0	83.33	100.00	100.00	100.0
	TOT	12	72.92	36.433	0.0	66.67	87.50	100.00	100.0
CHG FROM BSL	PLO	6	6.94	6.273	0.0	0.00	8.33	8.33	16.7
	ADA	6	6.94	11.076	0.0	0.00	0.00	16.67	25.0
	TOT	12	6.94	8.582	0.0	0.00	4.17	12.50	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BSL VALUE	PLO	7	89.29	19.670	50.0	75.00	100.00	100.00	100.0
	ADA	6	87.50	30.619	25.0	100.00	100.00	100.00	100.0
	TOT	13	88.46	24.185	25.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	7	96.43	9.449	75.0	100.00	100.00	100.00	100.0
	ADA	6	87.50	30.619	25.0	100.00	100.00	100.00	100.0
	TOT	13	92.31	21.371	25.0	100.00	100.00	100.00	100.0
CHG FROM BSL	PLO	7	7.14	12.199	0.0	0.00	0.00	25.00	25.0
	ADA	6	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	13	3.85	9.388	0.0	0.00	0.00	0.00	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BSL VALUE	PLO	7	57.14	37.401	0.0	25.00	50.00	100.00	100.0
	ADA	6	83.33	40.825	0.0	100.00	100.00	100.00	100.0
	TOT	13	69.23	39.731	0.0	50.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	7	75.00	25.000	25.0	75.00	75.00	100.00	100.0
	ADA	6	87.50	30.619	25.0	100.00	100.00	100.00	100.0
	TOT	13	80.77	27.298	25.0	75.00	100.00	100.00	100.0
CHG FROM BSL	PLO	7	17.86	23.780	-25.0	0.00	25.00	25.00	50.0
	ADA	6	4.17	10.206	0.0	0.00	0.00	0.00	25.0
	TOT	13	11.54	19.406	-25.0	0.00	0.00	25.00	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.2.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BSL VALUE	PLO	7	70.72	22.995	35.2	45.23	85.76	89.39	90.3
	ADA	6	75.85	29.862	15.4	81.70	87.52	89.62	93.3
	TOT	13	73.09	25.358	15.4	62.92	86.25	89.39	93.3
FINAL/ET VALUE	PLO	7	79.05	20.026	40.6	64.55	85.49	92.88	97.4
	ADA	6	82.35	28.491	25.0	87.20	93.16	97.42	98.2
	TOT	13	80.57	23.274	25.0	81.63	89.28	97.05	98.2
CHG FROM BSL	PLO	7	8.33	8.424	-4.8	4.55	7.12	18.71	19.3
	ADA	6	6.50	4.088	-0.5	3.71	8.07	9.58	10.0
	TOT	13	7.49	6.584	-4.8	4.55	7.58	9.58	19.3

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BSL VALUE	PLO	19	47.37	26.213	0.0	25.00	50.00	75.00	100.0
	ADA	19	47.37	24.853	25.0	25.00	50.00	50.00	100.0
	TOT	38	47.37	25.195	0.0	25.00	50.00	75.00	100.0
FINAL/ET VALUE	PLO	19	46.05	29.182	0.0	25.00	50.00	75.00	100.0
	ADA	19	43.42	33.168	0.0	25.00	25.00	75.00	100.0
	TOT	38	44.74	30.843	0.0	25.00	50.00	75.00	100.0
CHG FROM BSL	PLO	19	-1.32	24.258	-75.0	0.00	0.00	25.00	25.0
	ADA	19	-3.95	26.697	-50.0	-25.00	0.00	25.00	25.0
	TOT	38	-2.63	25.195	-75.0	-25.00	0.00	25.00	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BSL VALUE	PLO	19	60.00	16.330	40.0	40.00	60.00	80.00	80.0
	ADA	19	55.79	19.527	40.0	40.00	60.00	60.00	100.0
	TOT	38	57.89	17.882	40.0	40.00	60.00	60.00	100.0
FINAL/ET VALUE	PLO	19	54.74	21.952	20.0	40.00	60.00	80.00	100.0
	ADA	19	53.68	24.991	20.0	40.00	40.00	60.00	100.0
	TOT	38	54.21	23.207	20.0	40.00	40.00	60.00	100.0
CHG FROM BSL	PLO	19	-5.26	14.670	-40.0	-20.00	0.00	0.00	20.0
	ADA	19	-2.11	16.186	-40.0	-20.00	0.00	0.00	20.0
	TOT	38	-3.68	15.320	-40.0	-20.00	0.00	0.00	20.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BSL VALUE	PLO	19	81.58	22.193	25.0	62.50	87.50	100.00	100.0
	ADA	19	80.92	20.142	25.0	75.00	87.50	100.00	100.0
	TOT	38	81.25	20.906	25.0	75.00	87.50	100.00	100.0
FINAL/ET VALUE	PLO	19	83.55	18.187	50.0	75.00	87.50	100.00	100.0
	ADA	19	75.66	21.439	37.5	62.50	75.00	100.00	100.0
	TOT	38	79.61	20.013	37.5	75.00	75.00	100.00	100.0
CHG FROM BSL	PLO	19	1.97	17.806	-50.0	0.00	0.00	12.50	25.0
	ADA	19	-5.26	21.375	-50.0	-25.00	0.00	12.50	25.0
	TOT	38	-1.64	19.747	-50.0	-12.50	0.00	12.50	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BSL VALUE	PLO	19	65.79	27.624	0.0	58.33	75.00	83.33	100.0
	ADA	19	71.49	18.282	41.7	58.33	75.00	91.67	100.0
	TOT	38	68.64	23.285	0.0	58.33	75.00	83.33	100.0
FINAL/ET VALUE	PLO	19	69.52	24.847	25.0	50.00	66.67	100.00	100.0
	ADA	19	69.74	29.425	0.0	41.67	75.00	100.00	100.0
	TOT	38	69.63	26.862	0.0	50.00	75.00	100.00	100.0
CHG FROM BSL	PLO	19	3.73	17.286	-25.0	-4.17	0.00	8.33	41.7
	ADA	19	-1.75	30.248	-66.7	-16.67	8.33	25.00	33.3
	TOT	38	0.99	24.458	-66.7	-8.33	0.00	16.67	41.7

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BSL VALUE	PLO	19	74.56	24.132	41.7	50.00	83.33	100.00	100.0
	ADA	19	66.23	19.929	25.0	58.33	66.67	83.33	100.0
	TOT	38	70.39	22.234	25.0	50.00	66.67	91.67	100.0
FINAL/ET VALUE	PLO	19	74.56	25.226	33.3	50.00	83.33	100.00	100.0
	ADA	19	71.49	23.127	25.0	58.33	75.00	91.67	100.0
	TOT	38	73.03	23.921	25.0	50.00	79.17	100.00	100.0
CHG FROM BSL	PLO	19	0.00	13.889	-33.3	-8.33	0.00	8.33	25.0
	ADA	19	5.26	15.765	-25.0	0.00	8.33	16.67	33.3
	TOT	38	2.63	14.895	-33.3	0.00	0.00	16.67	33.3

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BSL VALUE	PLO	19	86.18	17.626	50.0	75.00	100.00	100.00	100.0
	ADA	19	87.50	15.590	50.0	75.00	87.50	100.00	100.0
	TOT	38	86.84	16.426	50.0	75.00	93.75	100.00	100.0
FINAL/ET VALUE	PLO	19	84.54	21.688	25.0	75.00	93.75	100.00	100.0
	ADA	19	82.89	20.074	50.0	62.50	100.00	100.00	100.0
	TOT	38	83.72	20.629	25.0	75.00	96.88	100.00	100.0
CHG FROM BSL	PLO	19	-1.64	8.292	-25.0	0.00	0.00	0.00	12.5
	ADA	19	-4.61	17.286	-50.0	-12.50	0.00	0.00	25.0
	TOT	38	-3.13	13.456	-50.0	-6.25	0.00	0.00	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BSL VALUE	PLO	19	69.41	27.075	12.5	50.00	81.25	93.75	100.0
	ADA	19	71.71	18.206	25.0	62.50	81.25	87.50	93.8
	TOT	38	70.56	22.787	12.5	62.50	81.25	87.50	100.0
FINAL/ET VALUE	PLO	19	72.70	28.353	12.5	50.00	81.25	93.75	100.0
	ADA	19	75.66	19.753	31.3	68.75	75.00	93.75	100.0
	TOT	38	74.18	24.148	12.5	50.00	81.25	93.75	100.0
CHG FROM BSL	PLO	19	3.29	13.072	-37.5	0.00	6.25	12.50	25.0
	ADA	19	3.95	19.456	-37.5	-6.25	12.50	18.75	25.0
	TOT	38	3.62	16.352	-37.5	0.00	6.25	12.50	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BSL VALUE	PLO	19	76.32	26.645	25.0	50.00	87.50	100.00	100.0
	ADA	19	80.92	18.337	50.0	75.00	75.00	100.00	100.0
	TOT	38	78.62	22.681	25.0	50.00	81.25	100.00	100.0
FINAL/ET VALUE	PLO	19	75.66	26.833	25.0	50.00	75.00	100.00	100.0
	ADA	19	80.92	19.261	50.0	62.50	75.00	100.00	100.0
	TOT	38	78.29	23.192	25.0	62.50	75.00	100.00	100.0
CHG FROM BSL	PLO	19	-0.66	19.753	-50.0	-12.50	0.00	0.00	50.0
	ADA	19	0.00	16.137	-37.5	-12.50	0.00	12.50	25.0
	TOT	38	-0.33	17.794	-50.0	-12.50	0.00	0.00	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BSL VALUE	PLO	19	85.09	26.871	16.7	75.00	100.00	100.00	100.0
	ADA	19	88.16	15.040	41.7	83.33	91.67	100.00	100.0
	TOT	38	86.62	21.535	16.7	83.33	100.00	100.00	100.0
FINAL/ET VALUE	PLO	19	82.89	28.528	16.7	58.33	100.00	100.00	100.0
	ADA	19	86.84	17.637	41.7	75.00	100.00	100.00	100.0
	TOT	38	84.87	23.479	16.7	75.00	100.00	100.00	100.0
CHG FROM BSL	PLO	19	-2.19	11.733	-50.0	0.00	0.00	0.00	8.3
	ADA	19	-1.32	20.462	-50.0	-8.33	0.00	0.00	58.3
	TOT	38	-1.75	16.458	-50.0	0.00	0.00	0.00	58.3

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BSL VALUE	PLO	14	61.90	32.803	0.0	50.00	62.50	91.67	100.0
	ADA	14	53.57	38.497	0.0	0.00	62.50	83.33	100.0
	TOT	28	57.74	35.350	0.0	33.33	62.50	83.33	100.0
FINAL/ET VALUE	PLO	14	62.80	31.200	0.0	33.33	70.83	83.33	100.0
	ADA	14	52.38	41.786	0.0	0.00	70.83	83.33	100.0
	TOT	28	57.59	36.572	0.0	25.00	70.83	83.33	100.0
CHG FROM BSL	PLO	14	0.89	13.093	-25.0	-4.17	0.00	8.33	25.0
	ADA	14	-1.19	18.449	-58.3	0.00	0.00	0.00	25.0
	TOT	28	-0.15	15.733	-58.3	0.00	0.00	4.17	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BSL VALUE	PLO	19	90.79	17.100	50.0	75.00	100.00	100.00	100.0
	ADA	19	90.79	14.932	50.0	75.00	100.00	100.00	100.0
	TOT	38	90.79	15.834	50.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	19	88.82	17.126	50.0	75.00	100.00	100.00	100.0
	ADA	19	90.79	14.932	50.0	75.00	100.00	100.00	100.0
	TOT	38	89.80	15.879	50.0	75.00	100.00	100.00	100.0
CHG FROM BSL	PLO	19	-1.97	10.428	-25.0	0.00	0.00	0.00	25.0
	ADA	19	0.00	11.785	-25.0	0.00	0.00	0.00	25.0
	TOT	38	-0.99	11.021	-25.0	0.00	0.00	0.00	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BSL VALUE	PLO	19	78.95	23.955	50.0	50.00	100.00	100.00	100.0
	ADA	19	73.68	17.626	50.0	50.00	75.00	75.00	100.0
	TOT	38	76.32	20.914	50.0	50.00	75.00	100.00	100.0
FINAL/ET VALUE	PLO	19	80.92	19.706	50.0	75.00	75.00	100.00	100.0
	ADA	19	77.63	23.415	25.0	50.00	75.00	100.00	100.0
	TOT	38	79.28	21.411	25.0	75.00	75.00	100.00	100.0
CHG FROM BSL	PLO	19	1.97	11.977	-25.0	0.00	0.00	0.00	25.0
	ADA	19	3.95	17.206	-25.0	0.00	0.00	25.00	25.0
	TOT	38	2.96	14.657	-25.0	0.00	0.00	0.00	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.3.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BSL VALUE	PLO	19	75.64	19.376	40.3	63.03	86.25	90.30	95.9
	ADA	19	75.12	12.635	54.0	68.17	73.83	83.29	98.9
	TOT	38	75.38	16.136	40.3	66.63	77.19	88.71	98.9
FINAL/ET VALUE	PLO	19	75.71	19.682	40.3	54.77	84.51	91.74	100.0
	ADA	19	75.02	19.194	33.1	59.00	79.83	91.63	100.0
	TOT	38	75.36	19.178	33.1	59.00	80.52	91.63	100.0
CHG FROM BSL	PLO	19	0.07	6.234	-15.4	-3.79	0.00	4.81	8.7
	ADA	19	-0.11	12.866	-33.6	-4.09	1.14	10.91	13.9
	TOT	38	-0.02	9.972	-33.6	-3.79	0.76	7.01	13.9

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BSL VALUE	PLO	1	25.00		25.0	25.00	25.00	25.00	25.0
	ADA	0							
	TOT	1	25.00		25.0	25.00	25.00	25.00	25.0
FINAL/ET VALUE	PLO	1	50.00		50.0	50.00	50.00	50.00	50.0
	ADA	0							
	TOT	1	50.00		50.0	50.00	50.00	50.00	50.0
CHG FROM BSL	PLO	1	25.00		25.0	25.00	25.00	25.00	25.0
	ADA	0							
	TOT	1	25.00		25.0	25.00	25.00	25.00	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BSL VALUE	PLO	1	80.00		80.0	80.00	80.00	80.00	80.0
	ADA	0							
	TOT	1	80.00		80.0	80.00	80.00	80.00	80.0
FINAL/ET VALUE	PLO	1	80.00		80.0	80.00	80.00	80.00	80.0
	ADA	0							
	TOT	1	80.00		80.0	80.00	80.00	80.00	80.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BSL VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	0							
	TOT	1	75.00		75.0	75.00	75.00	75.00	75.0
FINAL/ET VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	0							
	TOT	1	75.00		75.0	75.00	75.00	75.00	75.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BSL VALUE	PLO	1	91.67		91.7	91.67	91.67	91.67	91.7
	ADA	0							
	TOT	1	91.67		91.7	91.67	91.67	91.67	91.7
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	0							
	TOT	1	100.00		100.0	100.00	100.00	100.00	100.0
CHG FROM BSL	PLO	1	8.33		8.3	8.33	8.33	8.33	8.3
	ADA	0							
	TOT	1	8.33		8.3	8.33	8.33	8.33	8.3

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BSL VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	0							
	TOT	1	100.00		100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	0							
	TOT	1	100.00		100.0	100.00	100.00	100.00	100.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BSL VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	0							
	TOT	1	100.00		100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	0							
	TOT	1	100.00		100.0	100.00	100.00	100.00	100.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BSL VALUE	PLO	1	50.00		50.0	50.00	50.00	50.00	50.0
	ADA	0							
	TOT	1	50.00		50.0	50.00	50.00	50.00	50.0
FINAL/ET VALUE	PLO	1	81.25		81.3	81.25	81.25	81.25	81.3
	ADA	0							
	TOT	1	81.25		81.3	81.25	81.25	81.25	81.3
CHG FROM BSL	PLO	1	31.25		31.3	31.25	31.25	31.25	31.3
	ADA	0							
	TOT	1	31.25		31.3	31.25	31.25	31.25	31.3

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BSL VALUE	PLO	1	62.50		62.5	62.50	62.50	62.50	62.5
	ADA	0							
	TOT	1	62.50		62.5	62.50	62.50	62.50	62.5
FINAL/ET VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	0							
	TOT	1	75.00		75.0	75.00	75.00	75.00	75.0
CHG FROM BSL	PLO	1	12.50		12.5	12.50	12.50	12.50	12.5
	ADA	0							
	TOT	1	12.50		12.5	12.50	12.50	12.50	12.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BSL VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	0							
	TOT	1	100.00		100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	0							
	TOT	1	100.00		100.0	100.00	100.00	100.00	100.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BSL VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	0							
	TOT	1	75.00		75.0	75.00	75.00	75.00	75.0
FINAL/ET VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	0							
	TOT	1	75.00		75.0	75.00	75.00	75.00	75.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BSL VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	0							
	TOT	1	100.00		100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	0							
	TOT	1	100.00		100.0	100.00	100.00	100.00	100.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BSL VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	0							
	TOT	1	75.00		75.0	75.00	75.00	75.00	75.0
FINAL/ET VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	0							
	TOT	1	75.00		75.0	75.00	75.00	75.00	75.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.4.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BSL VALUE	PLO	1	82.65		82.7	82.65	82.65	82.65	82.7
	ADA	0							
	TOT	1	82.65		82.7	82.65	82.65	82.65	82.7
FINAL/ET VALUE	PLO	1	87.39		87.4	87.39	87.39	87.39	87.4
	ADA	0							
	TOT	1	87.39		87.4	87.39	87.39	87.39	87.4
CHG FROM BSL	PLO	1	4.73		4.7	4.73	4.73	4.73	4.7
	ADA	0							
	TOT	1	4.73		4.7	4.73	4.73	4.73	4.7

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.5.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER)

VISIT	TREATMENT N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX

** NO DATA IN THIS SEGMENT OR PART OF THIS TABLE. **

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BSL VALUE	PLO	5	55.00	20.917	25.0	50.00	50.00	75.00	75.0
	ADA	9	52.78	15.023	25.0	50.00	50.00	50.00	75.0
	TOT	14	53.57	16.575	25.0	50.00	50.00	75.00	75.0
FINAL/ET VALUE	PLO	5	40.00	28.504	0.0	25.00	50.00	50.00	75.0
	ADA	9	51.39	18.162	25.0	50.00	50.00	62.50	75.0
	TOT	14	47.32	22.024	0.0	25.00	50.00	62.50	75.0
CHG FROM BSL	PLO	5	-15.00	13.693	-25.0	-25.00	-25.00	0.00	0.0
	ADA	9	-1.39	9.772	-25.0	0.00	0.00	0.00	12.5
	TOT	14	-6.25	12.738	-25.0	-25.00	0.00	0.00	12.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BSL VALUE	PLO	5	64.00	16.733	40.0	60.00	60.00	80.00	80.0
	ADA	9	71.11	10.541	60.0	60.00	80.00	80.00	80.0
	TOT	14	68.57	12.924	40.0	60.00	70.00	80.00	80.0
FINAL/ET VALUE	PLO	5	56.00	21.909	40.0	40.00	40.00	80.00	80.0
	ADA	9	75.56	8.819	60.0	80.00	80.00	80.00	80.0
	TOT	14	68.57	17.033	40.0	60.00	80.00	80.00	80.0
CHG FROM BSL	PLO	5	-8.00	22.804	-40.0	-20.00	0.00	0.00	20.0
	ADA	9	4.44	13.333	-20.0	0.00	0.00	20.00	20.0
	TOT	14	0.00	17.541	-40.0	0.00	0.00	20.00	20.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BSL VALUE	PLO	5	77.50	20.540	50.0	62.50	87.50	87.50	100.0
	ADA	9	76.39	15.866	62.5	62.50	75.00	87.50	100.0
	TOT	14	76.79	16.883	50.0	62.50	75.00	87.50	100.0
FINAL/ET VALUE	PLO	5	65.00	24.044	37.5	50.00	62.50	75.00	100.0
	ADA	9	75.00	17.678	50.0	62.50	75.00	87.50	100.0
	TOT	14	71.43	19.873	37.5	62.50	68.75	87.50	100.0
CHG FROM BSL	PLO	5	-12.50	8.839	-25.0	-12.50	-12.50	-12.50	0.0
	ADA	9	-1.39	17.053	-25.0	-12.50	0.00	12.50	25.0
	TOT	14	-5.36	15.281	-25.0	-12.50	-6.25	0.00	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BSL VALUE	PLO	5	73.33	16.029	58.3	66.67	66.67	75.00	100.0
	ADA	9	70.37	20.460	50.0	50.00	66.67	83.33	100.0
	TOT	14	71.43	18.407	50.0	58.33	66.67	83.33	100.0
FINAL/ET VALUE	PLO	5	63.33	22.515	41.7	50.00	58.33	66.67	100.0
	ADA	9	82.41	16.897	50.0	75.00	83.33	100.00	100.0
	TOT	14	75.60	20.534	41.7	58.33	79.17	100.00	100.0
CHG FROM BSL	PLO	5	-10.00	6.972	-16.7	-16.67	-8.33	-8.33	0.0
	ADA	9	12.04	27.039	-33.3	0.00	8.33	33.33	50.0
	TOT	14	4.17	24.185	-33.3	-16.67	0.00	16.67	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BSL VALUE	PLO	5	71.67	24.721	33.3	66.67	75.00	83.33	100.0
	ADA	9	60.19	23.022	37.5	41.67	50.00	83.33	100.0
	TOT	14	64.29	23.383	33.3	41.67	62.50	83.33	100.0
FINAL/ET VALUE	PLO	5	63.33	26.745	25.0	58.33	66.67	66.67	100.0
	ADA	9	73.15	25.610	33.3	50.00	75.00	91.67	100.0
	TOT	14	69.64	25.446	25.0	50.00	70.83	91.67	100.0
CHG FROM BSL	PLO	5	-8.33	8.333	-16.7	-16.67	-8.33	0.00	0.0
	ADA	9	12.96	19.922	-8.3	-4.17	12.50	25.00	41.7
	TOT	14	5.36	19.436	-16.7	-8.33	0.00	16.67	41.7

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BSL VALUE	PLO	5	92.50	16.771	62.5	100.00	100.00	100.00	100.0
	ADA	9	79.17	19.764	50.0	62.50	87.50	87.50	100.0
	TOT	14	83.93	19.258	50.0	62.50	87.50	100.00	100.0
FINAL/ET VALUE	PLO	5	82.50	18.957	50.0	87.50	87.50	87.50	100.0
	ADA	9	86.81	19.376	50.0	75.00	100.00	100.00	100.0
	TOT	14	85.27	18.606	50.0	75.00	90.63	100.00	100.0
CHG FROM BSL	PLO	5	-10.00	5.590	-12.5	-12.50	-12.50	-12.50	0.0
	ADA	9	7.64	16.470	-25.0	0.00	12.50	12.50	37.5
	TOT	14	1.34	15.921	-25.0	-12.50	0.00	12.50	37.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BSL VALUE	PLO	5	60.00	32.656	18.8	31.25	75.00	87.50	87.5
	ADA	9	54.86	24.957	18.8	37.50	56.25	75.00	87.5
	TOT	14	56.70	26.794	18.8	31.25	62.50	81.25	87.5
FINAL/ET VALUE	PLO	5	51.25	31.375	12.5	25.00	62.50	68.75	87.5
	ADA	9	63.19	23.478	12.5	56.25	68.75	81.25	87.5
	TOT	14	58.93	26.026	12.5	43.75	65.63	81.25	87.5
CHG FROM BSL	PLO	5	-8.75	9.479	-25.0	-6.25	-6.25	-6.25	0.0
	ADA	9	8.33	19.009	-12.5	-6.25	0.00	25.00	37.5
	TOT	14	2.23	17.949	-25.0	-6.25	-3.13	12.50	37.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BSL VALUE	PLO	5	67.50	28.777	37.5	37.50	75.00	87.50	100.0
	ADA	9	61.11	22.917	25.0	37.50	62.50	75.00	87.5
	TOT	14	63.39	24.250	25.0	37.50	68.75	87.50	100.0
FINAL/ET VALUE	PLO	5	55.00	38.120	12.5	25.00	50.00	87.50	100.0
	ADA	9	83.33	16.536	50.0	75.00	87.50	100.00	100.0
	TOT	14	73.21	28.528	12.5	50.00	81.25	100.00	100.0
CHG FROM BSL	PLO	5	-12.50	12.500	-25.0	-25.00	-12.50	0.00	0.0
	ADA	9	22.22	31.111	-12.5	0.00	12.50	37.50	75.0
	TOT	14	9.82	30.689	-25.0	-12.50	0.00	25.00	75.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BSL VALUE	PLO	5	82.50	28.321	33.3	83.33	95.83	100.00	100.0
	ADA	9	68.52	35.789	8.3	58.33	83.33	100.00	100.0
	TOT	14	73.51	32.914	8.3	58.33	87.50	100.00	100.0
FINAL/ET VALUE	PLO	5	81.67	31.950	25.0	91.67	91.67	100.00	100.0
	ADA	9	90.74	14.699	66.7	83.33	100.00	100.00	100.0
	TOT	14	87.50	21.620	25.0	83.33	100.00	100.00	100.0
CHG FROM BSL	PLO	5	-0.83	10.375	-8.3	-8.33	-4.17	0.00	16.7
	ADA	9	22.22	22.822	0.0	0.00	16.67	41.67	58.3
	TOT	14	13.99	22.024	-8.3	0.00	4.17	25.00	58.3

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BSL VALUE	PLO	5	65.00	29.107	33.3	50.00	50.00	91.67	100.0
	ADA	5	31.67	45.795	0.0	0.00	0.00	58.33	100.0
	TOT	10	48.33	40.215	0.0	0.00	50.00	91.67	100.0
FINAL/ET VALUE	PLO	5	53.33	35.770	8.3	29.17	58.33	70.83	100.0
	ADA	5	51.67	50.139	0.0	0.00	58.33	100.00	100.0
	TOT	10	52.50	41.070	0.0	8.33	58.33	100.00	100.0
CHG FROM BSL	PLO	5	-11.67	19.852	-41.7	-20.83	-4.17	0.00	8.3
	ADA	5	20.00	53.554	-41.7	0.00	0.00	41.67	100.0
	TOT	10	4.17	41.574	-41.7	-20.83	0.00	8.33	100.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BSL VALUE	PLO	5	95.00	11.180	75.0	100.00	100.00	100.00	100.0
	ADA	9	86.11	22.048	50.0	75.00	100.00	100.00	100.0
	TOT	14	89.29	18.898	50.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	5	90.00	22.361	50.0	100.00	100.00	100.00	100.0
	ADA	9	88.89	33.333	0.0	100.00	100.00	100.00	100.0
	TOT	14	89.29	28.947	0.0	100.00	100.00	100.00	100.0
CHG FROM BSL	PLO	5	-5.00	11.180	-25.0	0.00	0.00	0.00	0.0
	ADA	9	2.78	26.352	-50.0	0.00	0.00	0.00	50.0
	TOT	14	0.00	21.926	-50.0	0.00	0.00	0.00	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BSL VALUE	PLO	5	75.00	30.619	25.0	75.00	75.00	100.00	100.0
	ADA	8	78.13	24.776	50.0	50.00	87.50	100.00	100.0
	TOT	13	76.92	25.944	25.0	50.00	75.00	100.00	100.0
FINAL/ET VALUE	PLO	5	65.00	28.504	25.0	50.00	75.00	75.00	100.0
	ADA	8	90.63	18.601	50.0	87.50	100.00	100.00	100.0
	TOT	13	80.77	25.318	25.0	75.00	100.00	100.00	100.0
CHG FROM BSL	PLO	5	-10.00	13.693	-25.0	-25.00	0.00	0.00	0.0
	ADA	8	12.50	18.898	0.0	0.00	0.00	25.00	50.0
	TOT	13	3.85	20.016	-25.0	0.00	0.00	0.00	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.6.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BSL VALUE	PLO	5	74.91	19.051	44.3	72.39	78.86	83.79	95.2
	ADA	9	68.49	18.079	47.5	52.23	74.32	78.21	93.0
	TOT	14	70.78	17.972	44.3	52.23	76.10	83.79	95.2
FINAL/ET VALUE	PLO	5	66.04	23.905	31.7	61.97	62.73	76.78	97.0
	ADA	9	79.07	15.755	54.7	65.80	84.33	89.88	96.5
	TOT	14	74.42	19.251	31.7	61.97	79.15	89.88	97.0
CHG FROM BSL	PLO	5	-8.87	7.013	-16.9	-12.61	-9.66	-7.01	1.8
	ADA	9	10.58	14.178	-8.9	7.14	11.58	13.56	37.0
	TOT	14	3.63	15.245	-16.9	-8.90	4.48	11.67	37.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.7.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BSL VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	1	75.00		75.0	75.00	75.00	75.00	75.0
	TOT	2	75.00	0.000	75.0	75.00	75.00	75.00	75.0
FINAL/ET VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	1	50.00		50.0	50.00	50.00	50.00	50.0
	TOT	2	62.50	17.678	50.0	50.00	62.50	75.00	75.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	-25.00		-25.0	-25.00	-25.00	-25.00	-25.0
	TOT	2	-12.50	17.678	-25.0	-25.00	-12.50	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.7.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BSL VALUE	PLO	1	80.00		80.0	80.00	80.00	80.00	80.0
	ADA	1	80.00		80.0	80.00	80.00	80.00	80.0
	TOT	2	80.00	0.000	80.0	80.00	80.00	80.00	80.0
FINAL/ET VALUE	PLO	1	80.00		80.0	80.00	80.00	80.00	80.0
	ADA	1	80.00		80.0	80.00	80.00	80.00	80.0
	TOT	2	80.00	0.000	80.0	80.00	80.00	80.00	80.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.7.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BSL VALUE	PLO	1	87.50		87.5	87.50	87.50	87.50	87.5
	ADA	1	87.50		87.5	87.50	87.50	87.50	87.5
	TOT	2	87.50	0.000	87.5	87.50	87.50	87.50	87.5
FINAL/ET VALUE	PLO	1	87.50		87.5	87.50	87.50	87.50	87.5
	ADA	1	62.50		62.5	62.50	62.50	62.50	62.5
	TOT	2	75.00	17.678	62.5	62.50	75.00	87.50	87.5
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	-25.00		-25.0	-25.00	-25.00	-25.00	-25.0
	TOT	2	-12.50	17.678	-25.0	-25.00	-12.50	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.7.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BSL VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	1	83.33		83.3	83.33	83.33	83.33	83.3
	TOT	2	79.17	5.893	75.0	75.00	79.17	83.33	83.3
FINAL/ET VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	1	83.33		83.3	83.33	83.33	83.33	83.3
	TOT	2	79.17	5.893	75.0	75.00	79.17	83.33	83.3
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.7.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BSL VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	1	66.67		66.7	66.67	66.67	66.67	66.7
	TOT	2	70.83	5.893	66.7	66.67	70.83	75.00	75.0
FINAL/ET VALUE	PLO	1	83.33		83.3	83.33	83.33	83.33	83.3
	ADA	1	83.33		83.3	83.33	83.33	83.33	83.3
	TOT	2	83.33	0.000	83.3	83.33	83.33	83.33	83.3
CHG FROM BSL	PLO	1	8.33		8.3	8.33	8.33	8.33	8.3
	ADA	1	16.67		16.7	16.67	16.67	16.67	16.7
	TOT	2	12.50	5.893	8.3	8.33	12.50	16.67	16.7

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.7.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BSL VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.7.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BSL VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	1	87.50		87.5	87.50	87.50	87.50	87.5
	TOT	2	81.25	8.839	75.0	75.00	81.25	87.50	87.5
FINAL/ET VALUE	PLO	1	87.50		87.5	87.50	87.50	87.50	87.5
	ADA	1	87.50		87.5	87.50	87.50	87.50	87.5
	TOT	2	87.50	0.000	87.5	87.50	87.50	87.50	87.5
CHG FROM BSL	PLO	1	12.50		12.5	12.50	12.50	12.50	12.5
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	6.25	8.839	0.0	0.00	6.25	12.50	12.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.7.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BSL VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	87.50	17.678	75.0	75.00	87.50	100.00	100.0
FINAL/ET VALUE	PLO	1	87.50		87.5	87.50	87.50	87.50	87.5
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	93.75	8.839	87.5	87.50	93.75	100.00	100.0
CHG FROM BSL	PLO	1	12.50		12.5	12.50	12.50	12.50	12.5
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	6.25	8.839	0.0	0.00	6.25	12.50	12.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.7.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BSL VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.7.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BSL VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	1	83.33		83.3	83.33	83.33	83.33	83.3
	TOT	2	79.17	5.893	75.0	75.00	79.17	83.33	83.3
FINAL/ET VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	1	83.33		83.3	83.33	83.33	83.33	83.3
	TOT	2	79.17	5.893	75.0	75.00	79.17	83.33	83.3
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.7.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BSL VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.7.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BSL VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	1	75.00		75.0	75.00	75.00	75.00	75.0
	TOT	2	75.00	0.000	75.0	75.00	75.00	75.00	75.0
FINAL/ET VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	87.50	17.678	75.0	75.00	87.50	100.00	100.0
CHG FROM BSL	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	25.00		25.0	25.00	25.00	25.00	25.0
	TOT	2	12.50	17.678	0.0	0.00	12.50	25.00	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.7.7.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BSL VALUE	PLO	1	83.41		83.4	83.41	83.41	83.41	83.4
	ADA	1	87.58		87.6	87.58	87.58	87.58	87.6
	TOT	2	85.49	2.946	83.4	83.41	85.49	87.58	87.6
FINAL/ET VALUE	PLO	1	86.44		86.4	86.44	86.44	86.44	86.4
	ADA	1	89.09		89.1	89.09	89.09	89.09	89.1
	TOT	2	87.77	1.875	86.4	86.44	87.77	89.09	89.1
CHG FROM BSL	PLO	1	3.03		3.0	3.03	3.03	3.03	3.0
	ADA	1	1.52		1.5	1.52	1.52	1.52	1.5
	TOT	2	2.27	1.071	1.5	1.52	2.27	3.03	3.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.8.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	24	53.13	21.255	25.0	37.50	50.00	75.00	100.0			
	ADA	22	54.55	14.712	25.0	50.00	50.00	75.00	75.0			
	TOT	46	53.80	18.233	25.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	24	53.13	25.868	0.0	50.00	50.00	75.00	100.0			
	ADA	22	52.27	18.755	0.0	50.00	50.00	75.00	75.0			
	TOT	46	52.72	22.502	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	24	0.00	16.485	-50.0	0.00	0.00	0.00	25.0			
	ADA	22	-2.27	20.279	-50.0	-25.00	0.00	0.00	25.0			
	TOT	46	-1.09	18.224	-50.0	0.00	0.00	0.00	25.0			
										-2.27	(-13.21, 8.67)	0.678A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.8.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	24	72.08	17.932	40.0	60.00	80.00	80.00	100.0			
	ADA	22	70.91	14.771	40.0	60.00	80.00	80.00	100.0			
	TOT	46	71.52	16.325	40.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	24	63.33	20.990	20.0	60.00	60.00	80.00	100.0			
	ADA	22	70.91	14.771	40.0	60.00	80.00	80.00	100.0			
	TOT	46	66.96	18.484	20.0	60.00	60.00	80.00	100.0			
CHG FROM BSL	PLO	24	-8.75	14.836	-40.0	-20.00	0.00	0.00	20.0			
	ADA	22	0.00	13.801	-40.0	0.00	0.00	0.00	20.0			
	TOT	46	-4.57	14.863	-40.0	-20.00	0.00	0.00	20.0			
										8.75	(0.21, 17.29)	0.045A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.8.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	24	77.08	20.743	25.0	62.50	75.00	100.00	100.0			
	ADA	22	76.42	24.085	25.0	75.00	84.38	100.00	100.0			
	TOT	46	76.77	22.153	25.0	62.50	78.13	100.00	100.0			
FINAL/ET VALUE	PLO	24	78.13	20.606	25.0	62.50	81.25	100.00	100.0			
	ADA	22	81.25	22.076	37.5	62.50	87.50	100.00	100.0			
	TOT	46	79.62	21.141	25.0	62.50	87.50	100.00	100.0			
CHG FROM BSL	PLO	24	1.04	13.248	-25.0	0.00	0.00	0.00	37.5			
	ADA	22	4.83	20.406	-25.0	0.00	0.00	12.50	62.5			
	TOT	46	2.85	16.961	-25.0	0.00	0.00	12.50	62.5			
										3.79	(-6.35, 13.93)	0.455A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.8.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	24	73.61	25.141	16.7	54.17	75.00	95.83	100.0			
	ADA	22	84.28	14.430	50.0	75.00	87.50	95.83	100.0			
	TOT	46	78.71	21.196	16.7	66.67	83.33	95.83	100.0			
FINAL/ET VALUE	PLO	24	76.22	22.505	16.7	66.67	83.33	91.67	100.0			
	ADA	22	87.69	14.575	58.3	79.17	91.67	100.00	100.0			
	TOT	46	81.70	19.788	16.7	75.00	83.33	100.00	100.0			
CHG FROM BSL	PLO	24	2.60	13.449	-25.0	-6.25	0.00	8.33	41.7			
	ADA	22	3.41	17.041	-33.3	0.00	0.00	16.67	33.3			
	TOT	46	2.99	15.104	-33.3	-4.17	0.00	8.33	41.7			
										0.80	(-8.28, 9.89)	0.859A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.8.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	24	74.31	26.228	8.3	58.33	83.33	100.00	100.0			
	ADA	22	84.47	13.979	58.3	75.00	89.58	95.83	100.0			
	TOT	46	79.17	21.660	8.3	66.67	83.33	100.00	100.0			
FINAL/ET VALUE	PLO	24	77.78	25.260	8.3	66.67	87.50	95.83	100.0			
	ADA	22	86.36	14.671	50.0	83.33	91.67	100.00	100.0			
	TOT	46	81.88	21.104	8.3	75.00	91.67	100.00	100.0			
CHG FROM BSL	PLO	24	3.47	15.526	-33.3	-8.33	4.17	8.33	33.3			
	ADA	22	1.89	16.504	-37.5	-8.33	0.00	16.67	33.3			
	TOT	46	2.72	15.841	-37.5	-8.33	0.00	8.33	33.3			
										-1.58	(-11.10, 7.94)	0.740A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.8.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	24	89.06	18.908	37.5	81.25	100.00	100.00	100.0			
	ADA	22	97.73	6.264	75.0	100.00	100.00	100.00	100.0			
	TOT	46	93.21	14.839	37.5	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	24	88.80	18.793	25.0	75.00	100.00	100.00	100.0			
	ADA	22	96.02	9.749	62.5	100.00	100.00	100.00	100.0			
	TOT	46	92.26	15.433	25.0	87.50	100.00	100.00	100.0			
CHG FROM BSL	PLO	24	-0.26	12.292	-37.5	0.00	0.00	0.00	25.0			
	ADA	22	-1.70	7.003	-25.0	0.00	0.00	0.00	12.5			
	TOT	46	-0.95	10.032	-37.5	0.00	0.00	0.00	25.0			
										-1.44	(-7.46, 4.57)	0.631A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.8.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	24	61.63	25.824	0.0	45.83	68.75	84.38	87.5			
	ADA	22	77.37	12.472	50.0	68.75	81.25	87.50	100.0			
	TOT	46	69.16	21.831	0.0	56.25	78.13	87.50	100.0			
FINAL/ET VALUE	PLO	24	66.41	29.935	0.0	50.00	78.13	87.50	100.0			
	ADA	22	80.68	15.777	37.5	75.00	81.25	93.75	100.0			
	TOT	46	73.23	25.023	0.0	68.75	81.25	93.75	100.0			
CHG FROM BSL	PLO	24	4.77	19.451	-56.3	0.00	6.25	12.50	31.3			
	ADA	22	3.31	12.740	-25.0	0.00	6.25	12.50	25.0			
	TOT	46	4.08	16.422	-56.3	0.00	6.25	12.50	31.3			
										-1.46	(-11.33, 8.41)	0.767A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.8.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	24	65.63	28.373	0.0	50.00	68.75	87.50	100.0			
	ADA	22	75.00	23.465	25.0	50.00	75.00	100.00	100.0			
	TOT	46	70.11	26.283	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	24	65.63	29.082	0.0	50.00	75.00	93.75	100.0			
	ADA	22	82.95	22.343	25.0	75.00	93.75	100.00	100.0			
	TOT	46	73.91	27.237	0.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	24	0.00	17.678	-62.5	0.00	0.00	12.50	25.0			
	ADA	22	7.95	20.610	-25.0	0.00	0.00	12.50	62.5			
	TOT	46	3.80	19.342	-62.5	0.00	0.00	12.50	62.5			
										7.95	(-3.43, 19.34)	0.166A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.8.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	24	82.29	30.526	0.0	75.00	100.00	100.00	100.0			
	ADA	22	88.26	16.599	41.7	75.00	100.00	100.00	100.0			
	TOT	46	85.14	24.778	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	24	81.60	30.789	8.3	66.67	100.00	100.00	100.0			
	ADA	22	92.42	16.042	41.7	91.67	100.00	100.00	100.0			
	TOT	46	86.78	25.189	8.3	91.67	100.00	100.00	100.0			
CHG FROM BSL	PLO	24	-0.69	21.691	-83.3	0.00	0.00	8.33	25.0			
	ADA	22	4.17	19.712	-41.7	0.00	0.00	8.33	58.3			
	TOT	46	1.63	20.684	-83.3	0.00	0.00	8.33	58.3			
										4.86	(-7.49, 17.22)	0.432A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.8.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	22	72.35	27.505	0.0	66.67	79.17	91.67	100.0			
	ADA	17	81.62	25.219	0.0	79.17	83.33	100.00	100.0			
	TOT	39	76.39	26.600	0.0	75.00	83.33	100.00	100.0			
FINAL/ET VALUE	PLO	22	63.45	28.199	0.0	58.33	72.92	83.33	100.0			
	ADA	17	78.92	24.494	0.0	75.00	83.33	100.00	100.0			
	TOT	39	70.19	27.432	0.0	58.33	75.00	83.33	100.0			
CHG FROM BSL	PLO	22	-8.90	12.552	-33.3	-20.83	-4.17	0.00	16.7			
	ADA	17	-2.70	9.876	-25.0	-8.33	0.00	0.00	16.7			
	TOT	39	-6.20	11.741	-33.3	-16.67	0.00	0.00	16.7			
										6.21	(-1.30, 13.71)	0.102A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.8.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	23	91.30	19.378	25.0	100.00	100.00	100.00	100.0			
	ADA	22	98.86	5.330	75.0	100.00	100.00	100.00	100.0			
	TOT	45	95.00	14.694	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	23	89.67	17.938	25.0	75.00	100.00	100.00	100.0			
	ADA	22	98.30	5.845	75.0	100.00	100.00	100.00	100.0			
	TOT	45	93.89	14.006	25.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	23	-1.63	12.098	-25.0	0.00	0.00	0.00	25.0			
	ADA	22	-0.57	8.162	-25.0	0.00	0.00	0.00	25.0			
	TOT	45	-1.11	10.260	-25.0	0.00	0.00	0.00	25.0			
										1.06	(-5.17, 7.30)	0.733A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.8.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	24	77.08	24.358	25.0	62.50	75.00	100.00	100.0			
	ADA	22	89.77	14.758	50.0	75.00	100.00	100.00	100.0			
	TOT	46	83.15	21.118	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	24	77.60	23.307	25.0	75.00	75.00	100.00	100.0			
	ADA	22	93.18	11.396	75.0	75.00	100.00	100.00	100.0			
	TOT	46	85.05	20.003	25.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	24	0.52	20.350	-50.0	0.00	0.00	0.00	50.0			
	ADA	22	3.41	19.358	-25.0	0.00	0.00	25.00	50.0			
	TOT	46	1.90	19.715	-50.0	0.00	0.00	0.00	50.0			
										2.89	(-8.94, 14.72)	0.625A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.8.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	24	75.98	19.272	25.3	64.32	84.83	89.38	95.6			
	ADA	22	84.07	8.896	68.2	79.58	86.09	91.55	97.4			
	TOT	46	79.85	15.603	25.3	73.07	85.71	90.61	97.4			
FINAL/ET VALUE	PLO	24	75.27	20.372	27.9	65.83	80.36	89.17	99.6			
	ADA	22	86.13	11.069	58.9	84.33	89.28	92.77	98.2			
	TOT	46	80.46	17.304	27.9	72.58	87.29	91.74	99.6			
CHG FROM BSL	PLO	24	-0.71	9.569	-28.0	-3.66	1.64	4.83	11.1			
	ADA	22	2.06	10.538	-23.1	-2.71	2.27	11.17	17.3			
	TOT	46	0.61	10.030	-28.0	-3.52	2.18	6.25	17.3			
										2.78	(-3.20, 8.75)	0.354A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.9.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	101	52.48	26.340	0.0	25.00	50.00	75.00	100.0			
	ADA	109	57.11	22.590	0.0	50.00	50.00	75.00	100.0			
	TOT	210	54.88	24.517	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	101	51.11	22.920	0.0	25.00	50.00	75.00	100.0			
	ADA	109	56.88	24.912	0.0	50.00	50.00	75.00	100.0			
	TOT	210	54.11	24.091	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	101	-1.36	19.677	-75.0	-25.00	0.00	0.00	50.0			
	ADA	109	-0.23	20.482	-50.0	-25.00	0.00	12.50	50.0			
	TOT	210	-0.77	20.059	-75.0	-25.00	0.00	0.00	50.0			
										1.13	(-4.34, 6.60)	0.684A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.9.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	101	66.93	16.355	20.0	60.00	60.00	80.00	100.0			
	ADA	108	66.85	15.746	40.0	60.00	60.00	80.00	100.0			
	TOT	209	66.89	16.005	20.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	101	64.36	18.244	20.0	60.00	60.00	80.00	100.0			
	ADA	108	69.54	19.971	20.0	60.00	80.00	80.00	100.0			
	TOT	209	67.03	19.285	20.0	60.00	80.00	80.00	100.0			
CHG FROM BSL	PLO	101	-2.57	15.916	-40.0	-20.00	0.00	0.00	40.0			
	ADA	108	2.69	16.441	-40.0	0.00	0.00	20.00	40.0			
	TOT	209	0.14	16.364	-40.0	0.00	0.00	0.00	40.0			
										5.26	(0.84, 9.68)	0.020A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.9.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	101	75.74	23.239	12.5	62.50	75.00	100.00	100.0			
	ADA	109	79.01	19.901	25.0	62.50	87.50	100.00	100.0			
	TOT	210	77.44	21.581	12.5	62.50	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	101	78.71	20.807	25.0	62.50	75.00	100.00	100.0			
	ADA	109	80.62	20.090	12.5	75.00	75.00	100.00	100.0			
	TOT	210	79.70	20.411	12.5	62.50	75.00	100.00	100.0			
CHG FROM BSL	PLO	101	2.97	18.213	-50.0	0.00	0.00	12.50	62.5			
	ADA	109	1.61	21.989	-62.5	-12.50	0.00	12.50	62.5			
	TOT	210	2.26	20.225	-62.5	0.00	0.00	12.50	62.5			
										-1.36	(-6.88, 4.15)	0.626A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.9.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	101	71.00	24.494	0.0	58.33	75.00	91.67	100.0			
	ADA	109	73.97	21.851	8.3	58.33	75.00	91.67	100.0			
	TOT	210	72.54	23.152	0.0	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	101	75.00	22.236	25.0	58.33	75.00	100.00	100.0			
	ADA	109	76.76	25.737	0.0	66.67	83.33	100.00	100.0			
	TOT	210	75.91	24.076	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	101	4.00	17.988	-33.3	-8.33	0.00	16.67	75.0			
	ADA	109	2.79	21.201	-75.0	-8.33	0.00	16.67	50.0			
	TOT	210	3.37	19.684	-75.0	-8.33	0.00	16.67	75.0			
										-1.21	(-6.58, 4.16)	0.657A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.9.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	101	74.01	22.891	16.7	58.33	83.33	91.67	100.0			
	ADA	109	73.85	21.433	8.3	58.33	75.00	91.67	100.0			
	TOT	210	73.93	22.093	8.3	58.33	79.17	91.67	100.0			
FINAL/ET VALUE	PLO	101	73.93	22.249	25.0	58.33	75.00	100.00	100.0			
	ADA	109	77.03	24.700	0.0	58.33	83.33	100.00	100.0			
	TOT	210	75.54	23.548	0.0	58.33	79.17	100.00	100.0			
CHG FROM BSL	PLO	101	-0.08	16.083	-41.7	-8.33	0.00	8.33	50.0			
	ADA	109	3.17	17.309	-50.0	-4.17	0.00	8.33	75.0			
	TOT	210	1.61	16.770	-50.0	-8.33	0.00	8.33	75.0			
										3.26	(-1.30, 7.81)	0.160A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.9.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	101	87.13	18.746	25.0	75.00	100.00	100.00	100.0			
	ADA	109	85.89	19.772	0.0	75.00	100.00	100.00	100.0			
	TOT	210	86.49	19.249	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	101	86.01	19.328	6.3	75.00	100.00	100.00	100.0			
	ADA	109	87.10	19.696	12.5	75.00	100.00	100.00	100.0			
	TOT	210	86.58	19.481	6.3	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	101	-1.11	13.387	-43.8	-6.25	0.00	0.00	37.5			
	ADA	109	1.20	15.555	-50.0	0.00	0.00	12.50	50.0			
	TOT	210	0.09	14.565	-50.0	0.00	0.00	0.00	50.0			
										2.32	(-1.64, 6.28)	0.250A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.9.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	101	64.73	24.021	6.3	50.00	68.75	81.25	100.0			
	ADA	109	63.34	23.963	0.0	43.75	68.75	81.25	100.0			
	TOT	210	64.01	23.943	0.0	50.00	68.75	81.25	100.0			
FINAL/ET VALUE	PLO	101	69.00	25.616	0.0	50.00	75.00	93.75	100.0			
	ADA	109	73.97	25.209	0.0	62.50	81.25	93.75	100.0			
	TOT	210	71.58	25.467	0.0	56.25	81.25	93.75	100.0			
CHG FROM BSL	PLO	101	4.27	17.874	-43.8	-6.25	6.25	12.50	68.8			
	ADA	109	10.63	18.638	-37.5	0.00	12.50	18.75	62.5			
	TOT	210	7.57	18.507	-43.8	0.00	6.25	18.75	68.8			
										6.36	(1.38, 11.33)	0.013A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.9.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	101	68.56	25.897	12.5	50.00	75.00	100.00	100.0			
	ADA	109	69.04	26.712	0.0	50.00	75.00	87.50	100.0			
	TOT	210	68.81	26.261	0.0	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	101	71.29	27.813	12.5	50.00	75.00	100.00	100.0			
	ADA	109	75.80	25.418	0.0	62.50	75.00	100.00	100.0			
	TOT	210	73.63	26.629	0.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	101	2.72	22.122	-50.0	-12.50	0.00	12.50	62.5			
	ADA	109	6.77	21.282	-50.0	0.00	0.00	12.50	75.0			
	TOT	210	4.82	21.733	-50.0	0.00	0.00	12.50	75.0			
										4.04	(-1.86, 9.95)	0.179A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.9.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	100	82.04	25.305	0.0	70.83	93.75	100.00	100.0			
	ADA	109	85.02	23.372	8.3	83.33	100.00	100.00	100.0			
	TOT	209	83.59	24.303	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	100	82.75	25.411	0.0	75.00	100.00	100.00	100.0			
	ADA	109	85.78	22.915	8.3	75.00	100.00	100.00	100.0			
	TOT	209	84.33	24.130	0.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	100	0.71	16.078	-58.3	0.00	0.00	0.00	75.0			
	ADA	109	0.76	16.099	-50.0	0.00	0.00	0.00	58.3			
	TOT	209	0.74	16.050	-58.3	0.00	0.00	0.00	75.0			
										0.06	(-4.34, 4.45)	0.980A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.9.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	82	69.11	28.531	0.0	58.33	83.33	91.67	100.0			
	ADA	83	66.32	33.814	0.0	50.00	83.33	91.67	100.0			
	TOT	165	67.70	31.236	0.0	50.00	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	82	67.38	28.007	0.0	50.00	75.00	91.67	100.0			
	ADA	83	68.27	32.891	0.0	58.33	83.33	100.00	100.0			
	TOT	165	67.83	30.472	0.0	50.00	75.00	91.67	100.0			
CHG FROM BSL	PLO	82	-1.73	15.808	-41.7	-8.33	0.00	0.00	66.7			
	ADA	83	1.96	22.806	-58.3	-8.33	0.00	8.33	100.0			
	TOT	165	0.13	19.670	-58.3	-8.33	0.00	8.33	100.0			
										3.69	(-2.35, 9.72)	0.230A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.9.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	100	89.50	18.181	25.0	75.00	100.00	100.00	100.0			
	ADA	108	93.52	15.426	25.0	100.00	100.00	100.00	100.0			
	TOT	208	91.59	16.886	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	100	90.75	16.149	50.0	75.00	100.00	100.00	100.0			
	ADA	108	92.82	18.422	0.0	100.00	100.00	100.00	100.0			
	TOT	208	91.83	17.356	0.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	100	1.25	13.472	-50.0	0.00	0.00	0.00	50.0			
	ADA	108	-0.69	12.996	-50.0	0.00	0.00	0.00	50.0			
	TOT	208	0.24	13.231	-50.0	0.00	0.00	0.00	50.0			
										-1.94	(-5.56, 1.67)	0.291A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.9.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	99	75.51	24.995	0.0	50.00	75.00	100.00	100.0			
	ADA	107	77.34	23.675	0.0	50.00	75.00	100.00	100.0			
	TOT	206	76.46	24.276	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	99	80.81	21.600	25.0	75.00	75.00	100.00	100.0			
	ADA	107	80.14	24.461	0.0	75.00	75.00	100.00	100.0			
	TOT	206	80.46	23.077	0.0	75.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	99	5.30	18.565	-25.0	0.00	0.00	25.00	50.0			
	ADA	107	2.80	19.824	-75.0	0.00	0.00	25.00	50.0			
	TOT	206	4.00	19.224	-75.0	0.00	0.00	25.00	50.0			
										-2.50	(-7.79, 2.79)	0.352A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.9.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	101	74.81	17.825	26.6	63.03	81.75	89.39	97.6			
	ADA	109	75.89	16.066	15.4	69.36	78.92	87.77	99.4			
	TOT	210	75.37	16.902	15.4	65.49	79.94	88.67	99.4			
FINAL/ET VALUE	PLO	101	76.22	17.908	31.7	64.55	81.63	92.88	100.0			
	ADA	109	78.82	19.442	12.4	70.11	85.08	93.64	100.0			
	TOT	210	77.57	18.721	12.4	65.68	84.02	92.88	100.0			
CHG FROM BSL	PLO	101	1.40	10.378	-30.9	-5.49	2.46	6.17	29.4			
	ADA	109	2.93	12.334	-33.6	-1.78	3.98	9.58	42.0			
	TOT	210	2.20	11.434	-33.6	-3.03	2.84	8.33	42.0			
										1.53	(-1.58, 4.64)	0.334A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.10.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	30	56.67	26.207	0.0	50.00	50.00	75.00	100.0			
	ADA	17	69.12	18.811	50.0	50.00	75.00	75.00	100.0			
	TOT	47	61.17	24.344	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	30	52.50	22.118	0.0	50.00	50.00	75.00	75.0			
	ADA	17	66.18	15.158	50.0	50.00	75.00	75.00	100.0			
	TOT	47	57.45	20.796	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	30	-4.17	18.666	-50.0	-25.00	0.00	0.00	25.0			
	ADA	17	-2.94	15.006	-25.0	0.00	0.00	0.00	25.0			
	TOT	47	-3.72	17.272	-50.0	-25.00	0.00	0.00	25.0			
										1.23	(-9.45, 11.90)	0.818A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.10.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	30	69.33	16.386	20.0	60.00	80.00	80.00	80.0			
	ADA	16	70.00	12.649	40.0	60.00	80.00	80.00	80.0			
	TOT	46	69.57	15.049	20.0	60.00	80.00	80.00	80.0			
FINAL/ET VALUE	PLO	30	62.67	19.464	20.0	60.00	60.00	80.00	80.0			
	ADA	16	72.50	10.000	60.0	60.00	80.00	80.00	80.0			
	TOT	46	66.09	17.318	20.0	60.00	70.00	80.00	80.0			
CHG FROM BSL	PLO	30	-6.67	13.218	-40.0	-20.00	0.00	0.00	20.0			
	ADA	16	2.50	12.383	-20.0	0.00	0.00	10.00	20.0			
	TOT	46	-3.48	13.535	-40.0	0.00	0.00	0.00	20.0			
										9.17	(1.09, 17.24)	0.027A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.10.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	30	77.92	22.429	25.0	62.50	75.00	100.00	100.0			
	ADA	17	83.82	15.790	50.0	75.00	87.50	100.00	100.0			
	TOT	47	80.05	20.300	25.0	62.50	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	30	81.67	20.165	25.0	75.00	81.25	100.00	100.0			
	ADA	17	82.35	19.294	37.5	75.00	87.50	100.00	100.0			
	TOT	47	81.91	19.645	25.0	75.00	87.50	100.00	100.0			
CHG FROM BSL	PLO	30	3.75	16.787	-50.0	0.00	0.00	12.50	50.0			
	ADA	17	-1.47	18.159	-50.0	0.00	0.00	12.50	25.0			
	TOT	47	1.86	17.285	-50.0	0.00	0.00	12.50	50.0			
										-5.22	(-15.79, 5.35)	0.325A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.10.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	30	74.72	22.583	16.7	58.33	75.00	91.67	100.0			
	ADA	17	75.74	21.562	33.3	50.00	83.33	91.67	100.0			
	TOT	47	75.09	21.988	16.7	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	30	77.64	19.528	33.3	66.67	83.33	91.67	100.0			
	ADA	17	81.86	18.218	33.3	75.00	83.33	91.67	100.0			
	TOT	47	79.17	18.975	33.3	66.67	83.33	91.67	100.0			
CHG FROM BSL	PLO	30	2.92	14.481	-25.0	-8.33	0.00	16.67	41.7			
	ADA	17	6.13	20.525	-25.0	-8.33	0.00	16.67	50.0			
	TOT	47	4.08	16.768	-25.0	-8.33	0.00	16.67	50.0			
										3.21	(-7.11, 13.53)	0.534A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.10.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	30	79.72	18.785	33.3	66.67	83.33	91.67	100.0			
	ADA	17	77.70	19.485	41.7	66.67	83.33	91.67	100.0			
	TOT	47	78.99	18.855	33.3	66.67	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	30	76.25	21.306	25.0	62.50	83.33	91.67	100.0			
	ADA	17	84.80	20.034	33.3	75.00	91.67	100.00	100.0			
	TOT	47	79.34	21.049	25.0	66.67	91.67	91.67	100.0			
CHG FROM BSL	PLO	30	-3.47	15.007	-41.7	-8.33	0.00	0.00	25.0			
	ADA	17	7.11	15.006	-16.7	-8.33	8.33	16.67	41.7			
	TOT	47	0.35	15.707	-41.7	-8.33	0.00	8.33	41.7			
										10.58	(1.40, 19.76)	0.025A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.10.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	30	89.58	18.881	37.5	87.50	100.00	100.00	100.0			
	ADA	17	88.97	15.234	50.0	87.50	100.00	100.00	100.0			
	TOT	47	89.36	17.480	37.5	87.50	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	30	89.38	15.323	50.0	75.00	100.00	100.00	100.0			
	ADA	17	93.38	14.736	50.0	100.00	100.00	100.00	100.0			
	TOT	47	90.82	15.077	50.0	87.50	100.00	100.00	100.0			
CHG FROM BSL	PLO	30	-0.21	11.429	-25.0	0.00	0.00	0.00	37.5			
	ADA	17	4.41	11.643	-12.5	0.00	0.00	12.50	37.5			
	TOT	47	1.46	11.599	-25.0	0.00	0.00	0.00	37.5			
										4.62	(-2.41, 11.65)	0.193A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
· TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.10.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	30	66.04	22.063	12.5	50.00	75.00	81.25	93.8			
	ADA	17	64.71	17.250	31.3	56.25	68.75	68.75	100.0			
	TOT	47	65.56	20.268	12.5	50.00	68.75	81.25	100.0			
FINAL/ET VALUE	PLO	30	72.50	21.249	25.0	56.25	78.13	87.50	100.0			
	ADA	17	70.22	21.141	25.0	62.50	75.00	81.25	100.0			
	TOT	47	71.68	21.008	25.0	56.25	75.00	87.50	100.0			
CHG FROM BSL	PLO	30	6.46	13.877	-31.3	0.00	6.25	12.50	50.0			
	ADA	17	5.51	17.936	-31.3	-6.25	0.00	12.50	37.5			
	TOT	47	6.12	15.281	-31.3	0.00	6.25	12.50	50.0			
										-0.94	(-10.39, 8.50)	0.841A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.10.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	30	68.75	24.729	12.5	50.00	62.50	87.50	100.0			
	ADA	17	77.21	23.896	37.5	50.00	87.50	100.00	100.0			
	TOT	47	71.81	24.515	12.5	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	30	68.75	28.570	25.0	50.00	75.00	100.00	100.0			
	ADA	17	74.26	23.581	25.0	62.50	75.00	87.50	100.0			
	TOT	47	70.74	26.743	25.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	30	0.00	16.082	-37.5	-12.50	0.00	12.50	25.0			
	ADA	17	-2.94	22.763	-37.5	-12.50	0.00	0.00	50.0			
	TOT	47	-1.06	18.583	-37.5	-12.50	0.00	12.50	50.0			
										-2.94	(-14.39, 8.51)	0.608A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.10.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	30	84.72	20.422	41.7	66.67	100.00	100.00	100.0			
	ADA	17	90.69	14.989	58.3	83.33	100.00	100.00	100.0			
	TOT	47	86.88	18.694	41.7	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	30	87.78	19.418	41.7	75.00	100.00	100.00	100.0			
	ADA	17	92.16	17.045	50.0	100.00	100.00	100.00	100.0			
	TOT	47	89.36	18.528	41.7	83.33	100.00	100.00	100.0			
CHG FROM BSL	PLO	30	3.06	13.218	-41.7	0.00	0.00	8.33	33.3			
	ADA	17	1.47	14.801	-33.3	0.00	0.00	0.00	41.7			
	TOT	47	2.48	13.673	-41.7	0.00	0.00	0.00	41.7			
										-1.58	(-10.02, 6.85)	0.707A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.10.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	27	73.77	24.861	0.0	66.67	83.33	91.67	100.0			
	ADA	15	74.17	30.949	0.0	58.33	87.50	100.00	100.0			
	TOT	42	73.91	26.815	0.0	66.67	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	27	71.60	22.998	0.0	50.00	83.33	87.50	100.0			
	ADA	15	66.11	29.457	0.0	58.33	66.67	91.67	100.0			
	TOT	42	69.64	25.274	0.0	58.33	75.00	87.50	100.0			
CHG FROM BSL	PLO	27	-2.16	13.545	-33.3	-8.33	0.00	0.00	16.7			
	ADA	15	-8.06	18.532	-41.7	-16.67	-8.33	0.00	41.7			
	TOT	42	-4.27	15.549	-41.7	-16.67	0.00	0.00	41.7			
										-5.90	(-15.97, 4.18)	0.244A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.10.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	29	92.24	17.808	50.0	100.00	100.00	100.00	100.0			
	ADA	17	95.59	13.215	50.0	100.00	100.00	100.00	100.0			
	TOT	46	93.48	16.189	50.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	29	92.67	13.160	50.0	87.50	100.00	100.00	100.0			
	ADA	17	100.00	0.000	100.0	100.00	100.00	100.00	100.0			
	TOT	46	95.38	10.979	50.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	29	0.43	12.714	-25.0	0.00	0.00	0.00	25.0			
	ADA	17	4.41	13.215	0.0	0.00	0.00	0.00	50.0			
	TOT	46	1.90	12.901	-25.0	0.00	0.00	0.00	50.0			
										3.98	(-3.96, 11.92)	0.318A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.10.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	30	82.50	20.917	25.0	75.00	87.50	100.00	100.0			
	ADA	17	88.24	19.995	50.0	75.00	100.00	100.00	100.0			
	TOT	47	84.57	20.558	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	30	82.92	19.828	25.0	75.00	81.25	100.00	100.0			
	ADA	17	86.76	17.936	50.0	75.00	100.00	100.00	100.0			
	TOT	47	84.31	19.059	25.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	30	0.42	15.565	-25.0	0.00	0.00	0.00	25.0			
	ADA	17	-1.47	18.689	-25.0	0.00	0.00	0.00	50.0			
	TOT	47	-0.27	16.585	-25.0	0.00	0.00	0.00	50.0			
										-1.89	(-12.12, 8.35)	0.712A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.10.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	30	78.10	17.374	26.6	71.36	86.57	90.23	95.5			
	ADA	17	80.85	13.384	48.1	74.32	86.70	89.66	94.6			
	TOT	47	79.09	15.950	26.6	71.48	86.63	90.23	95.5			
FINAL/ET VALUE	PLO	30	78.47	16.942	35.9	69.73	82.85	92.88	98.2			
	ADA	17	82.47	13.176	48.6	81.42	88.14	89.46	97.0			
	TOT	47	79.91	15.656	35.9	71.55	84.51	92.31	98.2			
CHG FROM BSL	PLO	30	0.37	9.246	-30.9	-5.49	2.18	6.25	19.3			
	ADA	17	1.62	11.899	-19.8	-3.03	0.30	3.71	37.0			
	TOT	47	0.82	10.174	-30.9	-5.49	0.57	4.92	37.0			
										1.25	(-5.02, 7.53)	0.690A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.11.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	34	54.41	22.589	25.0	50.00	50.00	75.00	100.0			
	ADA	41	53.05	18.704	0.0	50.00	50.00	75.00	100.0			
	TOT	75	53.67	20.423	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	34	53.68	21.437	25.0	50.00	50.00	75.00	100.0			
	ADA	41	55.79	24.060	0.0	50.00	50.00	75.00	100.0			
	TOT	75	54.83	22.781	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	34	-0.74	17.928	-50.0	0.00	0.00	0.00	25.0			
	ADA	41	2.74	21.562	-50.0	0.00	0.00	25.00	50.0			
	TOT	75	1.17	19.942	-50.0	0.00	0.00	25.00	50.0			
										3.48	(-5.77, 12.73)	0.456A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.11.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	34	69.41	17.222	40.0	60.00	60.00	80.00	100.0			
	ADA	41	70.73	14.898	40.0	60.00	80.00	80.00	100.0			
	TOT	75	70.13	15.896	40.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	34	68.24	15.661	40.0	60.00	60.00	80.00	100.0			
	ADA	41	72.93	18.199	20.0	60.00	80.00	80.00	100.0			
	TOT	75	70.80	17.145	20.0	60.00	80.00	80.00	100.0			
CHG FROM BSL	PLO	34	-1.18	19.032	-40.0	-20.00	0.00	20.00	40.0			
	ADA	41	2.20	16.049	-40.0	0.00	0.00	20.00	20.0			
	TOT	75	0.67	17.424	-40.0	0.00	0.00	20.00	40.0			
										3.37	(-4.70, 11.44)	0.408A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.11.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	34	77.21	25.277	12.5	62.50	87.50	100.00	100.0			
	ADA	41	77.90	21.924	25.0	75.00	75.00	100.00	100.0			
	TOT	75	77.58	23.342	12.5	62.50	81.25	100.00	100.0			
FINAL/ET VALUE	PLO	34	79.41	19.434	37.5	62.50	81.25	100.00	100.0			
	ADA	41	81.71	21.120	12.5	62.50	87.50	100.00	100.0			
	TOT	75	80.67	20.270	12.5	62.50	87.50	100.00	100.0			
CHG FROM BSL	PLO	34	2.21	18.067	-25.0	-12.50	0.00	0.00	62.5			
	ADA	41	3.81	25.575	-62.5	-12.50	0.00	12.50	62.5			
	TOT	75	3.08	22.355	-62.5	-12.50	0.00	12.50	62.5			
										1.61	(-8.79, 12.00)	0.759A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.11.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	34	77.21	22.314	16.7	66.67	79.17	100.00	100.0			
	ADA	41	75.41	20.237	25.0	66.67	75.00	91.67	100.0			
	TOT	75	76.22	21.077	16.7	66.67	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	34	78.19	22.846	25.0	58.33	83.33	100.00	100.0			
	ADA	41	80.18	20.891	0.0	75.00	83.33	100.00	100.0			
	TOT	75	79.28	21.672	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	34	0.98	14.760	-33.3	-8.33	0.00	8.33	33.3			
	ADA	41	4.78	22.775	-75.0	0.00	8.33	16.67	41.7			
	TOT	75	3.06	19.523	-75.0	-8.33	0.00	16.67	41.7			
										3.80	(-5.25, 12.84)	0.406A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.11.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	34	77.70	22.911	16.7	66.67	83.33	100.00	100.0			
	ADA	41	77.64	19.649	25.0	66.67	83.33	91.67	100.0			
	TOT	75	77.67	21.042	16.7	66.67	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	34	79.41	18.146	33.3	66.67	79.17	100.00	100.0			
	ADA	41	80.39	21.169	0.0	66.67	83.33	100.00	100.0			
	TOT	75	79.94	19.731	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	34	1.72	15.594	-33.3	-8.33	0.00	8.33	41.7			
	ADA	41	2.74	20.804	-50.0	-8.33	0.00	8.33	75.0			
	TOT	75	2.28	18.511	-50.0	-8.33	0.00	8.33	75.0			
										1.03	(-7.58, 9.64)	0.813A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.11.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	34	90.81	17.760	25.0	87.50	100.00	100.00	100.0			
	ADA	41	89.94	16.822	25.0	87.50	100.00	100.00	100.0			
	TOT	75	90.33	17.141	25.0	87.50	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	34	91.18	14.279	50.0	75.00	100.00	100.00	100.0			
	ADA	41	89.63	16.275	25.0	87.50	100.00	100.00	100.0			
	TOT	75	90.33	15.319	25.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	34	0.37	13.231	-37.5	0.00	0.00	0.00	37.5			
	ADA	41	-0.30	16.415	-25.0	0.00	0.00	0.00	50.0			
	TOT	75	0.00	14.961	-37.5	0.00	0.00	0.00	50.0			
										-0.67	(-7.63, 6.29)	0.848A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.11.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	34	68.57	20.556	12.5	56.25	71.88	87.50	93.8			
	ADA	41	66.77	25.672	0.0	56.25	81.25	81.25	100.0			
	TOT	75	67.58	23.356	0.0	56.25	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	34	72.79	21.034	18.8	62.50	81.25	87.50	100.0			
	ADA	41	77.13	21.813	12.5	68.75	81.25	93.75	100.0			
	TOT	75	75.17	21.429	12.5	62.50	81.25	93.75	100.0			
CHG FROM BSL	PLO	34	4.23	19.445	-37.5	0.00	6.25	18.75	43.8			
	ADA	41	10.37	18.467	-25.0	0.00	12.50	18.75	62.5			
	TOT	75	7.58	19.038	-37.5	0.00	6.25	18.75	62.5			
										6.14	(-2.61, 14.88)	0.166A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.11.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	34	69.85	24.641	25.0	50.00	75.00	100.00	100.0			
	ADA	41	68.29	25.632	12.5	50.00	75.00	87.50	100.0			
	TOT	75	69.00	25.030	12.5	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	34	73.90	24.107	25.0	50.00	75.00	100.00	100.0			
	ADA	41	75.00	24.843	25.0	50.00	75.00	100.00	100.0			
	TOT	75	74.50	24.353	25.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	34	4.04	18.648	-37.5	0.00	0.00	12.50	50.0			
	ADA	41	6.71	21.668	-50.0	0.00	0.00	12.50	62.5			
	TOT	75	5.50	20.264	-50.0	0.00	0.00	12.50	62.5			
										2.66	(-6.75, 12.07)	0.574A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.11.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	34	85.17	18.611	33.3	75.00	91.67	100.00	100.0			
	ADA	41	87.40	21.820	8.3	83.33	100.00	100.00	100.0			
	TOT	75	86.39	20.324	8.3	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	34	85.78	20.051	41.7	75.00	100.00	100.00	100.0			
	ADA	41	89.23	17.702	16.7	83.33	100.00	100.00	100.0			
	TOT	75	87.67	18.752	16.7	83.33	100.00	100.00	100.0			
CHG FROM BSL	PLO	34	0.61	13.221	-41.7	0.00	0.00	0.00	33.3			
	ADA	41	1.83	16.299	-41.7	0.00	0.00	0.00	58.3			
	TOT	75	1.28	14.897	-41.7	0.00	0.00	0.00	58.3			
										1.22	(-5.71, 8.14)	0.727A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.11.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	27	75.31	19.575	33.3	62.50	83.33	91.67	100.0			
	ADA	29	72.84	25.796	0.0	66.67	79.17	91.67	100.0			
	TOT	56	74.03	22.835	0.0	64.58	81.25	91.67	100.0			
FINAL/ET VALUE	PLO	27	72.53	24.220	8.3	58.33	75.00	91.67	100.0			
	ADA	29	74.86	26.080	0.0	66.67	83.33	100.00	100.0			
	TOT	56	73.74	24.999	0.0	58.33	79.17	91.67	100.0			
CHG FROM BSL	PLO	27	-2.78	13.327	-41.7	-8.33	0.00	0.00	16.7			
	ADA	29	2.01	12.481	-33.3	0.00	0.00	8.33	25.0			
	TOT	56	-0.30	13.004	-41.7	-8.33	0.00	8.33	25.0			
										4.79	(-2.12, 11.70)	0.171A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.11.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	34	88.97	17.615	50.0	75.00	100.00	100.00	100.0			
	ADA	40	96.88	10.108	50.0	100.00	100.00	100.00	100.0			
	TOT	74	93.24	14.511	50.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	34	90.44	16.301	50.0	75.00	100.00	100.00	100.0			
	ADA	40	95.31	12.560	50.0	100.00	100.00	100.00	100.0			
	TOT	74	93.07	14.504	50.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	34	1.47	12.218	-25.0	0.00	0.00	0.00	25.0			
	ADA	40	-1.56	8.100	-25.0	0.00	0.00	0.00	25.0			
	TOT	74	-0.17	10.240	-25.0	0.00	0.00	0.00	25.0			
										-3.03	(-7.77, 1.71)	0.206A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.11.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#		P-VALUE@
PERIPHERAL VISION													
BSL VALUE	PLO	33	75.00	24.206	25.0	50.00	75.00	100.00	100.0				
	ADA	40	76.88	24.276	25.0	50.00	75.00	100.00	100.0				
	TOT	73	76.03	24.094	25.0	50.00	75.00	100.00	100.0				
FINAL/ET VALUE	PLO	33	84.09	20.557	25.0	75.00	100.00	100.00	100.0				
	ADA	40	81.25	24.515	0.0	75.00	87.50	100.00	100.0				
	TOT	73	82.53	22.702	0.0	75.00	100.00	100.00	100.0				
CHG FROM BSL	PLO	33	9.09	23.233	-50.0	0.00	0.00	25.00	50.0				
	ADA	40	4.38	21.844	-75.0	0.00	0.00	25.00	50.0				
	TOT	73	6.51	22.449	-75.0	0.00	0.00	25.00	50.0				
										-4.72	(-15.26,	5.83)	0.375A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.11.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	34	77.50	15.922	43.6	65.71	83.48	90.50	96.0			
	ADA	41	78.27	14.377	43.7	71.82	82.08	88.52	97.6			
	TOT	75	77.92	14.998	43.6	70.42	82.73	90.29	97.6			
FINAL/ET VALUE	PLO	34	79.54	15.777	45.9	65.30	86.33	92.88	97.7			
	ADA	41	81.27	17.238	12.4	70.80	86.82	92.50	100.0			
	TOT	75	80.48	16.503	12.4	67.01	86.63	92.88	100.0			
CHG FROM BSL	PLO	34	2.04	10.474	-28.0	-0.68	2.71	6.25	29.4			
	ADA	41	2.99	13.915	-31.3	-1.78	3.90	12.31	42.0			
	TOT	75	2.56	12.402	-31.3	-1.78	2.95	10.04	42.0			
										0.95	(-4.82, 6.72)	0.743A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.12.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	60	48.75	25.803	0.0	25.00	50.00	75.00	100.0			
	ADA	71	55.99	22.938	25.0	50.00	50.00	75.00	100.0			
	TOT	131	52.67	24.466	0.0	25.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	60	48.96	24.604	0.0	25.00	50.00	75.00	100.0			
	ADA	71	54.40	25.363	0.0	25.00	50.00	75.00	100.0			
	TOT	131	51.91	25.071	0.0	25.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	60	0.21	20.128	-75.0	0.00	0.00	6.25	50.0			
	ADA	71	-1.58	20.909	-50.0	-25.00	0.00	12.50	50.0			
	TOT	131	-0.76	20.496	-75.0	-25.00	0.00	12.50	50.0			
										-1.79	(-8.92, 5.34)	0.620A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.12.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	60	66.50	16.857	40.0	60.00	60.00	80.00	100.0			
	ADA	71	64.79	16.376	40.0	60.00	60.00	80.00	100.0			
	TOT	131	65.57	16.556	40.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	60	62.67	19.989	20.0	40.00	60.00	80.00	100.0			
	ADA	71	67.32	21.177	20.0	60.00	80.00	80.00	100.0			
	TOT	131	65.19	20.694	20.0	40.00	60.00	80.00	100.0			
CHG FROM BSL	PLO	60	-3.83	15.193	-40.0	-20.00	0.00	0.00	20.0			
	ADA	71	2.54	16.879	-40.0	0.00	0.00	20.00	40.0			
	TOT	131	-0.38	16.380	-40.0	0.00	0.00	0.00	40.0			
										6.37	(0.77, 11.96)	0.026A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.12.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	60	74.38	21.763	25.0	56.25	75.00	93.75	100.0			
	ADA	71	78.17	20.886	25.0	62.50	87.50	100.00	100.0			
	TOT	131	76.43	21.295	25.0	62.50	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	60	76.67	21.890	25.0	62.50	75.00	100.00	100.0			
	ADA	71	79.93	20.646	37.5	62.50	75.00	100.00	100.0			
	TOT	131	78.44	21.205	25.0	62.50	75.00	100.00	100.0			
CHG FROM BSL	PLO	60	2.29	17.601	-50.0	0.00	0.00	12.50	62.5			
	ADA	71	1.76	20.299	-50.0	-12.50	0.00	12.50	50.0			
	TOT	131	2.00	19.040	-50.0	-12.50	0.00	12.50	62.5			
										-0.53	(-7.16, 6.10)	0.874A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.12.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	60	66.32	26.041	0.0	50.00	75.00	91.67	100.0			
	ADA	71	75.41	21.892	8.3	58.33	75.00	91.67	100.0			
	TOT	131	71.25	24.218	0.0	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	60	71.94	22.961	16.7	54.17	75.00	95.83	100.0			
	ADA	71	76.64	27.946	0.0	66.67	83.33	100.00	100.0			
	TOT	131	74.49	25.794	0.0	58.33	83.33	100.00	100.0			
CHG FROM BSL	PLO	60	5.63	19.646	-33.3	-4.17	0.00	16.67	75.0			
	ADA	71	1.23	19.459	-66.7	-8.33	0.00	16.67	41.7			
	TOT	131	3.24	19.593	-66.7	-8.33	0.00	16.67	75.0			
										-4.39	(-11.17, 2.39)	0.202A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.12.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	60	68.75	25.006	8.3	50.00	75.00	91.67	100.0			
	ADA	71	73.42	21.655	8.3	58.33	75.00	91.67	100.0			
	TOT	131	71.28	23.275	8.3	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	60	70.76	25.391	8.3	58.33	66.67	100.00	100.0			
	ADA	71	76.06	25.740	0.0	58.33	83.33	100.00	100.0			
	TOT	131	73.63	25.620	0.0	58.33	75.00	100.00	100.0			
CHG FROM BSL	PLO	60	2.01	16.693	-33.3	-8.33	0.00	8.33	50.0			
	ADA	71	2.64	15.109	-41.7	0.00	0.00	8.33	41.7			
	TOT	131	2.35	15.795	-41.7	0.00	0.00	8.33	50.0			
										0.63	(-4.87, 6.13)	0.822A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.12.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	60	84.38	19.065	37.5	75.00	100.00	100.00	100.0			
	ADA	71	86.09	20.653	0.0	75.00	100.00	100.00	100.0			
	TOT	131	85.31	19.884	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	60	82.29	22.495	6.3	75.00	87.50	100.00	100.0			
	ADA	71	86.88	20.814	12.5	75.00	100.00	100.00	100.0			
	TOT	131	84.78	21.638	6.3	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	60	-2.08	14.078	-43.8	-12.50	0.00	0.00	25.0			
	ADA	71	0.79	13.852	-50.0	0.00	0.00	12.50	25.0			
	TOT	131	-0.52	13.976	-50.0	0.00	0.00	0.00	25.0			
										2.88	(-1.97, 7.72)	0.242A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.12.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	60	60.38	27.075	0.0	39.58	62.50	81.25	100.0			
	ADA	71	64.96	23.093	0.0	50.00	68.75	83.33	93.8			
	TOT	131	62.87	25.002	0.0	43.75	68.75	81.25	100.0			
FINAL/ET VALUE	PLO	60	63.75	30.765	0.0	37.50	75.00	93.75	100.0			
	ADA	71	75.00	26.114	0.0	62.50	81.25	93.75	100.0			
	TOT	131	69.85	28.782	0.0	50.00	75.00	93.75	100.0			
CHG FROM BSL	PLO	60	3.37	19.483	-56.3	-6.25	6.25	12.50	68.8			
	ADA	71	10.04	17.943	-37.5	0.00	12.50	18.75	62.5			
	TOT	131	6.98	18.888	-56.3	0.00	6.25	16.67	68.8			
										6.67	(0.19, 13.14)	0.044A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.12.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	60	66.46	28.420	0.0	50.00	75.00	100.00	100.0			
	ADA	71	69.19	27.454	0.0	50.00	75.00	87.50	100.0			
	TOT	131	67.94	27.826	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	60	68.33	29.960	0.0	43.75	75.00	100.00	100.0			
	ADA	71	79.05	25.858	0.0	62.50	87.50	100.00	100.0			
	TOT	131	74.14	28.216	0.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	60	1.88	24.875	-62.5	-12.50	0.00	12.50	62.5			
	ADA	71	9.86	20.035	-37.5	0.00	0.00	12.50	75.0			
	TOT	131	6.20	22.648	-62.5	0.00	0.00	12.50	75.0			
										7.98	(0.22, 15.75)	0.044A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.12.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	59	78.67	32.099	0.0	58.33	100.00	100.00	100.0			
	ADA	71	82.86	24.148	8.3	75.00	91.67	100.00	100.0			
	TOT	130	80.96	28.001	0.0	75.00	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	59	77.68	31.806	0.0	58.33	91.67	100.00	100.0			
	ADA	71	84.27	25.140	8.3	75.00	100.00	100.00	100.0			
	TOT	130	81.28	28.437	0.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	59	-0.99	20.881	-83.3	0.00	0.00	0.00	75.0			
	ADA	71	1.41	17.536	-50.0	0.00	0.00	8.33	58.3			
	TOT	130	0.32	19.088	-83.3	0.00	0.00	8.33	75.0			
										2.40	(-4.27, 9.06)	0.478A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.12.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	49	63.95	32.957	0.0	50.00	75.00	91.67	100.0			
	ADA	55	65.15	36.855	0.0	41.67	83.33	91.67	100.0			
	TOT	104	64.58	34.909	0.0	50.00	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	49	59.78	31.117	0.0	41.67	66.67	83.33	100.0			
	ADA	55	68.56	35.399	0.0	58.33	83.33	100.00	100.0			
	TOT	104	64.42	33.580	0.0	50.00	75.00	91.67	100.0			
CHG FROM BSL	PLO	49	-4.17	17.657	-41.7	-16.67	0.00	0.00	66.7			
	ADA	55	3.41	24.975	-58.3	0.00	0.00	8.33	100.0			
	TOT	104	-0.16	22.063	-58.3	-8.33	0.00	0.00	100.0			
										7.58	(-0.93, 16.09)	0.080A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.12.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	59	88.98	19.293	25.0	75.00	100.00	100.00	100.0			
	ADA	71	92.61	16.580	25.0	100.00	100.00	100.00	100.0			
	TOT	130	90.96	17.883	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	59	89.41	18.101	25.0	75.00	100.00	100.00	100.0			
	ADA	71	91.20	20.744	0.0	100.00	100.00	100.00	100.0			
	TOT	130	90.38	19.535	0.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	59	0.42	14.302	-50.0	0.00	0.00	0.00	50.0			
	ADA	71	-1.41	13.943	-50.0	0.00	0.00	0.00	50.0			
	TOT	130	-0.58	14.082	-50.0	0.00	0.00	0.00	50.0			
										-1.83	(-6.75, 3.09)	0.462A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.12.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	59	72.46	26.545	0.0	50.00	75.00	100.00	100.0			
	ADA	70	78.21	22.491	0.0	75.00	75.00	100.00	100.0			
	TOT	129	75.58	24.500	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	59	76.27	23.292	25.0	50.00	75.00	100.00	100.0			
	ADA	70	82.14	24.131	25.0	75.00	100.00	100.00	100.0			
	TOT	129	79.46	23.840	25.0	75.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	59	3.81	17.716	-25.0	0.00	0.00	25.00	50.0			
	ADA	70	3.93	18.374	-50.0	0.00	0.00	25.00	50.0			
	TOT	129	3.88	18.006	-50.0	0.00	0.00	25.00	50.0			
										0.12	(-6.21, 6.44)	0.971A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.12.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	60	71.87	19.279	25.3	55.66	77.23	88.43	97.6			
	ADA	71	75.52	16.441	15.4	69.13	79.13	87.58	99.4			
	TOT	131	73.85	17.820	15.4	63.03	78.92	87.65	99.4			
FINAL/ET VALUE	PLO	60	72.55	19.952	27.9	56.16	75.34	87.71	100.0			
	ADA	71	78.75	20.497	20.4	66.42	85.76	95.53	100.0			
	TOT	131	75.91	20.409	20.4	62.73	82.84	92.77	100.0			
CHG FROM BSL	PLO	60	0.68	10.738	-28.3	-5.74	0.34	5.30	25.0			
	ADA	71	3.23	11.011	-33.6	-0.45	4.36	9.58	22.7			
	TOT	131	2.06	10.920	-33.6	-2.46	3.14	8.52	25.0			
										2.56	(-1.22, 6.33)	0.183A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
NOTE: 3 SUBJECTS HAD INTERMEDIATE AND POSTERIOR UVEITIS.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.13.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BSL VALUE	PLO	53	57.08	25.654	0.0	50.00	50.00	75.00	100.0			
	ADA	45	57.78	22.501	25.0	50.00	50.00	75.00	100.0			
	TOT	98	57.40	24.137	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	53	53.77	20.449	0.0	50.00	50.00	75.00	100.0			
	ADA	45	57.78	23.730	0.0	50.00	75.00	75.00	100.0			
	TOT	98	55.61	21.992	0.0	50.00	50.00	75.00	100.0			
CHG FROM BSL	PLO	53	-3.30	19.635	-50.0	-25.00	0.00	0.00	50.0			
	ADA	45	0.00	19.218	-25.0	-25.00	0.00	25.00	25.0			
	TOT	98	-1.79	19.415	-50.0	-25.00	0.00	0.00	50.0			
										3.30	(-4.52, 11.13)	0.404A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.13.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BSL VALUE	PLO	53	70.00	18.397	20.0	60.00	80.00	80.00	100.0			
	ADA	45	68.89	15.699	40.0	60.00	80.00	80.00	100.0			
	TOT	98	69.49	17.133	20.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	53	61.51	18.334	20.0	40.00	60.00	80.00	100.0			
	ADA	45	71.11	16.817	40.0	60.00	80.00	80.00	100.0			
	TOT	98	65.92	18.210	20.0	60.00	60.00	80.00	100.0			
CHG FROM BSL	PLO	53	-8.49	15.114	-40.0	-20.00	0.00	0.00	20.0			
	ADA	45	2.22	12.227	-20.0	0.00	0.00	0.00	40.0			
	TOT	98	-3.57	14.801	-40.0	-20.00	0.00	0.00	40.0			
										10.71	(5.13, 16.29)	<0.001A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.13.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BSL VALUE	PLO	53	79.95	21.836	25.0	62.50	87.50	100.00	100.0			
	ADA	45	80.83	20.226	37.5	75.00	87.50	100.00	100.0			
	TOT	98	80.36	21.009	25.0	62.50	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	53	83.96	15.958	50.0	75.00	87.50	100.00	100.0			
	ADA	45	83.06	19.971	37.5	75.00	87.50	100.00	100.0			
	TOT	98	83.55	17.823	37.5	75.00	87.50	100.00	100.0			
CHG FROM BSL	PLO	53	4.01	15.654	-25.0	0.00	0.00	12.50	62.5			
	ADA	45	2.22	21.861	-62.5	-12.50	0.00	12.50	62.5			
	TOT	98	3.19	18.680	-62.5	0.00	0.00	12.50	62.5			
										-1.79	(-9.33, 5.76)	0.639A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.13.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BSL VALUE	PLO	53	74.14	24.884	12.5	58.33	75.00	91.67	100.0			
	ADA	45	78.06	21.911	8.3	58.33	83.33	100.00	100.0			
	TOT	98	75.94	23.529	8.3	58.33	83.33	95.83	100.0			
FINAL/ET VALUE	PLO	53	75.00	23.342	16.7	58.33	83.33	91.67	100.0			
	ADA	45	79.44	21.216	0.0	75.00	83.33	100.00	100.0			
	TOT	98	77.04	22.388	0.0	66.67	83.33	100.00	100.0			
CHG FROM BSL	PLO	53	0.86	16.734	-33.3	-8.33	0.00	8.33	62.5			
	ADA	45	1.39	16.948	-41.7	-8.33	0.00	8.33	33.3			
	TOT	98	1.11	16.748	-41.7	-8.33	0.00	8.33	62.5			
										0.52	(-6.25, 7.30)	0.878A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.13.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BSL VALUE	PLO	53	77.99	22.174	8.3	66.67	83.33	91.67	100.0			
	ADA	45	76.94	22.466	25.0	66.67	83.33	91.67	100.0			
	TOT	98	77.51	22.200	8.3	66.67	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	53	74.21	23.811	8.3	58.33	83.33	91.67	100.0			
	ADA	45	79.72	22.953	0.0	66.67	87.50	100.00	100.0			
	TOT	98	76.74	23.463	0.0	58.33	83.33	100.00	100.0			
CHG FROM BSL	PLO	53	-3.77	13.030	-33.3	-8.33	0.00	0.00	25.0			
	ADA	45	2.78	16.500	-41.7	0.00	0.00	8.33	75.0			
	TOT	98	-0.77	15.009	-41.7	-8.33	0.00	8.33	75.0			
										6.55	(0.63, 12.48)	0.031A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.13.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BSL VALUE	PLO	53	91.27	16.551	37.5	87.50	100.00	100.00	100.0			
	ADA	45	91.39	14.307	50.0	87.50	100.00	100.00	100.0			
	TOT	98	91.33	15.483	37.5	87.50	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	53	90.21	15.383	50.0	75.00	100.00	100.00	100.0			
	ADA	45	90.28	17.453	37.5	87.50	100.00	100.00	100.0			
	TOT	98	90.24	16.280	37.5	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	53	-1.06	10.088	-25.0	0.00	0.00	0.00	25.0			
	ADA	45	-1.11	14.796	-50.0	0.00	0.00	0.00	50.0			
	TOT	98	-1.08	12.404	-50.0	0.00	0.00	0.00	50.0			
										-0.05	(-5.07, 4.97)	0.984A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.13.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BSL VALUE	PLO	53	65.53	21.989	12.5	50.00	75.00	81.25	100.0			
	ADA	45	66.71	21.996	6.3	56.25	68.75	81.25	93.8			
	TOT	98	66.07	21.887	6.3	50.00	68.75	81.25	100.0			
FINAL/ET VALUE	PLO	53	68.16	24.827	12.5	50.00	75.00	87.50	100.0			
	ADA	45	76.67	22.941	12.5	62.50	81.25	93.75	100.0			
	TOT	98	72.07	24.234	12.5	50.00	81.25	93.75	100.0			
CHG FROM BSL	PLO	53	2.63	14.538	-37.5	-6.25	6.25	12.50	31.3			
	ADA	45	9.95	18.781	-31.3	0.00	6.25	12.50	62.5			
	TOT	98	5.99	16.934	-37.5	0.00	6.25	12.50	62.5			
										7.32	(0.63, 14.01)	0.032A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.13.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BSL VALUE	PLO	53	68.16	25.068	12.5	50.00	62.50	87.50	100.0			
	ADA	45	73.06	27.172	12.5	50.00	87.50	100.00	100.0			
	TOT	98	70.41	26.035	12.5	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	53	66.51	27.926	25.0	50.00	75.00	100.00	100.0			
	ADA	45	76.67	22.392	25.0	62.50	75.00	100.00	100.0			
	TOT	98	71.17	25.912	25.0	50.00	75.00	100.00	100.0			
CHG FROM BSL	PLO	53	-1.65	19.921	-50.0	-12.50	0.00	12.50	50.0			
	ADA	45	3.61	20.405	-37.5	0.00	0.00	12.50	62.5			
	TOT	98	0.77	20.213	-50.0	-12.50	0.00	12.50	62.5			
										5.26	(-2.84, 13.37)	0.201A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.13.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BSL VALUE	PLO	52	83.01	26.710	0.0	70.83	100.00	100.00	100.0			
	ADA	45	86.48	22.353	8.3	83.33	100.00	100.00	100.0			
	TOT	97	84.62	24.719	0.0	83.33	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	52	84.94	27.318	0.0	83.33	100.00	100.00	100.0			
	ADA	45	87.78	22.375	8.3	83.33	100.00	100.00	100.0			
	TOT	97	86.25	25.059	0.0	83.33	100.00	100.00	100.0			
CHG FROM BSL	PLO	52	1.92	12.417	-50.0	0.00	0.00	4.17	33.3			
	ADA	45	1.30	14.753	-33.3	0.00	0.00	0.00	50.0			
	TOT	97	1.63	13.482	-50.0	0.00	0.00	0.00	50.0			
										-0.63	(-6.10, 4.85)	0.821A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.13.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BSL VALUE	PLO	49	69.13	29.265	0.0	58.33	83.33	91.67	100.0			
	ADA	35	71.90	30.923	0.0	50.00	83.33	100.00	100.0			
	TOT	84	70.29	29.814	0.0	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	49	66.24	28.441	0.0	50.00	75.00	83.33	100.0			
	ADA	35	69.76	29.085	0.0	58.33	75.00	91.67	100.0			
	TOT	84	67.71	28.590	0.0	54.17	75.00	83.33	100.0			
CHG FROM BSL	PLO	49	-2.89	13.154	-41.7	-8.33	0.00	0.00	25.0			
	ADA	35	-2.14	16.830	-41.7	-8.33	0.00	8.33	41.7			
	TOT	84	-2.58	14.705	-41.7	-8.33	0.00	0.00	41.7			
										0.75	(-5.76, 7.26)	0.820A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.13.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BSL VALUE	PLO	52	90.38	19.898	25.0	100.00	100.00	100.00	100.0			
	ADA	45	97.78	7.195	75.0	100.00	100.00	100.00	100.0			
	TOT	97	93.81	15.742	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	52	91.35	17.771	25.0	100.00	100.00	100.00	100.0			
	ADA	45	95.00	12.613	50.0	100.00	100.00	100.00	100.0			
	TOT	97	93.04	15.622	25.0	100.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	52	0.96	12.088	-50.0	0.00	0.00	0.00	25.0			
	ADA	45	-2.78	10.952	-50.0	0.00	0.00	0.00	25.0			
	TOT	97	-0.77	11.667	-50.0	0.00	0.00	0.00	25.0			
										-3.74	(-8.42, 0.94)	0.116A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.13.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BSL VALUE	PLO	51	79.90	25.505	0.0	75.00	100.00	100.00	100.0			
	ADA	45	83.33	19.943	50.0	75.00	100.00	100.00	100.0			
	TOT	96	81.51	23.012	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	51	82.60	21.371	25.0	75.00	87.50	100.00	100.0			
	ADA	45	84.44	20.148	25.0	75.00	100.00	100.00	100.0			
	TOT	96	83.46	20.719	25.0	75.00	100.00	100.00	100.0			
CHG FROM BSL	PLO	51	2.70	16.453	-25.0	0.00	0.00	0.00	50.0			
	ADA	45	1.11	18.429	-50.0	0.00	0.00	0.00	50.0			
	TOT	96	1.95	17.333	-50.0	0.00	0.00	0.00	50.0			
										-1.58	(-8.65, 5.48)	0.657A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.13.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BSL VALUE	PLO	53	77.10	18.912	25.3	67.65	86.46	90.30	97.6			
	ADA	45	79.56	14.015	42.7	71.36	83.29	89.28	99.4			
	TOT	98	78.23	16.803	25.3	70.79	84.10	90.23	99.4			
FINAL/ET VALUE	PLO	53	76.80	18.118	27.9	69.85	81.78	92.88	98.2			
	ADA	45	81.22	15.731	35.1	75.64	83.92	92.08	100.0			
	TOT	98	78.83	17.121	27.9	70.80	82.75	92.88	100.0			
CHG FROM BSL	PLO	53	-0.30	8.076	-28.3	-5.68	0.57	4.81	19.3			
	ADA	45	1.66	11.296	-30.8	-2.08	1.14	4.73	42.0			
	TOT	98	0.60	9.685	-30.8	-3.96	0.91	4.81	42.0			
										1.96	(-1.94, 5.86)	0.321A

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BASELINE TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BASELINE TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.14.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BSL VALUE	PLO	14	60.71	25.409	25.0	50.00	62.50	75.00	100.0
	ADA	15	61.67	15.999	50.0	50.00	50.00	75.00	100.0
	TOT	29	61.21	20.687	25.0	50.00	50.00	75.00	100.0
FINAL/ET VALUE	PLO	14	58.93	21.047	25.0	50.00	50.00	75.00	100.0
	ADA	15	60.00	18.420	25.0	50.00	50.00	75.00	100.0
	TOT	29	59.48	19.381	25.0	50.00	50.00	75.00	100.0
CHG FROM BSL	PLO	14	-1.79	15.393	-25.0	0.00	0.00	0.00	25.0
	ADA	15	-1.67	24.029	-50.0	-25.00	0.00	0.00	50.0
	TOT	29	-1.72	19.968	-50.0	0.00	0.00	0.00	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.14.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BSL VALUE	PLO	14	67.14	14.899	40.0	60.00	60.00	80.00	100.0
	ADA	15	69.33	10.328	60.0	60.00	60.00	80.00	80.0
	TOT	29	68.28	12.555	40.0	60.00	60.00	80.00	100.0
FINAL/ET VALUE	PLO	14	68.57	12.924	40.0	60.00	70.00	80.00	80.0
	ADA	15	73.33	12.344	60.0	60.00	80.00	80.00	100.0
	TOT	29	71.03	12.634	40.0	60.00	80.00	80.00	100.0
CHG FROM BSL	PLO	14	1.43	14.601	-20.0	0.00	0.00	20.00	20.0
	ADA	15	4.00	13.522	-20.0	0.00	0.00	20.00	20.0
	TOT	29	2.76	13.861	-20.0	0.00	0.00	20.00	20.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.14.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BSL VALUE	PLO	14	80.36	18.157	50.0	62.50	87.50	100.00	100.0
	ADA	15	86.25	13.815	50.0	75.00	87.50	100.00	100.0
	TOT	29	83.41	16.046	50.0	75.00	87.50	100.00	100.0
FINAL/ET VALUE	PLO	14	81.25	18.830	50.0	75.00	75.00	100.00	100.0
	ADA	15	86.67	15.999	62.5	75.00	100.00	100.00	100.0
	TOT	29	84.05	17.326	50.0	75.00	87.50	100.00	100.0
CHG FROM BSL	PLO	14	0.89	11.461	-25.0	0.00	0.00	12.50	12.5
	ADA	15	0.42	18.670	-25.0	-25.00	0.00	12.50	25.0
	TOT	29	0.65	15.341	-25.0	-12.50	0.00	12.50	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.14.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BSL VALUE	PLO	14	72.02	27.074	16.7	50.00	70.83	100.00	100.0
	ADA	15	72.22	23.918	25.0	50.00	75.00	100.00	100.0
	TOT	29	72.13	25.027	16.7	50.00	75.00	100.00	100.0
FINAL/ET VALUE	PLO	14	77.98	25.863	33.3	58.33	91.67	100.00	100.0
	ADA	15	82.22	17.780	41.7	75.00	83.33	100.00	100.0
	TOT	29	80.17	21.755	33.3	66.67	83.33	100.00	100.0
CHG FROM BSL	PLO	14	5.95	18.898	-33.3	0.00	4.17	16.67	50.0
	ADA	15	10.00	14.840	-25.0	0.00	8.33	25.00	25.0
	TOT	29	8.05	16.738	-33.3	0.00	8.33	16.67	50.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.14.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BSL VALUE	PLO	14	78.57	23.956	16.7	66.67	87.50	100.00	100.0
	ADA	15	76.11	16.326	50.0	66.67	75.00	91.67	100.0
	TOT	29	77.30	20.032	16.7	66.67	83.33	91.67	100.0
FINAL/ET VALUE	PLO	14	82.74	20.006	41.7	66.67	91.67	100.00	100.0
	ADA	15	80.00	16.306	50.0	66.67	83.33	91.67	100.0
	TOT	29	81.32	17.908	41.7	66.67	83.33	100.00	100.0
CHG FROM BSL	PLO	14	4.17	12.972	-25.0	0.00	0.00	8.33	25.0
	ADA	15	3.89	11.729	-16.7	0.00	8.33	8.33	25.0
	TOT	29	4.02	12.121	-25.0	0.00	0.00	8.33	25.0

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.14.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BSL VALUE	PLO	14	86.61	21.631	25.0	75.00	100.00	100.00	100.0
	ADA	15	85.83	15.574	50.0	75.00	87.50	100.00	100.0
	TOT	29	86.21	18.403	25.0	75.00	87.50	100.00	100.0
FINAL/ET VALUE	PLO	14	90.18	14.021	62.5	75.00	100.00	100.00	100.0
	ADA	15	90.00	11.764	62.5	87.50	87.50	100.00	100.0
	TOT	29	90.09	12.668	62.5	75.00	100.00	100.00	100.0
CHG FROM BSL	PLO	14	3.57	11.423	-12.5	0.00	0.00	0.00	37.5
	ADA	15	4.17	13.909	-25.0	0.00	0.00	12.50	25.0
	TOT	29	3.88	12.546	-25.0	0.00	0.00	12.50	37.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.14.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BSL VALUE	PLO	14	70.09	19.943	25.0	56.25	68.75	87.50	93.8
	ADA	15	62.92	21.058	18.8	50.00	68.75	81.25	87.5
	TOT	29	66.38	20.486	18.8	56.25	68.75	81.25	93.8
FINAL/ET VALUE	PLO	14	75.45	21.715	31.3	62.50	87.50	93.75	93.8
	ADA	15	76.67	16.615	43.8	62.50	75.00	93.75	100.0
	TOT	29	76.08	18.903	31.3	62.50	81.25	93.75	100.0
CHG FROM BSL	PLO	14	5.36	13.169	-31.3	0.00	6.25	12.50	25.0
	ADA	15	13.75	16.229	-12.5	6.25	12.50	25.00	43.8
	TOT	29	9.70	15.180	-31.3	0.00	6.25	18.75	43.8

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__2000.4.1.1.14.I

CHANGE FROM BASELINE TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-880)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BSL VALUE	PLO	14	69.64	28.043	25.0	50.00	68.75	100.00	100.0
	ADA	15	65.00	22.261	25.0	50.00	62.50	87.50	100.0
	TOT	29	67.24	24.869	25.0	50.00	62.50	87.50	100.0
FINAL/ET VALUE	PLO	14	78.57	24.724	37.5	62.50	87.50	100.00	100.0
	ADA	15	75.83	22.394	37.5	50.00	75.00	100.00	100.0
	TOT	29	77.16	23.162	37.5	62.50	75.00	100.00	100.0
CHG FROM BSL	PLO	14	8.93	11.423	-12.5	0.00	12.50	12.50	25.0
	ADA	15	10.83	16.947	-25.0	0.00	12.50	25.00	37.5
	TOT	29	9.91	14.322	-25.0	0.00	12.50	25.00	37.5

NOTE: ONLY SUBJECTS WITH BOTH BASELINE AND FINAL/ET VISIT VALUES ARE SHOWN.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]